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A B S T R A C T
Background
Apical vaginal prolapse is a descent of the uterus or vaginal vault (post-hysterectomy). Various surgical treatments are available and
there are no guidelines to recommend which is the best.
Objectives
To evaluate the safety and efficacy of any surgical intervention compared to another intervention for the management of apical vaginal
prolapse.
Search methods
We searched the Cochrane Incontinence Group’s Specialised Register of controlled trials, which contains trials identified from the
Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, ClinicalTrials.gov, WHO ICTRP and handsearching of
journals and conference proceedings (searched July 2015) and ClinicalTrials.gov (searched January 2016).
Selection criteria
We included randomised controlled trials (RCTs).
Data collection and analysis
We used Cochrane methods. Our primary outcomes were awareness of prolapse, repeat surgery and recurrent prolapse (any site).
Main results
We included 30 RCTs (3414 women) comparing surgical procedures for apical vaginal prolapse. Evidence quality ranged from low to
moderate. Limitations included imprecision, poor methodological reporting and inconsistency.
Vaginal procedures versus sacral colpopexy (six RCTs, n = 583; one to four-year review).
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Awareness of prolapse was more common after vaginal procedures (risk ratio (RR) 2.11, 95% confidence interval (CI) 1.06 to 4.21, 3
RCTs, n = 277, I2 = 0%, moderate-quality evidence). If 7% of women are aware of prolapse after sacral colpopexy, 14% (7% to 27%)
are likely to be aware after vaginal procedures.
Repeat surgery for prolapse was more common after vaginal procedures (RR 2.28, 95% CI 1.20 to 4.32; 4 RCTs, n = 383, I2 = 0%,
moderate-quality evidence). The confidence interval suggests that if 4% of women require repeat prolapse surgery after sacral colpopexy,
between 5% and 18% would require it after vaginal procedures.
We found no conclusive evidence that vaginal procedures increaserepeat surgery for stress urinary incontinence (SUI) (RR 1.87, 95%
CI 0.72 to 4.86; 4 RCTs, n = 395; I2 = 0%, moderate-quality evidence). If 3% of women require repeat surgery for SUI after sacral
colpopexy, between 2% and 16% are likely to do so after vaginal procedures.
Recurrent prolapse is probably more common after vaginal procedures (RR 1.89, 95% CI 1.33 to 2.70; 4 RCTs, n = 390; I2 = 41%,
moderate-quality evidence). If 23% of women have recurrent prolapse after sacral colpopexy, about 41% (31% to 63%) are likely to
do so after vaginal procedures.
The effect of vaginal procedures on bladder injury was uncertain (RR 0.57, 95% CI 0.14 to 2.36; 5 RCTs, n = 511; I2 = 0%, moderate-
quality evidence).
SUI was more common after vaginal procedures (RR 1.86, 95%CI 1.17 to 2.94; 3 RCTs, n = 263; I2 = 0%, moderate-quality evidence).
Dyspareunia was also more common after vaginal procedures (RR 2.53, 95% CI 1.17 to 5.50; 3 RCTs, n = 106, I2 = 43%, low-quality
evidence).
Vaginal surgery with mesh versus without mesh (6 RCTs, n = 598, 1-3 year review).
Awareness of prolapse - There may be little or no difference between the groups for this outcome (RR 1.08 95% CI 0.35 to 3.30 1 RCT
n = 54, low quality evidence). The confidence interval was wide suggesting that if 18% of women are aware of prolapse after surgery
without mesh, between 6% and 59% will be aware of prolapse after surgery with mesh.
Repeat surgery for prolapse - There may be little or no difference between the groups for this outcome (RR 0.69, 95% CI 0.30 to 1.60;
5 RCTs, n = 497; I2 = 9%, low-quality evidence). If 4% of women require repeat surgery for prolapse after surgery without mesh, 1%
to 7% are likely to do so after surgery with mesh.
We found no conclusive evidence that surgery with mesh increases repeat surgery for SUI (RR 4.91, 95% CI 0.86 to 27.94; 2 RCTs,
n = 220; I2 = 0%, low-quality evidence). The confidence interval was wide suggesting that if 2% of women require repeat surgery for
SUI after vaginal colpopexy without mesh, 2% to 53% are likely to do so after surgery with mesh.
We found no clear evidence that surgery with mesh decreases recurrent prolapse (RR 0.36, 95% CI 0.09 to 1.40; 3 RCTs n = 269; I2 =
91%, low-quality evidence). The confidence interval was very wide and there was serious inconsistency between the studies.
Other outcomes
There is probably little or no difference between the groups in rates of SUI (de novo) (RR 1.37, 95% CI 0.94 to 1.99; 4 RCTs, n =
295; I2 = 0%, moderate-quality evidence) or dyspareunia (RR 1.21, 95% CI 0.55 to 2.66; 5 RCTs, n = 501; I2 = 0% moderate-quality
evidence). We are uncertain whether there is any difference for bladder injury (RR 3.00, 95% CI 0.91 to 9.89; 4 RCTs, n = 445; I2 =
0%; very low-quality evidence).
Vaginal hysterectomy versus alternatives for uterine prolapse (six studies, n = 667)
No clear conclusions could be reached from the available evidence, though one RCT found that awareness of prolapse was less likely
after hysterectomy than after abdominal sacrohysteropexy (RR 0.38, 955 CI 0.15 to 0.98, n = 84, moderate-quality evidence).
Other comparisons
There was no evidence of a difference for any of our primary review outcomes between different types of vaginal native tissue repair (two
RCTs), comparisons of graft materials for vaginal support (two RCTs), different routes for sacral colpopexy (four RCTs), or between
sacral colpopexy with and without continence surgery (four RCTs).
Authors’ conclusions
Sacral colpopexy is associated with lower risk of awareness of prolapse, recurrent prolapse on examination, repeat surgery for prolapse,
postoperative SUI and dyspareunia than a variety of vaginal interventions.
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The limited evidence does not support use of transvaginal mesh compared to native tissue repair for apical vaginal prolapse. Most of
the evaluated transvaginal meshes are no longer available and new lighter meshes currently lack evidence of safety
The evidence was inconclusive when comparing access routes for sacral colpopexy.
No clear conclusion can be reached from the available data comparing uterine preserving surgery versus vaginal hysterectomy for uterine
prolapse.
P L A I N L A N G U A G E S U M M A R Y
Surgical management of pelvic organ prolapse in women
Review question
Which surgical interventions for apical vaginal prolapse have the best outcomes?
Background
Apical vaginal prolapse is a descent of the uterus or (after hysterectomy) the upper vagina (vault). Various surgical treatments are
available and there are no guidelines to recommend which is the best.
Study characteristics
Thirty randomised controlled trials evaluated 3414 women who underwent surgery for apical vaginal prolapse. The most common
comparisons were between vaginal surgery and sacral colpopexy (an abdominal procedure suspending the upper vagina to the sacrum
with a graft ) (six RCTs), vaginal surgery with mesh versus without (six RCTs), vaginal hysterectomy versus alternatives (six RCTs), and
different types or routes of sacral colpopexy (eight RCTs). The evidence is current to July 2015.
Key results
Compared to various vaginal repairs, sacral colpopexy was associated with lower rates of awareness of prolapse, repeat surgery for
prolapse, prolapse on examination, urinary stress incontinence (SUI) and painful intercourse. If 7% of women are aware of prolapse
after sacral colpopexy, 14% (7% to 27%) are likely to be aware after vaginal procedures. If 4% of women require repeat prolapse surgery
after sacral colpopexy, between 5% and 18% would require it after vaginal procedures.
We found no conclusive evidence that vaginal procedures increase the need for repeat surgery for SUI. If 3% of women require repeat
surgery for SUI after sacral colpopexy, between 2% and 16% are likely to do so after vaginal procedures.
The limited evidence does not support the use of transvaginal mesh compared to native tissue repairs. The evidence was imprecise, but
suggests that if 18% of women are aware of prolapse after surgery without mesh, between 6% and 59% will be aware after surgery with
mesh. If 4% of women require repeat surgery for prolapse after surgery without mesh, 1% to 7% are likely to do so after surgery with
mesh. We found no clear evidence that surgery with mesh decreases recurrent prolapse. Most of the evaluated transvaginal meshes are
no longer available and new lighter meshes lack evidence of safety.
The evidence was inconclusive in comparisons of uterine preserving surgery versus vaginal hysterectomy, and different access routes for
sacral colpopexy.
Quality of the evidence
Evidence quality ranged from very low to moderate. Limitations included imprecision, poor reporting of study methods and inconsis-
tency.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vaginal procedure versus sacral colpopexy for the repair of apical prolapse.
Population: Women with apical compartment pelvic organ prolapse
Setting: Inpat ient
Intervention: Vaginal procedures
Comparison: Sacral colpopexy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Sacral colpopexy Vaginal surgery
Awareness of prolapse
(2 years)
65 per 1000 137 per 1000
(69 to 274)
RR 2.11
(1.06 to 4.21)
277
(3 studies)
⊕⊕⊕©
moderate1
Repeat surgery for pro-
lapse
(2 to 4 years)
41 per 1000 93 per 1000
(49 to 177)
RR 2.28
(1.20 to 4.32)
383
(4 studies)
⊕⊕⊕©
moderate1
Repeat surgery for stress
urinary incontinence
(2 years)
32 per 1000 61 per 1000
(23 to 157)
RR 1.87
(0.72 to 4.86)
395
(4 studies)
⊕⊕⊕©
moderate1
Recurrent prolapse on ex-
amination (1 to 2 years)
232 per 1000 438 per 1000
(309 to 626)
RR 1.89
(1.33 to 2.70)
390
(4 studies)
⊕⊕⊕©
moderate2
Bladder injury 16 per 1000 9 per 1000
(2 to 39)
RR 0.57
(0.14 to 2.36)
511
(5 studies)
⊕⊕⊕©
moderate1
Stress urinary incontinence
(2 years)
139 per 1000 259 per 1000
(163 to 409)
RR 1.86
(1.17 to 2.94)
263
(3 studies)
⊕⊕⊕©
moderate 2
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Dyspareunia
(2 years)
91 per 1000 230 per 1000
(106 to 501)
RR 2.53
(1.17 to 5.50)
106
(3 studies)
⊕⊕©©
low1,2
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Imprecision: wide conf idence intervals and or low event rates suggest ing imprecision: downgraded one level
2 Unclear management of detect ion bias in 3 of 4 studies and outcome dependent upon reviewer assessment: down graded
one level for serious risk of bias
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B A C K G R O U N D
Description of the condition
Pelvic organ prolapse is common and is seen on examination in
40% to 60% of parous women (Handa 2004;Hendrix 2002). The
annual aggregated rate of associated surgery in the USA is in the
range of 10 to 30 per 10,000 women (Brubaker 2002). While an-
terior vaginal prolapse is the most common site of prolapse, loss of
apical support is usually present in women with prolapse that ex-
tends beyond the hymen Brubaker 2009. There is growing recog-
nition that adequate support for the vaginal apex is an essential
component of a durable surgical repair for women with advanced
prolapse Brubaker 2009. Because of the significant contribution
of the apex to vaginal support, anterior and posterior vaginal re-
pairs may fail unless the apex is adequately supported Hsu 2008.
Surgical correction of the apex has several good options with rela-
tively high success rates. Apical suspension procedures can broadly
be separated into those performed transvaginally and those per-
formed abdominally. Abdominal procedures can be performed via
laparotomy or using conventional laparoscopic or robotically as-
sisted-laparoscopic techniques. Although precise estimates are not
available, most studies suggest that the vaginal approach is most
common with 80 to 90% of procedures being performed through
this route. The individual woman’s surgical history and goals, as
well as her individual risks for surgical complications, prolapse
recurrence and de novo symptoms affect surgical planning and
choice of procedure for apical pelvic organ prolapse (POP).
Pelvic organ prolapse is the descent of one or more of the pelvic
organs (uterus, vagina, bladder or bowel). The different types of
prolapse include:
1. apical vaginal prolapse i.e. uterus, vaginal vault (after
hysterectomy when the top of the vagina drops down);
2. anterior vaginal wall prolapse i.e. cystocele (bladder
descends), urethrocele (urethra descends), paravaginal defect
(pelvic fascia defect);
3. posterior vaginal wall prolapse i.e. enterocele (small bowel
descends), rectocele (rectum descends), perineal deficiency.
A woman can present with prolapse of one or more of these sites.
Women with prolapse commonly have a variety of pelvic floor
symptoms only some of which are directly related to the prolapse.
Generalised symptoms of prolapse include pelvic heaviness; bulge,
lump or protrusion coming down from the vagina; a dragging
sensation in the vagina; or backache. Symptoms of bladder, bowel
or sexual dysfunction are frequently present. For example, women
may need to reduce the prolapse by using their fingers to push the
prolapse up to aid urinary voiding or defecation. These symptoms
may be directly related to the prolapsed organ, for example poor
urinary streamwhen a cystocele is present or obstructed defecation
when a rectocele is present. They may also be independent of
the prolapse, for example symptoms of overactive bladder when a
cystocele is present.
These symptoms require careful evaluation prior to surgical cor-
rection of prolapse to ensure the women understands what can
and cannot be expected post-intervention.
Description of the intervention
Treatment of prolapse depends on the severity of the prolapse, its
symptoms, the woman’s general health, and the surgeon’s prefer-
ence and capabilities. Options available for treatment are conser-
vative, mechanical or surgical interventions.
Generally, conservative or mechanical treatments are considered
for women with a mild degree of prolapse, those who wish to
have more children, the frail or those women unwilling to un-
dergo surgery. Conservative and mechanical interventions have
been considered in separate Cochrane reviews (Bugge 2013Hagen
2011). There was no good evidence to guide management in ei-
ther of these reviews.
Previously the Cochrane review on the surgical management of
pelvic organ prolapse evaluated all aspects of prolapse surgery and
in this update the review has been split into six separate reviews.
This review evaluates the surgeries for apical prolapse and further
detail regarding other reviews is stated in Differences between
protocol and review.
Surgery is aimed at re-suspending the upper vagina which may in-
clude the uterus or in post-hysterectomywomen, the vaginal vault.
Suspension of the upper vagina can be achieved via the vagina
or the abdominal approach. The vaginal approach can include
native suspensions to the uterosacral or sacrospinous ligament or
mesh suspensions usually also to the sacrospinous ligament. The
abdominal approach can involve suspension of the vaginal apex to
the sacrum (sacral colpopexy) or uterosacral ligaments. Abdomi-
nal suspension of the uterus to the sacrum is a sacral hysteropexy
and to the uterosacral ligament is a suture hysteropexy. Abdominal
surgery can be performed through an open incision or keyhole
incisions via the laparoscope or robotically.
The current review considers all surgical procedures for women
with apical vaginal prolapse.
How the intervention might work
A combination of the above-mentioned procedures and other con-
tinence and prolapse operations may be employed in the surgical
correction of apical vaginal prolapse as frequently more than one
type of prolapse occurs. The choice of operation depends on a
number of factors, which include the nature, site and severity of
the prolapse; whether there are additional symptoms affecting uri-
nary, bowel or sexual function; the general health of the woman;
the wish to preserve the uterus and the surgeon’s preference and
capability.
To aid the assessment of the success of surgery, clear pre and post-
operative site-specific vaginal grading and details of the operative
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intervention should be recorded in the reports.
Why it is important to do this review
The wide variety of surgical treatments available for prolapse in-
dicates the lack of consensus as to the optimal treatment for apical
vaginal prolapse. No guidelines exist to direct the surgeon and the
women as to the preferred surgical intervention. Provided that suf-
ficient numbers of trials of adequate quality have been conducted,
the most reliable evidence is likely to come from the consideration
of randomised controlled trials, and this is the basis for the review.
The aim is to help identify optimal practice and to highlight where
there is a need for further research.
O B J E C T I V E S
To evaluate the safety and efficacy of any surgical intervention as
compared to another intervention for the management of apical
vaginal prolapse.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished randomised controlled
trials (RCTs) in which any surgery for apical vaginal prolapse was
compared with any other surgery for apical vaginal prolapse. We
excluded quasi-randomised studies (e.g. studies with evidence of
inadequate sequence generation such as alternate days, patient
numbers) as they are associated with a high risk of bias. As this
is a systematic review of surgical interventions, cross-over studies
were excluded as the design was not valid in this context.
Trials were required to have at least six months’ follow-up and at
least 20 women in each arm in order to be eligible for the review.
Types of participants
Eligible studies included adultwomen seeking treatment for symp-
tomatic apical vaginal prolapse, either primary or recurrent.
Types of apical vaginal prolapse include:
1. uterine prolapse;
2. vault prolapse (post-hysterectomy);
3. unspecified vaginal prolapse (uterine and/or vault prolapse).
Types of interventions
Eligible studies compared different types of surgery for apical vagi-
nal prolapse, including the following.
Differences in route:
1. transvaginal;
2. abdominal;
3. open, laparoscopic or robotic.
Differences in type of repair:
1. with or without mesh;
2. types of native tissue repair;
3. whether uterus is spared.
Differences in extent of surgery:
1. hysterectomy versus uterine-preserving;
2. with and without continence surgery.
Types of outcome measures
Primary outcomes
1. Awareness of prolapse: any affirmative response to questions
relating to awareness of prolapse or vaginal bulge, or any affirma-
tive response to question three of Pelvic floor distress inventory
(PFDI-20) “Do you usually have a bulge or something falling out
that you can see or feel in the vaginal area?”
2. Repeat surgery:
2.1 repeat surgery for prolapse;
2.2 repeat surgery for stress urinary incontinence.
3. Any recurrent prolapse Defined as any stage 2 or greater vaginal
prolapse (Pelvic Organ ProlapseQuantification (POPQ): prolapse
- 1 cm above the hymen or below).
Secondary outcomes
4. Adverse events: outcomes to be reported include but are not
limited to:
4.1 death (related to surgery);
4.2 mesh exposure;
4.3 injury to bladder (cystotomy);
4.4 injury to bowel (enterotomy);
4.5 repeat surgery for mesh exposure.
5. Prolapse outcomes:
5.1 objective failure;
5.1.1 stage 2 or greater anterior compartment prolapse (point Ba
at or beyond 1 cm inside the introitus);
5.1.2 stage 2 or greater apical compartment prolapse: (point C at
or beyond 1 cm inside the introitus);
5.1.3 stage 2 or greater posterior vaginal compartment prolapse
(Point Bp at or beyond 1 cm inside the introitus);
5.1.4 Pelvic Organ Prolapse Quantification ( POPQ) system
scores: POPQ scores describe nine measurements of the vagina to
quantify and describe vaginal prolapse. For simplicity we report
four of these basic measurements.
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1. Point Ba on POPQ measurement (range -3 to +10 cm).
Point Ba is approximately mid-point of the anterior vaginal wall.
2. Point Bp on POPQ measurements (range -3 to +10 cm).
Point Bp is approximately mid-point of posterior vaginal wall.
3. Point C on POPQ measurements range from -10 cm to
non determined limit). Point C describes the vaginal apex (upper
vagina).
4. Total vaginal length (TVL) in cm range (0 to 14 cm): TVL
is length from the vaginal entrance to apex (cervix or vaginal
cuff ).
6. Bladder function:
6.1 stress urinary incontinence;
6.2 de novo stress urinary incontinence;
6.3 surgery for stress urinary incontinence;
6.4 de novo bladder overactivity or urge incontinence;
6.5 urinary voiding dysfunction.
7. Bowel function:
7.1 de novo fecal incontinence;
7.2 de novo obstructed defecation;
7.3 constipation.
8. Sexual function:
8.1 dyspareunia;
8.2 de novo dyspareunia;
8.3 Pelvic organ prolapse/ urinary incontinence sexual question-
naire (PISQ) (PISQ-12; range zero to 48, the higher the score the
better the sexual function).
9. Quality of life and satisfaction (Continuous data):
9.1 Patient Global Impression of Improvment (PG1-1) question-
naire: data presented as seven-point Likert scale and responses
of “much” or “very much” better considered affirmative and pre-
sented as dichotomous outcome;
9.2 Prolapse Quality of Life questionnaire (PQOL): range from
zero to100, the higher the score the greater the dysfunction;
9.3 Pelvic Floor Distress Inventory (PFDI-20): range zero to 300,
the higher the score the greater the dysfunction;
9.4 Pelvic Floor Impact Questionnaire (PFIQ-7): range zero to
300, the higher the score the greater the dysfunction.
10. Measures associated with surgery:
10.1 operating time (minutes);
10.2 length of hospital stay;
10.3 blood transfusion.
Search methods for identification of studies
We did not impose any language or other limits on any of the
searches which are detailed below.
Electronic searches
This review drew on the search strategy developed for the
Cochrane Incontinence Group. Relevant trials were identified
from the Group’s Specialised Register of controlled trials which is
described, along with the Review Group search strategy, under the
Group’s module in the Cochrane Library. The Register contains
trials identified from the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, MEDLINE in process, Clini-
calTrials.gov, WHO ICTRP and handsearching of journals and
conference proceedings.
The Incontinence Group Specialised Register was searched on 6
July 2015 using theGroup’s own keyword system; the search terms
used are given in Appendix 1.
In addition, we searched ClinicalTrials.gov in January 2016.
Searching other resources
We handsearched conference proceedings for the International
Urogynecology Society (IUGA) and International Continence So-
ciety (ICS) for podium presentations 2012 to June 2015. We
searched the reference lists of relevant articles, and contacted re-
searchers in the field.
Data collection and analysis
Selection of studies
Two review authors assessed the titles and, if available, abstracts
of all possibly eligible studies for compliance with the inclusion
criteria for the review. Full-text reports of each study likely to be
eligible were then independently assessed by at least two review
authors. Excluded studies are listed with the reasons for their ex-
clusion in the table Characteristics of excluded studies. The selec-
tion process can be referred to in the PRISMA flow chart (Figure
1).
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Figure 1. PRISMA study flow diagram.
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Data extraction and management
Data extraction was undertaken independently by at least two re-
view authors and comparisons made to ensure accuracy. Discrep-
ancies were resolved by discussion or by referral to a third party.
Data extracted included study characteristics and outcome data.
Where studies had multiple publications, we collated the multiple
reports of the same study, so that each study rather than each re-
port is the unit of interest in the review, and we gave these studies
a single study ID with multiple references.
Where trial data were not reported adequately, we attempted to
acquire the necessary information from the trialist.
Assessment of risk of bias in included studies
Two review authors independently assessed the included studies
for risk of bias using the Cochrane ’Risk of bias’ assessment tool
(Higgins 2011) to assess: selection (random sequence generation
and allocation concealment); performance (blinding of partici-
pants and personnel); detection (blinding of outcome assessors);
attrition (incomplete outcome data); reporting (selective report-
ing); and other bias. Disagreements were resolved by discussion
or by a third review author. We describe all judgements fully and
present the conclusions in the ’Risk of bias’ tables, which were
incorporated into the interpretation of review findings by means
of sensitivity analyses (see below).
Measures of treatment effect
For dichotomous data we used the numbers of events in the con-
trol and intervention groups of each study to calculate Mantel-
Haenszel risk ratios (RRs). For continuous data, if all studies re-
ported exactly the same outcomes we calculated the mean differ-
ence (MDs) between treatment groups. If similar outcomes were
reported on different scales, we planned to calculate the standard-
ised mean difference (SMD).We presented 95% confidence inter-
vals for all outcomes. We compared the magnitude and direction
of effect reported by studies with how they are presented in the
review, taking account of legitimate differences. We would have
interpreted the SMD as follows: an effect size of 0.2 is a small
effect, an effect size of 0.5 is a medium effect, and an effect size of
0.8 is a large effect (Cohen 1988).
Unit of analysis issues
All analyses were per woman randomised.
Dealing with missing data
We analysed the data on an intention-to-treat basis (once ran-
domised to an intervention the participants are analysed in that
intervention and analysis includes all randomised participants) as
far as possible, and attempts were made to obtain missing data
from the original trialists. Where these were unobtainable we anal-
ysed only the available data.
Assessment of heterogeneity
We considered whether the clinical and methodological charac-
teristics of the included studies were sufficiently similar for meta-
analysis to provide a clinically meaningful summary. We assessed
statistical heterogeneity by the measure of the I2. An I2 measure-
ment greater than 50% was taken to indicate substantial hetero-
geneity (Higgins 2011), and a random-effects calculation was un-
dertaken to express greater uncertainly bywidening the confidence
intervals.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publica-
tion bias and other reporting biases, we aimed to minimise their
potential impact by ensuring a comprehensive search for eligible
studies and by being alert for duplication of data. Had there been
10 or more studies in an analysis, we planned to use a funnel plot
to explore the possibility of small-study effects(a tendency for es-
timates of the intervention effect to be more beneficial in smaller
studies).
Data synthesis
Where studies were sufficiently similar, we combined the data
using a fixed-effect model in the following comparisons.
1. Vaginal procedure versus sacral colpopexy
2. Vaginal surgery with mesh versus without mesh
3. Vaginal surgery: comparison of one native tissue repair
versus another
4. Vaginal hysterectomy versus alternative surgery for uterine
prolapse
i) vaginal hysterectomy versus abdominal hysterectomy
ii) vaginal hysterectomy versus vaginal uterus-preserving
surgery
iii) vaginal hysterectomy versus abdominal uterus-
preserving surgery
5. Sacral colpopexy with mesh versus without
6. Sacral colpopexy: laparoscopic versus other
i) laparoscopic versus open
ii) laparoscopic versus robotic
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7. Sacral colpopexy with continence surgery versus without
An increase in the odds of a particular outcome, which may be
beneficial (for example. patient’s global impression of improve-
ment ) or detrimental (for example, re-operation for prolapse), is
displayed graphically in the meta-analyses to the right of the cen-
tre-line, and a decrease in the odds of an outcome to the left of
the centre-line.
We did not intend to pool data unless the intervention arm was
clinically homogeneous.
Subgroup analysis and investigation of heterogeneity
No subgroup analysis was planned.
If we detected substantial heterogeneity, we explored possible ex-
planations in sensitivity analyses. We took any statistical hetero-
geneity into account when interpreting the results, especially if
there was any variation in the direction of effect.
Sensitivity analysis
We conducted sensitivity analyses for the primary outcomes to
determine whether the conclusions were robust to arbitrary deci-
sions made regarding the eligibility and analysis. These analyses
included consideration of whether the review conclusions would
have differed if:
1. a random-effects model had been adopted;
2. the summary effect measure had been odds ratio (OR)
rather than risk ratio (RR).
Overall quality of the body of evidence: ’Summary of
findings’ tables
We prepared ’Summary of findings’ tables using GRADEPRO
software, using Cochrane methods. Two review authors working
independently evaluated the overall quality of the body of evi-
dence for the main review outcomes (awareness of prolapse, re-
peat surgery for prolapse or stress incontinence, recurrent prolapse
on examination, bladder injury, stress urinary incontinence and
dyspareunia) with regard to the main review comparisons (vaginal
procedures versus sacral colpopexy and vaginal surgery with ver-
sus without mesh). We used GRADE criteria (study limitations
(i.e. risk of bias), consistency of effect, imprecision, indirectness
and publication bias). Judgements about evidence quality (high,
moderate or low) were justified, documented, and incorporated
into reporting of results for each outcome.
R E S U L T S
Description of studies
Results of the search
Four hundred and fifty-one abstracts were screened and 390
recordswere excluded. Sixty-one full text articleswere screened and
52 publications associated with 30 studies were included (Anger
2014; Barber 2014; Benson 1996; Braun 2007; Brubaker 2008;
Costantini 2007; Costantini 2008; Costantini 2013; Culligan
2005; Culligan 2013; da Silviera 2015; Detollenaere 2015; de
Tayrac 2008, Dietz 2010; Halaska 2012; Iglesia 2010; Jeng 2005,
Lim 2012; Lo 1998; Maher 2004; Maher 2011; Meschia 2004a;
Natale 2010; Freeman 2013; Paraiso 2011; Rahmanou 2015;
Rondini 2015; Roovers 2004; Svabik 2014; Trabuco 2014). Five
studies were excluded and four studies are ongoing. No studies are
awaiting classification.
Full details of the included trials are given in the ’Characteristics
of included studies’ table.
The flow of literature through the assessment process is shown in
the PRISMA flowchart (Figure 1).
Included studies
Study design and setting
Thirty trials were included and were conducted in eight countries
(Australia, Chile, CzeckRepublic, England,Holland, Italy, Taiwan
and the USA). All trials were parallel design.
Participants
A total of 3414 women were randomised in the 30 included trials.
All trials reported age and parity. The mean age of participants
was between 60 and 70 years in all trials except in Anger 2014;
Barber 2014; Rondini 2015; Roovers 2004, where the mean age
was between 55 to 60 years. Median parity was less than three in
all trials except Rondini 2015 with a mean parity of 3.8.
Interventions
1. Six trials (Benson 1996; Lim 2012, Lo 1998; Maher 2004;
Maher 2011; Rondini 2015) compared a vaginal-based apical pro-
lapse repair with sacral colpopexy for apical prolapse and ran-
domised 583 women, of which 83% were post-hysterectomy.
Post-hysterectomy prolapse-only patients were included in Maher
2004; Maher 2011 and the remainder included both uterine and
post-hysterectomy prolapse. All trials included those with stage 2
or greater apical prolapse and abdominal intervention in all trials
was an open sacral colpopexy except for Maher 2011 were laparo-
scopic access to the abdomen was utilised and Lim 2012 were ei-
ther a laparoscopic or open approach was performed. The vaginal
colpopexy was to the sacrospinous ligament in three trials (Benson
1996 bilateral; Lo 1998; Maher 2004), uterosacral ligament (Lim
2012; Rondini 2015), and with transvaginal polypropylene mesh
(Lim 2012; Maher 2011).
2 Six trials (da Silviera 2015; de Tayrac 2008;Halaska 2012; Iglesia
2010; Meschia 2004a; Svabik 2014) compared vaginal apical pro-
cedures with mesh versus vaginal apical procedures without mesh
in 598 women. In all studies a sacrospinous colpopexy was per-
formed in the native tissue arm (n = 297) and the mesh (n = 301)
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was polypropylene. THe polypropylenemesh was a monofilament
weave in four studies (da Silviera 2015; Halaska 2012; Iglesia
2010; Svabik 2014) and multi-filament in two studies (de Tayrac
2008, Meschia 2004a). Two studies (Halaska 2012; Svabik 2014)
included only those with post-hysterectomy prolapse, while the
remainder included those with apical prolapse (uterine and vault).
3 Two additional trials were identified (Barber 2014; Natale 2010)
including 545 women. Both studies are quite different in respect
to interventions and baseline interventions and are not suitable for
group analysis. Barber 2014 reported a multi-centre trial compar-
ing uterosacral (n = 188) and sacrospinous colpopexy (n = 186)
for apical (uterine or vault) prolapse with two-year review. All pa-
tients had symptomatic prolapse, and prolapse equal or beyond -
1 cm from the hymen and stress urinary incontinence. A separate
analysis compared treatment with and without a program of be-
havioural therapy and pelvic floor muscle training (BPMT) and
the reader is directed to a a separate review under preparation Peri-
operative interventions at prolapse surgery review for further de-
tails of this comparison. Natale 2010 compared two vaginal api-
cal suspending procedures, high levator myorrhaphy (HLM) (n
= 116) and uterosacral colpopexy (USLS) (n = 113), in patients
with stage 2 or more uterine prolapse. All women underwent vagi-
nal hysterectomy and anterior repair with concomitant mono-fil-
ament polypropylene mesh in over 90% of women
4. Six trials reported on uterine prolapse (Braun 2007;
Detollenaere 2015; Dietz 2010; Jeng 2005, Rahmanou 2015;
Roovers 2004) evaluating 663 women; with three comparing vagi-
nal hysterectomy versus alternatives for uterine prolapse, includ-
ing vaginal sacrospinous hysteropexy (uterine preserving) inter-
vention (Detollenaere 2015; Dietz 2010; Jeng 2005); abdominal
sacrohysteropexy (Rahmanou 2015; Roovers 2004), and abdom-
inal hysterectomy (Braun 2007).
5. Two trials with 204 women compared different graft materials
utilised to suspend the vagina from the sacrum at sacral colpopexy.
Culligan 2005 compared polypropylene mesh (Trelex Boston,)
with cadaveric fascia lata (Tutoplast, Mentor) and more recently
Culligan 2013 polypropylene mesh (Pelvitex, Bard) with acellular
collagen matrix porcine dermis (Pelvisoft, Bard).
6. Four trials compared access routes for sacral colpopexy. Sacral
colpopexy can be performed with an abdominal incision (ASC),
laparoscopically (LSC) or robotically (RSC) and two trials with
120 women (Costantini 2013; Freeman 2013) compared ASC
and LSC and Anger 2014 and Paraiso 2011 with 157 women
compared LSC and RSC.
7. Four trials evaluated the efficacy of performing continence
surgery at the time of sacrocolpopexy including 544 women
(Brubaker 2008; Costantini 2007; Costantini 2008; Trabuco
2014). Three evaluated with and without colposuspension (
Brubaker 2008; Costantini 2007; Costantini 2008) and Trabuco
2014 compared colposuspension with mid-urethral sling at the
time of sacrocolpopexy. In Brubaker 2008 and Costantini 2007,
the women had prolapse and were continent and in Costantini
2008 and Trabuco 2014, prolapse and urinary stress incontinence
(SUI) were the inclusion criteria.
Follow-up
Fifteen trials reportedmedian/mean follow-up of less thanone year
(Anger 2014; Costantini 2013; Culligan 2013; da Silviera 2015;
Detollenaere 2015; Dietz 2010; Freeman 2013; Halaska 2012;
Jeng 2005; Lim 2012; Natale 2010; Paraiso 2011; Rahmanou
2015; Svabik 2014; Trabuco 2014).
Two-year results were reported in six studies (Barber 2014; Benson
1996; Braun 2007; Lo 1998; Maher 2004; Maher 2011).
Three to four-year outcomes were reported in three trials (
Costantini 2008; Iglesia 2010; Rondini 2015), and four trials
reported outcomes at greater than five years (Brubaker 2008,
Costantini 2007, Culligan 2005, Roovers 2004).
Outcomes
Twenty-four studies reported data in a form suitable for analysis
on at least one of the primary outcomes.
1. Nine reported awareness of prolapse (Barber 2014; Benson
1996; Brubaker 2008; Culligan 2005; Detollenaere 2015; Iglesia
2010; Maher 2004; Maher 2011; Roovers 2004).
2. Twenty-one reported re-operation for prolapse (Barber
2014; Benson 1996; Braun 2007; Brubaker 2008; Costantini
2007; Costantini 2008; Culligan 2005; Culligan 2013; da
Silviera 2015; de Tayrac 2008; Detollenaere 2015; Dietz 2010;
Freeman 2013; Halaska 2012; Iglesia 2010; Maher 2004; Maher
2011; Rahmanou 2015; Rondini 2015; Roovers 2004; Svabik
2014).
3. Fourteen reported prolapse on examination at any site
(Braun 2007; Brubaker 2008; Culligan 2005; Culligan 2013;
Detollenaere 2015; Freeman 2013; Halaska 2012; Iglesia 2010;
Lim 2012; Lo 1998; Maher 2004; Maher 2011; Paraiso 2011;
Svabik 2014).
Six trials did not report any primary outcome but all reported at
least one secondary outcome (Anger 2014; Costantini 2013; Jeng
2005; Meschia 2004a, Natale 2010; Trabuco 2014).
Excluded studies
Overall five studies were excluded from the review (Altman 2013;
Balci 2011; Chao 2012;Heinonen 2011 Juneja 2010). Full details
are given in the ’Characteristics of excluded studies’ table.
Risk of bias in included studies
Allocation
Random sequence generation and allocation concealment
Seventeen trials adequately described the allocation process and
confirmed that secure concealment of the randomisation process
was used, for example allocation by a remote person or sealed en-
velopes (Anger 2014; Barber 2014; Benson 1996; Brubaker 2008;
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Culligan 2005; Culligan 2013, Detollenaere 2015 Dietz 2010;
Iglesia 2010; Lim 2012, Lo 1998, Maher 2004; Maher 2011;
Meschia 2004a Paraiso 2011 Rondini 2015; Roovers 2004). How-
ever, in one of these trials, four women received the opposite treat-
ment to their randomised allocation (mesh instead of fascia) and
were subsequently analysed in themesh group thus compromising
the randomisation process; an intention-to-treat analysis was not
used (Culligan 2005). Svabik 2014 described computer-generated
randomisation based on hospital numbers.
Of the remainder, 11 trials stated that they used computer-gen-
erated number lists but it was unclear whether the allocation was
concealed before assignment (Braun 2007; Costantini 2007; de
Tayrac 2008; Freeman 2013;Halaska 2012; Lo1998;Natale 2010;
Paraiso 2011; Svabik 2014).
Twenty-five trials were rated as at low risk of bias related to se-
quence generation and five as at unclear risk. Eighteen trials were
rated as low risk of bias related to allocation concealment and 12
as at unclear risk.
Blinding
Women and surgeons could not be blinded to the procedure when
different surgical routes were compared (Benson 1996; Braun
2007; da Silviera 2015; Maher 2004; Maher 2011; Rahmanou
2015; Roovers 2004; Svabik 2014). Blinding of patients and
the postoperative reviewer were performed in six trials (Barber
2014; Brubaker 2008;Culligan 2005;Culligan 2013; Iglesia 2010;
Paraiso 2011). Outcome assessments were conducted by non-
surgeons in 13 trials (Anger 2014; Barber 2014; Benson 1996;
Costantini 2008; Culligan 2005; Culligan 2013; Iglesia 2010;
Maher 2004; Maher 2011; Paraiso 2011; Roovers 2004; Svabik
2014; Trabuco 2014). These findings are summarised in Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Six trials were at low risk of performance bias, 17 an unclear risk
and 7 at high risk of bias in this domain. Fifteen were at low risk
of detection bias, 10 at an unclear risk and five were at high risk
of detection bias.
Incomplete outcome data
Loss to follow-up ranged fromzero (Braun 2007;Costantini 2008;
Detollenaere 2015, to less than 10% in eight trials (Anger 2014;
Benson 1996; Culligan 2013; Dietz 2010; Halaska 2012; Maher
2004; Maher 2011; Svabik 2014) At one year Rahmanou 2015
reported 37% attrition rate and generally as review time increased
attrition rate also climbed. At five years Culligan 2005 reported
a 46% loss to follow-up that increased to 62% at the seven-year
evaluation of the Care study (Nygaard 2013). Roovers 2004 had
a 27% attrition rate and Costantini 2007 a 6% attrition rate at
eight years. Attrition rate not stated in Costantini 2013.
Twenty-three studies were rated as at low risk of attrition bias, two
studies were rated as at high risk of attrition bias and five as at
unclear risk.
Selective reporting
Twenty-three trials were at low risk and seven at unclear risk of
reporting bias. Data relating to a number of outcomes were not
available in a suitable format to be included in a meta-analysis, as
mean and standard deviations were not reported when describing
the central tendency and dispersion of data.
Other potential sources of bias
In 12 trials, data were analysed on an intention-to-treat basis (
Barber 2014, Brubaker 2008; Culligan 2013; Detollenaere 2015;
Dietz 2010, Iglesia 2010; Jeng 2005; Maher 2004; Maher 2011;
Paraiso 2011;Rondini 2015 Roovers 2004).
Baseline descriptive characteristics were reported in all trials and
were equally distributed except for: Meschia 2004a were women
in the vaginal sacrospinous colpopexy arm were significantly older.
Barber 2014 compared sacrospinous and uterosacral colpopexy
and in the uterosacral group there was lower body mass index
(BMI), higher parity and less prolapse as compared to sacrospinous
colpopexy group. In Detollenaere 2015, in the vaginal hysterec-
tomy group, more posterior repairs were performed than in the
sacrohysteropexy group.
Preoperative prolapse status was reported in all trials but equal dis-
tribution and severity of prolapse between groups was not specifi-
cally reported in Benson 1996; Meschia 2004a, or Freeman 2013.
Thirteen trials were at low risk of bias related to financial conflict
of interest with risk being unclear in 16 trials and high in one.
These findings are summarised in Figure 2 and Figure 3.
Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Effects of interventions
See: Summary of findings for the main comparison Vaginal
procedure versus sacral colpopexy; Summary of findings 2
Vaginal surgery with mesh versus without mesh
1 Vaginal procedure versus sacral colpopexy
Six trials (583women) reported on this comparison (Benson 1996;
Lim 2012; Lo 1998; Maher 2004; Maher 2011; Rondini 2015).
The trials compared vaginal procedures with laparoscopic or open
colpopexy.
PRIMARY OUTCOMES
1.1 Awareness of prolapse
Awareness of prolapse was more common after vaginal procedures
than after sacral colpopexy (risk ratio (RR) 2.11, 95% confidence
interval (CI) 1.06 to 4.21; 3 RCTs, n = 277; I2 = 0% moderate-
quality evidence, Analysis 1.1; Figure 4). If 7%of women are aware
of prolapse after sacral colpopexy, 14% (7% to 27%) are likely to
be aware after vaginal procedures.
Figure 4. Forest plot of comparison: 1 Vaginal procedure versus sacral colpopexy, outcome: 1.1 Awareness
of prolapse (2 years).
1.2 Repeat surgery
1.2.1 Repeat surgery for prolapse
Repeat surgery for prolapse was more common after vaginal pro-
cedures than sacral colpopexy at two- to four-year follow-up (RR
2.28, 95% CI 1.20 to 4.32; 4 RCTs, n = 383; I2 = 0% moderate-
quality evidence, Analysis 1.2; Figure 5). The confidence interval
suggests that if 4% of women require repeat prolapse surgery af-
ter sacral colpopexy, between 5% and 18% would require it after
vaginal procedures.
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Figure 5. Forest plot of comparison: 1 Vaginal procedure versus sacral colpopexy, outcome: 1.2 Repeat
surgery (2-4 years).
1.2.2 Repeat surgery for stress incontinence (SUI)
We found no conclusive evidence that vaginal procedures increase
repeat surgery for SUI (RR 1.87, 95% CI 0.72 to 4.86; 4 RCTs,
n = 395; I2 = 0%, moderate-quality evidence). If 3% of women
require repeat surgery for SUI after sacral colpopexy, between 2%
and 16% are likely to do so after vaginal procedures. (Analysis 1.2;
Figure 5)
1.3 Any recurrent prolapse
After one to two years follow-up, recurrent prolapse on examina-
tion (those with stage 2 or greater prolapse at any site) is probably
more common after vaginal procedures (RR 1.89, 95% CI 1.33
to 2.70; 4 RCTs, n = 390; I2 = 41%, moderate-quality evidence).
If 23% of women have recurrent prolapse after sacral colpopexy,
about 41% (31% to 63%) are likely to do so after vaginal proce-
dures. (Analysis 1.3, Figure 6)
Figure 6. Forest plot of comparison: 1 Vaginal procedure versus sacral colpopexy, outcome: 1.3 Any
recurrent prolapse (1-2 years).
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SECONDARY OUTCOMES
1.4 Adverse events
1.4.1 Death related to surgery
No data were reported for this outcome.
1.4.2 Mesh exposure
There was no evidence of a difference between the groups; vaginal
procedure 4% (9/291) versus sacral colpopexy 3% (8/283) for
mesh exposure (RR 1.13; 95% CI 0.47 to 2.69, 6 RCTs, n = 574;
I2 = 28%, Analysis 1.4).
1.4.3 Bladder injury
The effect of vaginal procedures on bladder injury was uncertain,
due to imprecision associated with low event rates: vaginal pro-
cedure 0.7% (2/267) versus sacral colpopexy 1.8% (4/244): (RR
0.57, 95% CI 0.14 to 2.36; 5 RCTs, n = 511; I2 = 0%, Analysis
1.5.1; moderate-quality evidence). If bladder injury occurred in
2% of women after sacral colpopexy, then up to 4% would have
bladder injury following vaginal procedures.
1.4.4 Bowel injury
There was no evidence of a difference between the groups: vaginal
procedure 0.6% (1/163) versus sacral colpopexy 1.4% (2/143) for
bowel injury (RR 0.63, 95% CI 0.12 to 3.23; 3 RCTs, n = 306; I2
= 0%, Analysis 1.5.2). Caution should be taken when interpreting
these results due to the low event rates.
1.4.5 Repeat surgery for mesh exposure
There was no evidence of a difference between vaginal procedures
and sacral colpopexy for repeat surgery for mesh exposure at one-
to four-year follow-up (RR 1.14; 95% CI 0.35 to 3.64; I2 = 48%
5 RCTs, n = 497. Analysis 1.2.3).
1.5 Objective failure, by site
1.5.1 Objective failure of anterior compartment
Anterior compartment prolapse was more likely after vaginal pro-
cedures than after sacral colpopexy (RR 4.02, 95% CI 1.71 to
9.49; 2 RCTs, n = 199; I2 = 22%, Analysis 1.7)
1.5.2 Objective failure of apical compartment
Apical prolapse was more likely after vaginal procedures than after
sacral colpopexy (RR 8.15, 95% CI 2.71 to 24.49; 3 RCTs, n=
275; I2 = 0%, Analysis 1.7).
1.5.3 Objective failure of posterior vaginal compartment
Posterior compartment prolapse was more likely after vaginal pro-
cedures than after sacral colpopexy (RR 3.43, 95% CI 1.10 to
10.66; 2 RCTs, n=199; I2 = 0%, Analysis 1.7).
1.5.4 Pelvic organ prolapse quantification (POPQ) scores
1. Point Ba was less supported in the vaginal procedure group
than the sacral colpopexy group (mean difference (MD) 0.80
cm, 95% CI 0.41 to 1.19; 1 RCT, n = 108, Analysis 1.8).
2. Point Bp was less supported in the vaginal procedure group
as compared to sacral colpopexy (MD 0.77 cm, 95% CI 0.38 to
1.16; 1 RCT, n = 108, Analysis 1.8).
3. Point C was less supported in the vaginal procedure group
compared to sacral colpopexy (MD 0.50 cm, 95% CI 0.11 to
0.88; 1 RCT, n = 108, Analysis 1.8).
4. Total vaginal length was less in the vaginal procedure group
compared to sacral colpopexy (MD -0.89 cm, 95%CI -1.29 to -
0.50; 1 RCT, n = 108, Analysis 1.8).
1.6 Bladder function
1.6.1 Stress urinary incontinence (SUI)
Postoperative SUI is probablymore common following the vaginal
procedures (RR 1.86, 95% CI 1.17 to 2.94; 3 RCTs, n = 263; I2 =
0% moderate-quality evidence, Analysis 1.9). These data suggest
that if SUI occurs in 14% of women after sacral colpopexy, then
16% to 40% will develop SUI after vaginal procedures.
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1.6.2 de novo stress urinary incontinence (SUI)
No data were reported for this outcome.
1.6.3 de novo urge incontinence
There was no evidence of a difference between the vaginal proce-
dure and sacral colpopexy groups for de novo urge incontinence
(RR 1.61, 95% CI 0.68 to 3.81; 1 RCT, n = 62, Analysis 1.10).
Caution should be taken in interpreting these results due to small
sample size, low event rates and wide confidence intervals.
1.6.4 Urinary voiding dysfunction
There was no evidence of a difference between the vaginal pro-
cedure and sacral colpopexy groups for de novo urinary voiding
dysfunction (RR 1.03, 95% CI 0.07 to 15.82, 1 RCT, n = 75,
Analysis 1.11). Caution should be taken in interpreting these re-
sults due to small sample size, low event rates and wide confidence
intervals.
1.7 Bowel function
No data were reported for any of the bowel function outcomes (de
novo fecal incontinence, de novo obstructed defecation, constipa-
tion).
1.8 Sexual function
1.8.1 Dyspareunia
Dyspareunia rates may be higher after the vaginal procedures than
after sacral colpopexy (RR 2.53, 95% CI 1.17 to 5.50; 3 RCTs, n
= 106, I2 = 43%, Analysis 1.12; Figure 7, low-quality evidence).
These data suggest that if 9% of women have dyspareunia after
sacral colpopexy then 11% to 50% will be affected after vaginal
procedures.
Figure 7. Forest plot of comparison: 1 Vaginal procedure versus sacral colpopexy, outcome: 1.12
Dyspareunia.
1.8.2 de novo dyspareunia
No data were reported for this outcome
1.8.3 Pelvic organ prolapse/ urinary incontinence sexual
questionnaire (PISQ)
There was no evidence of a difference between the groups in PISQ
scores (MD-1.20, 95%CI -4.35 to 1.95; 1 RCT, n = 110, Analysis
1.13).
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1.9 Quality of life and satisfaction measures
1.9.1 No data were reported for the Patient Global Impression of
Improvement (PGI-1) questionnaire.
1.9.2 A single study Rondini 2015 reported no evidence of a dif-
ference between the vaginal procedure and the sacral colpopexy
group for the Prolapse quality of Life Questionnaire (PQoL) (MD
22.70, 95% CI -7.53 to 52.93, 1 RCT, n = 110, Analysis 1.14).
1.9.3 A small advantage was seen in the sacral colpopexy group
compared with the vaginal procedure group in the Pelvic Floor
Distress Inventory (PFDI-20) (MD 7.90 95% CI 0.70 to 15.10;
1 RCT, n = 110, Analysis 1.14).
1.9.4 No data were reported for the Pelvic Floor Impact Ques-
tionnaire (PFIQ-7).
1.10 Measures associated with surgery
1.10.1 Operating time
Vaginal proceduresmay be associatedwith a shorter operating time
than sacral colpopexy (MD -21.49 minutes, 95% CI; -28.00 to -
14.98, 4 RCTs, n = 403, I2 = 0%, low-quality evidence, Analysis
1.15).
1.10.2 Length of hospital stay
Sacral colpopexy was associated with a shorter length of stay com-
pared with vaginal procedures (MD 0.63 days, 95% CI 0.44 to
1.03; 4 RCTs n = 403; I2 = 84%). When a random-effects model
was used, the association was no longer evident and there was no
evidence of a difference between the vaginal procedure and sacral
colpopexy groups for length of hospital stay (MD 0.19 days ran-
dom-effects 95% CI -0.50 to 0.89, 4 RCTs, n = 403, I2 = 84%,
Analysis 1.16).
1.10.3 Blood transfusion rate
Theremay be no difference between the groups: vaginal procedure
0% (0/97) compared to sacral colpopexy 3% (3/91) for the need
for blood transfusions (RR 0.26, 95% CI 0.04 to 1.57; 3 RCTs,
n = 277; I2 = 0%, Analysis 1.17).
Findings are summarised in Summary of findings for the main
comparison.
2 Vaginal surgery with mesh versus without mesh
Six trials da Silviera 2015; de Tayrac 2008; Halaska 2012; Iglesia
2010; Meschia 2004a; Svabik 2014 randomised 598 women.
In all studies a sacrospinous colpopexy was performed in the native
tissue arm (n = 297) and the mesh (n = 301) was polypropylene.
A polypropylene mesh was a monofilament weave in four studies
(da Silviera 2015; Halaska 2012; Iglesia 2010; Svabik 2014), and
multi-filament in two studies (de Tayrac 2008, Meschia 2004a).
Two studies (Halaska 2012; Svabik 2014) included only those with
post-hysterectomy prolapse while the remainder included those
with apical prolapse (uterine and vault).
PRIMARY OUTCOMES
2.1 Awareness of prolapse
There may be little or no difference between the groups for this
outcome (RR 1.08 95% CI 0.35 to 3.30 1 RCT n = 54, low-
quality evidence). The confidence interval was wide suggesting
that if 18% of women are aware of prolapse after surgery without
mesh, between 6% and 59%will be aware of prolapse after surgery
with mesh (Analysis 2.1).
2.2 Repeat surgery
2.2.1 Repeat surgery for prolapse
There may be little or no difference between the groups for this
outcome (RR 0.69, 95% CI 0.30 to 1.60; 5 RCTs, n = 497; I2 =
9%, low-quality evidence). If 4% of women require repeat surgery
for prolapse after surgery without mesh, 1% to 7% are likely to
do so after surgery with mesh (Analysis 2.2).
2.2.2 Repeat surgery for stress urinary incontinence
We found no conclusive evidence that surgery with mesh increases
repeat surgery for SUI (RR 4.91, 95% CI 0.86 to 27.94; 2 RCTs,
n = 220; I2 = 0%, low-quality evidence, Analysis 2.2.2). The con-
fidence interval was wide suggesting that if 2% of women require
repeat surgery for SUI after vaginal colpopexy without mesh, 2%
to 53% are likely to do so after surgery with mesh. Caution should
be used in interpreting the results due to serious imprecision with
wide confidence intervals, small sample size and low event rates.
2.3 Any recurrent prolapse
We found no clear evidence that surgery with mesh decreases re-
current prolapse at one to three years (RR 0.36, 95% CI 0.09 to
1.40; 3 RCTs n = 269; I2 = 91%, low-quality evidence). However,
caution should be used in interpreting the results as the confidence
interval was very wide and there was serious inconsistency between
the studies. (Analysis 2.3; Figure 8)
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Figure 8. Forest plot of comparison: 2 Vaginal surgery with mesh versus without mesh, outcome: 2.3
Recurrent prolapse on examination (1-3 years).
SECONDARY OUTCOMES
2.4 Adverse events
2.4.1 Death related to surgery
No data were reported for this outcome.
2.4.2 Mesh exposure
Only total data for mesh exposure (18%; 42/235) were reported
and this was not separated by intervention group (Table 1).
2.4.3 Bladder injury
We are uncertain whether there is any difference between the
groups: vaginal surgery with mesh 4% (8/205) versus vaginal
surgery withoutmesh 1% (2/195) (RR3.00, 95%CI 0.91 to 9.89;
4 RCTs, n = 445; I2 = 0% very low-quality evidence).These data
suggest that if cystotomy occurs in 1% of women during vaginal
surgery without mesh, then 1% to 12% would have cystotomy
during vaginal surgery with mesh (Analysis 2.4).
2.4.4 Bowel injury
There was no evidence of a difference between groups (RR 3.00,
95%CI 0.12 to 72.65; 3 RCTs, n = 389; I2 = 0%).Two of the trials
(n = 213) reported no events in either group (Analysis 2.4). Cau-
tion is advised in interpreting these data due the limited number
of trials with evidence of imprecision shown by wide confidence
intervals and low event rates.
2.4.5 Repeat surgery for mesh exposure
Only total data for repeat operation for mesh exposure (9.5%; 22/
235) were reported and these were not separated by intervention
group (Table 2).
2.5 Objective failure by site
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2.5.1 Objective failure of anterior compartment
Recurrent anterior wall prolapse (stage 2 or greater): there was
no evidence of a difference between groups: vaginal surgery with
mesh 18.5% (10/54) versus vaginal surgery without mesh (native
tissue) 30% (17/57) (RR 0.61, 95% CI 0.31 to 1.20; 2 RCTs,
n = 111; I2 = 47%; Analysis 2.5). For recurrent anterior vaginal
prolapse beyond the hymen, there was no evidence of a difference
between the groups (RR 0.84, 95% CI 0.52 to 1.38; 1 RCT, n =
169; Analysis 2.3).
2.5.2 Objective failure of apical compartment
Recurrent apical prolapse (stage 2or greater): therewas no evidence
of a difference between groups: vaginal surgery with mesh 4% (2/
54) versus vaginal surgery without mesh (vaginal colpopexy) 0%
(0/57) (RR 3.20, 95% CI 0.34 to 29.82; 2 RCTs, n = 111; I2 =
0%; Analysis 2.5). For recurrent apical vaginal prolapse beyond the
hymen, there was no evidence of a difference between the groups
(RR 0.50, 95% CI 0.21 to 1.18; 1 RCT, n = 169; Analysis 2.3).
2.5.3 Objective failure of posterior vaginal compartment
Recurrent posterior vaginal prolapse (stage 2 or greater): there was
no evidence of a difference between groups: vaginal surgery with
mesh 8.7% (5/57) versus vaginal surgery without mesh (vaginal
colpopexy) 10.5% (6/57) (RR0.85, 95%CI 0.29 to 2.45; 2RCTs,
n = 114; I2 = 0%; Analysis 2.5)
Recurrent posterior vaginal prolapse beyond the hymen appeared
to be lower after vaginal surgery with mesh 2% (2/82) than with
vaginal surgery without mesh 21% (17/81) (RR 0.11, 95% CI
0.03 to 0.45; 1 RCT, n = 169; Analysis 2.3).
2.5.4 Pelvic organ prolapse quantification (POPQ) scores
At one year POPQ assessment was reported in two trials (da
Silviera 2015; Svabik 2014).
1. Point Ba - was less supported in the vaginal surgery with
mesh group than the vaginal surgery without mesh group (MD -
1.71, 95% CI -2.88 to -0.55; 2 RCTs n = 239; Analysis 2.6).
2. Point Bp - was less supported in the vaginal surgery with
mesh group than the vaginal surgery without mesh group (MD -
0.59, 95% CI -1.07 to -0.12; 2 RCTs, n = 239; Analysis 2.6).
3. Point C - There was no evidence of a difference between
vaginal surgery with mesh and vaginal surgery without mesh
groups (MD -1.93, 95% CI -3.99 to 0.13; 2 RCTs n = 239;
Analysis 2.6).
4. Total vaginal length - No data were reported for this
outcome.
2.6 Bladder function
2.6.1 Stress urinary incontinence
No data were reported for this outcome.
2.6.2 De novo stress urinary incontinence
There is probably little or no difference between the groups in rates
of de novo stress urinary incontinence (RR 1.37, 95% CI 0.94
to 1.99; 4 RCTs, n = 295; I2 = 0%, moderate-quality evidence;
Analysis 2.7). These data suggest that if de novo stress urinary
incontinence occurs in 22% of women after vaginal surgery with-
out mesh surgery, then 21% to 44% will develop stress urinary
incontinence after vaginal surgery with mesh.
2.6.3 De novo urge incontinence
There was no evidence of a difference found for de novo urge
incontinence between the groups: vaginal surgery with mesh 10%
(18/183) versus vaginal surgery without mesh 7% (12/179) (RR
1.42, 0.72 to 2.82; 4 RCTs, n = 362; I2 = 10%, Analysis 2.8).
2.6.4 Urinary voiding dysfunction
There was no evidence of a difference in postoperative voiding
dysfunction: vaginal surgery with mesh 17% ( 9/54) versus vaginal
surgery without mesh 28% (16/57) (RR 0.59, 95% CI 0.29 to
1.24; 2 RCTs, n = 111; Analysis 2.9 ).
2.7 Bowel function
No data were reported for any of the bowel function outcomes
pre-specified in this review (de novo faecal incontinence, de novo
obstructed defecation, constipation).
2.8 Sexual function
2.8.1 Dyspareunia
There is probably little or no difference between the groups in rates
of dyspareunia: vaginal surgery with mesh 5% (13/257) versus
vaginal surgery without mesh 4% (10/243) (RR 1.21, 95% CI
0.55 to 2.66; 5 RCTs, n = 501; I2 = 0%, moderate quality evidence
Analysis 2.10). These data suggest that if dyspareunia occurs in
3% of women after vaginal surgery without mesh, then between
2% and 9%will have dyspareunia after vaginal surgery with mesh.
One study (Halaska 2012), of 151 women, reported no evidence
of a difference between the vaginal surgery with mesh (6/79) and
the vaginal surgery without mesh (sacral colpopexy) (3/72) groups
for vaginal pain (RR 1.82, 95%CI 0.47 to 7.02; 1 RCT, n = 151).
2.8.2 De novo dyspareunia
No data were reported for this outcome.
2.8.3 Pelvic organ prolapse/ urinary incontinence sexual question-
naire (PISQ)
There was no evidence of a difference between the groups for the
PISQ (MD -1.72, 95% CI -3.57 to 0.14; 3 RCTs, n = 180; I2 =
7%; Analysis 2.11)
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2.9 Quality of life and satisfaction
2.9.1 Patient Global Impression of Improvement (PGI-1) - There
was no evidence of a difference between vaginal surgery with mesh
and vaginal surgery without mesh for women who reported an
improvement of ’much better’ or ’very much better’ (RR 1.75,
95% CI 0.37 to 8.24; 1 RCT, n = 51, Analysis 2.12).
2.9.2 Prolapse Quality of Life Questionnaire (PQOL) - Surgery
with vaginal mesh was associated with a reduced quality of life
compared with surgery without mesh (RR 5.70, 95% CI 1.53 to
9.87; 1 RCT, n = 167, Analysis 2.13).
2.9.3 Pelvic Floor Distress Inventory (PFDI-20) - No trials re-
ported data for this questionnaire.
2.9.4 Pelvic Floor Impact Questionnaire (PFIQ-7) - No trials re-
ported data for this questionnaire.
2.10 Measures associated with surgery
2.10.1 Operating time
There was no evidence of a difference between vaginal surgery with
mesh or vaginal surgery without mesh (sacral colpopexy) groups
(MD -3.27, 95% CI -14.96 to 8.43; 3 RCTs, n = 294; I2 = 54%;
Analysis 2.14).
2.10.2 Length of hospital stay
No data were reported for this outcome.
2.10.3 Blood transfusion rate
There was no evidence of a difference between the vaginal surgery
with mesh 2% (2/127) and vaginal surgery without mesh 2% (2/
122) (RR 0.96, 95%CI 0.17 to 5.46; 2 RCTs, n = 249; I2 = 0%,
Analysis 2.15).
Findings are summarised in Summary of findings 2.
3 Vaginal surgery: comparison of one native tissue
repair versus another
Two trials are reviewed (Barber 2014; Natale 2010). Natale 2010,
compared uterosacral colpopexy and high levator myorrhaphy for
uterine prolapse and Barber 2014 compared uterosacral colpopexy
and sacrospinous colpopexy for apical vaginal (uterine and vault)
prolapse.
PRIMARY OUTCOMES
3.1 Awareness of prolapse
There may be no difference between uterosacral and sacrospinous
colpopexy in rates of awareness of prolapse (RR 0.91, 95% CI
0.58 to 1.43; 1 RCT, n = 303; Analysis 3.1; low-quality evidence).
This suggests that if 6% of women were aware of prolapse af-
ter sacrospinous hysteropexy then between 2% to 17% would be
aware of prolapse after uterosacral colpopexy.
3.2 Repeat surgery
3.2.1 Repeat surgery for prolapse
There may be no difference between uterosacral and sacrospinous
colpopexy for repeat surgery for prolapse (RR 1.20, 95% CI 0.33
to 4.40; 1 RCT, n = 316; Analysis 3.2). This suggests that if 6%
of women had repeat surgery for prolapse after sacrospinous hys-
teropexy then between 1% to 55% would have repeat surgery for
prolapse after uterosacral colpopexy.
3.2.2 Repeat surgery for stress incontinence
No data were reported for repeat surgery for stress incontinence.
3.3 Any recurrent prolapse
No data were reported for this outcome.
SECONDARY OUTCOMES
3.4 Adverse events
3.4.1 Death (related to surgery)
No data were reported for this outcome.
3.4.2 Mesh exposure
No data were reported for this outcome.
3.4.3 Bladder injury
There was no evidence of a difference between the uterosacral and
sacrospinous colpopexy groups (RR 8.67, 95%CI 0.47 to 159.64;
1 RCT, n = 316; Analysis 3.3). Intra-operative ureteric injury was
more frequent at uterosacral colpopexy than with other vaginal
procedures (RR 15.91, 95% CI 2.13 to 118.51; 2 RCTs, n = 544;
I2 = 0%, Analysis 3.3). There was no evidence of a difference
between uterosacral colpopexy and other vaginal procedures for
ureteric injury postoperatively (RR 2.89, 95% CI 0.12 to 70.38;
2 RCTs, n = 544; I2 = 0% Analysis 3.3). Caution is advised in
interpreting these data due the limited number of trials with evi-
dence of imprecision shown by wide confidence intervals and low
event rates.
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3.4.4 Bowel Injury
There was no evidence of a difference between uterosacral and
sacrospinous colpopexy (RR 0.32, 95% CI 0.01 to 7.82; 1 RCT,
n = 316; Analysis 3.3). Caution is advised in interpreting these
data due the data being available from a single trial with evidence
of imprecision shown by wide confidence intervals and low event
rates.
3.4.5 Repeat surgery for mesh exposure
No data were reported for this outcome.
3.5 Objective failure by site
3.5.1 Objective failure of anterior compartment
There was no evidence of a difference between uterosacral
colpopexy and other vaginal procedures for this outcome (RR
1.15, 95% CI 0.85 to 1.57; 2 RCTs, n = 537; I2 = 0%, Analysis
3.4).
3.5.2 Objective failure of apical compartment
There was no evidence of a difference between uterosacral
colpopexy and other vaginal procedures for this outcome (RR
0.80, 95% CI 0.38 to 1.67; 2 RCTs, n = 536; I2 = 0%, Analysis
3.4).
3.5.3 Objective failure of posterior vaginal compartment
There was no evidence of a difference between the uterosacral
colpopexy and other vaginal procedures for this outcome (RR
1.14, 95% CI 0.63 to 2.06; 2 RCTs, n = 537; I2 = 0%, Analysis
3.4).
3.5.4 Pelvic Organ Prolapse Quantification (POPQ) score
1. Point Ba - There was no evidence of a difference between
uterosacral colpopexy and other vaginal procedures (MD -0.10,
95% CI -0.39 to 0.19; 1 RCT, n = 374).
2. Point Bp -There was no evidence of a difference between
uterosacral colpopexy and other vaginal procedures (MD 0.00,
95% CI -0.04 to 0.04; 1 RCT, n = 374).
3. Point C - No data were reported for this outcome.
4. Total vaginal length - No data were reported for this
outcome.
3.6 Bladder function
3.6.1 Stress urinary incontinence
No data were reported for this outcome.
3.6.2 De novo stress urinary incontinence
There was no evidence of a difference between uterosacral
colpopexy and high levator myorrhaphy (RR 1.60, 95% CI 0.64
to 3.98; 1 RCT, n = 228 Analysis 3.6)
3.6.3 Urinary urge incontinence
There was no evidence of a difference between uterosacral
colpopexy and high levator myorrhaphy (RR 3.50, 95% CI 0.76
to 16.14; 1 RCT, n = 116; Analysis 3.7)
3.6.4 Urinary voiding dysfunction
No data were reported for this outcome.
3.7 Bowel function
No data were reported for any of the pre-specified outcomes for
bowel function (de novo fecal incontinence, de novo obstructed
defecation, constipation).
3.8 Sexual function
3.8.1 Dyspareunia
There may be no difference between uterosacral colpopexy and
high levator myorrhaphy for this outcome (RR 1.19, 95%CI 0.73
to 1.95; 1 RCT, n = 228; Analysis 3.8). This suggests that if 20%
of women had dyspareunia after sacrospinous hysteropexy then
between 14.6% to 39% would have dyspareunia after uterosacral
colpopexy.
3.8.2 De novo dyspareunia
There may be no difference between uterosacral colpopexy and
high levator myorrhaphy for this outcome (RR 1.31, 95%CI 0.50
to 3.39; 1 RCT, n = 228; Analysis 3.8)
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3.8.3 Pelvic organ prolapse/urinary incontinence sexual
questionnaire (PISQ)
No data were reported for this outcome.
3.9 Quality of life and satisfaction
There were no data in suitable format for analysis for this outcome.
3.10 Measures associated with surgery
3.10.1 Operating time
No data were reported for this outcome.
3.10.2 Length of hospital stay
No data were reported for this outcome.
3.10.3 Blood transfusion
There may be no difference between uterosacral and sacrospinous
colpopexy for this outcome (RR 1.67, 95% CI 0.50 to 5.60; 1
RCT, n = 315; Analysis 3.9).
4 Vaginal hysterectomy versus alternative surgery for
uterine prolapse
Vaginal hysterectomy versus abdominal hysterectomy was com-
pared in one trial Braun 2007.
Vaginal hysterectomy with vault support versus vaginal
sacrospinous hysteropexy (uterine preserving) was reported in
three trials Detollenaere 2015; Dietz 2010; Jeng 2005. Data from
the Jeng 2005 trial was not included in analysis as no anatomical
or peri-operative data were supplied.
Vaginal hysterectomy with vault support versus abdominal sacro-
hysteropexy (uterine preserving) was reported in two trials (
Rahmanou 2015; Roovers 2004). Roovers 2004 used an open ap-
proach and Rahmanou 2015 a laparoscopic approached was em-
ployed.
PRIMARY OUTCOMES
4.1 Awareness of prolapse:
1. No data were reported comparing vaginal and abdominal
hysterectomy.
2. There may be no difference between vaginal hysterectomy
and vaginal sacrospinous hysteropexy for this outcome (RR 0.98,
95% CI 0.33 to 2.94; 1 RCT, n = 208; low-quality evidence;
Analysis 4.1). These data suggest that if 6% of women were
aware of prolapse after sacrospinous hysteropexy, then 2% to
17% would be aware of prolapse after vaginal hysterectomy with
vault support.
3. Women who have vaginal hysterectomy may have lower
rates of awareness of prolapse than those who have
sacrohysteropexy (RR 0.38, 95% CI 0.15 to 0.98;1 RCT, n = 84,
low-quality evidence; Analysis 4.1). These data suggest that if
31% of women were aware of prolapse after sacrohysteropexy,
then 5% to 30% would be aware of prolapse after vaginal
hysterectomy with vault support.
4.2 Repeat surgery
4.2.1 Repeat surgery for prolapse
1. We are uncertain whether there is a difference between
vaginal and abdominal hysterectomy for repeat surgery for
prolapse (RR 2.88, 95% CI 0.12 to 67.29; 1 RCT, n = 47, very
low-quality evidence, Analysis 4.2.1)
2. There may be no difference between vaginal hysterectomy
with vault support and vaginal sacrospinous hysteropexy for
repeat surgery for prolapse (RR 1.31, 95% CI 0.19 to 8.91; 2
RCTs, n= 270; I2 = 51% low-quality evidence Analysis 4.2).
These data suggest that if 6.2% require repeat prolapse surgery
after sacrospinous hysteropexy, between 1.2% to 55.2% would
require prolapse surgery after vaginal hysterectomy with vault
support.
3. There may be no difference between vaginal hysterectomy
with vault support and abdominal sacrohysteropexy for repeat
surgery for prolapse (RR 0.68, 95% CI 0.36 to 1.31; 2 RCTs, n
= 182, I2 = 0%, low-quality evidence, Analysis 4.2). These data
suggest that if 21% of women require repeat prolapse surgery
after abdominal sacrohysteropexy, then 7% to 28% would
require prolapse surgery after vaginal hysterectomy with vault
support.
4.2.2 Repeat surgery for stress incontinence
1. No data were reported on the need for repeat surgery for
urinary incontinence for the comparison of vaginal versus
abdominal hysterectomy.
2. We are uncertain whether there is a difference between
vaginal hysterectomy with vault support and vaginal
sacrospinous hysteropexy with respect to the need for repeat
surgery for urinary incontinence (RR 4.00, 95% CI 0.45 to
35.18, 1 RCT, n = 204, very low-quality evidence, Analysis 4.8).
3. No data were reported on the need for repeat surgery for
urinary incontinence in the comparison of vaginal hysterectomy
with vault support versus abdominal sacrohysteropexy.
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4.3 Any recurrent prolapse
1. We are uncertain whether there is a difference between
vaginal and abdominal hysterectomy for any recurrent prolapse
(RR 4.80, 95% CI 0.24 to 94.90; 1 RCT, n = 47, very low-
quality evidence, Analysis 4.3).
2. There may be no difference between vaginal hysterectomy
with vault support and vaginal sacrospinous hysteropexy for any
recurrent prolapse (RR 0.90, 95% CI 0.67 to 1.21; 1 RCT, n =
204, low-quality evidence) These data suggest that if 49% of
women had any recurrent prolapse on examination after
sacrospinous hysteropexy, then 33% to 59% would have any
prolapse on examination after vaginal hysterectomy with apical
support.
3. No data were reported for any recurrent prolapse for the
comparison of vaginal hysterectomy with vault support versus
abdominal sacrohysteropexy.
SECONDARY OUTCOMES
4.4 Adverse events
4.4.1 Death (related to surgery)
No data were reported for this outcome.
4.4.2 Mesh exposure
1. We are uncertain whether there is a difference in the rate of
mesh exposure between vaginal and abdominal hysterectomy
(RR 0.32, 95% CI 0.01 to 7.48, 1 RCT, n = 47, Analysis 4.6).
2. We are uncertain whether there is a difference in the rate of
mesh exposure between vaginal hysterectomy with vault support
and abdominal sacrohysteropexy. (RR 0.20, 95% CI 0.01 to
4.04, 1 RCT, n = 82, Analysis 4.6).
4.4.3 Bladder injury
1. No data were reported on bladder injury for the
comparison of vaginal versus abdominal hysterectomy.
2. There were no events of bladder injury reported in a single
trial of 65 women comparing vaginal hysterectomy with vault
support versus vaginal sacrospinous hysteropexy (Analysis 4.4).
3. No data were reported on bladder injury for the
comparison of vaginal hysterectomy with vault support versus
abdominal sacrohysteropexy.
4.4.4 Bowel injury
1. No data were reported for bowel injury for the comparison
of vaginal versus abdominal hysterectomy.
2. There were no events of bowel injury reported in a single
trial of 66 women comparing vaginal hysterectomy with vault
support versus vaginal sacrospinous hysteropexy (Analysis 4.5).
3. We are uncertain whether there is a difference in the rate of
bowel injury between vaginal hysterectomy with vault support
and abdominal sacrohysteropexy (RR 3.00, 95% CI 0.13 to
71.56; 1 RCT, n = 82 Analysis 4.5).
4.4.5 Repeat surgery for mesh exposure
1. No data were reported on the need for repeat surgery for
mesh exposure for the comparison of vaginal and abdominal
hysterectomy.
2. No data were reported on the need for repeat surgery for
mesh exposure for the comparison of vaginal hysterectomy with
vault support versus vaginal sacrospinous hysteropexy.
3. We are uncertain whether there is a difference in the need
for repeat operation for mesh exposure between vaginal
hysterectomy with vault support versus abdominal
sacrohysteropexy (RR 0.20, 95% CI 0.01 to 4.04, 1 RCT, n =
82; Analysis 4.6).
4.5 Objective failure, by site
4.5.1 Objective failure of anterior vaginal compartment
1. There were no data reported for this outcome for the
comparison of vaginal versus abdominal hysterectomy.
2. For recurrent anterior wall prolapse (stage 2 or greater),
there may be no difference between vaginal hysterectomy with
vault support and vaginal sacrospinous hysteropexy (RR 0.95,
95% CI 0.53 to 1.70; 2 RCTs, n = 265; I2 = 78%; Analysis 4.9).
3. We are uncertain whether there is a difference between
vaginal hysterectomy with vault support and abdominal
sacrohysteropexy for this outcome (RR 1.04, 95% CI 0.60 to
1.82; 1 RCT, n = 83; Analysis 4.9).
4.5.2 Objective failure of apical compartment
1. There were no data comparing vaginal and abdominal
hysterectomy for this outcome.
2. There was no evidence of a difference between vaginal
hysterectomy with vault support and vaginal sacrospinous
hysteropexy (RR 0.80, 95% CI 0.04 to 17.59; 2 RCTs, n = 267;
I2 = 83% Analysis 4.10).
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3. We are uncertain whether there is a difference between
vaginal hysterectomy and sacrohysteropexy (RR 1.00, 95% CI
0.15 to 6.76; 1 RCT, n = 82; Analysis 4.10).
4.5.3 Objective failure of posterior vaginal compartment
1. There were no data comparing vaginal and abdominal
hysterectomy for this outcome.
2. When vaginal hysterectomy was compared with
sacrospinous hysteropexy, recurrent posterior wall prolapse (stage
2 or greater) was more likely in the hysterectomy group (18%:
23/130) than in the sacrospinous hysteropexy group (7%: 10/
135) (RR 2.43, 95% CI 1.22 to 4.87; 2 RCTs, n = 265; I2 =
16%, Analysis 4.11).
3. We are uncertain whether there is a difference between
vaginal hysterectomy with vault support and abdominal
sacrohysteropexy (RR 3.07, 95% CI 0.66 to 14.35; 1 RCT, n =
83; Analysis 4.11).
4.5.4 Pelvic organ prolapse quantification (POPQ) scores
1. Point Ba
i) There were no data comparing vaginal and abdominal
hysterectomy for this outcome.
ii) There was no evidence of a difference between vaginal
hysterectomy with vault support and vaginal sacrospinous
hysteropexy (MD 0.40; 95% CI -0.48 to 1.28, 1 RCT, n = 57;
Analysis 4.12).
iii) There may be no difference between vaginal
hysterectomy with vault support and abdominal
sacrohysteropexy (MD -0.30; 95% CI -0.65 to 0.05, 1 RCT, n =
208; Analysis 4.12).
2. Point Bp
i) There were no data comparing vaginal and abdominal
hysterectomy for this outcome.
ii) We are uncertain whether there is a difference between
vaginal hysterectomy with vault support and vaginal
sacrospinous hysteropexy (MD 0.20; 95% CI -0.45 to 0.85; 1
RCT, n = 57; Analysis 4.13).
iii) There may be no difference between vaginal
hysterectomy with vault support and abdominal
sacrohysteropexy (MD 0.10, 95% CI -0.14 to 0.34; 1 RCT, n =
208; Analysis 4.13).
3. Point C
i) There were no data comparing vaginal and abdominal
hysterectomy for this outcome.
ii) There were no data comparing vaginal hysterectomy
with vault support versus vaginal sacrospinous hysteropexy for
this outcome.
iii) There may be a difference between vaginal
hysterectomy and sacrohysteropexy in favour of sacrohysteropexy
(MD 0.80; 95% CI 0.27 to 1.33; 1 RCT, n = 208; Analysis
4.14).
4. Total vaginal length
i) There were no data comparing vaginal and abdominal
hysterectomy for this outcome.
ii) Vaginal hysterectomy with vault support may be
associated with a reduced total vaginal length compared with
vaginal sacrospinous hysteropexy (MD -0.98, 95% CI -1.86 to -
0.11; 2 RCTs, n = 265; I2 = 80%; random-effects model).
iii) There were no data comparing vaginal hysterectomy
with vault support versus abdominal sacrohysteropexy.
4.6 Bladder function
4.6.1 Stress urinary incontinence
No data were reported for this outcome.
4.6.2 de novo stress urinary incontinence
No data were reported for this outcome.
4.6.3 de novo urge incontinence
No data were reported for this outcome.
4.6.4 urinary voiding dysfunction
No data were reported for this outcome.
4.7 Bowel function
4.7.1 de novo faecal incontinence
No data were reported for this outcome.
4.7.2 de novo obstructed defecation
No data were reported for this outcome.
4.7.3 constipation
No data were reported for this outcome.
27Surgery for women with apical vaginal prolapse (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4.8 Sexual function
4.8.1 Dyspareunia
1. No data were reported comparing vaginal versus abdominal
hysterectomy.
2. We are uncertain whether there is a difference between
vaginal hysterectomy with vault support and vaginal sacrospinous
hysteropexy (RR 1.03, 95% CI 0.27 to 3.96; 1 RCT, n = 158;
Analysis 4.16). This suggests that if 5% of women experienced
dyspareunia after sacrospinous hysteropexy then between 1% to
20% would experience dyspareunia after vaginal hysterectomy.
3. No data were reported comparing vaginal hysterectomy
with vault support versus abdominal sacrohysteropexy.
4.8.2 de novo dyspareunia
No data were reported for this outcome.
4.8.3 Prolapse and Incontinence Sexual questionnaire (PISQ)
1. No data were reported comparing vaginal and abdominal
hysterectomy.
2. There may be no difference between vaginal hysterectomy
with vault support and vaginal sacrospinous hysteropexy (MD
0.00, 95% CI -1.23 to 1.23; 1 RCT, n = 208; Analysis 4.17).
3. No data were reported comparing vaginal hysterectomy and
sacrohysteropexy.
4.9 Quality of life and satisfaction
No data were reported for this outcome in the included studies or
data were not in a suitable format for analysis. Detollenaere 2015
provided mean and range data for Urogenital Distress Inventory
(UDI), Defecatory distress inventory (DDI), Incontinence im-
pact questionnaire (IIQ) and Short Form-36 9SF-36) and demon-
strated no evidence of a difference between the groups. Dietz 2010
also provided data on UDI and IIQ and demonstrated no differ-
ences between the groups.
4.10 Measures associated with surgery
4.10.1 Operating time (minutes)
1. No data were reported comparing vaginal and abdominal
hysterectomy.
2. Operating time may be longer for vaginal hysterectomy
with vault support compared to vaginal sacrospinous hysteropexy
(MD 13.00 minutes, 95% CI 8.26 to 17.74; 1 RCT, n = 207;
Analysis 4.18).
3. Operating time may be longer for vaginal hysterectomy
with vault support versus abdominal sacrohysteropexy (MD
10.00 minutes, 95% CI 8.20 to 11.80; 1 RCT, n = 83; Analysis
4.18).
4.10.2 Length of hospital stay (days)
1. No data were reported comparing vaginal and abdominal
hysterectomy.
2. There may be no difference between vaginal hysterectomy
with vault support and vaginal sacrospinous hysteropexy (MD
0.00, 95% CI -0.27 to 0.27; 1 RCT, n = 207; Analysis 4.19).
3. There may be no difference between vaginal hysterectomy
with vault support and abdominal sacrohysteropexy (MD -0.10,
95% CI -0.21 to 0.01; 1 RCT, n = 83; Analysis 4.19).
4.10.3 Blood transfusion
1. No data were reported comparing vaginal and abdominal
hysterectomy.
2. No data were reported comparing vaginal hysterectomy
with vault support and vaginal sacrospinous hysteropexy.
3. We are uncertain whether there is a difference between
vaginal hysterectomy with vault support and abdominal
sacrohysteropexy for the need for a blood transfusion (RR 2.00,
95% CI 0.19 to 21.21; 1 RCT, n = 82 Analysis 4.20 ).
5.0 Sacral colpopexy with mesh versus without
Two trials with 204 women compared different graft materials
utilised to suspend the vagina from the sacrum at sacral colpopexy.
Culligan 2005 compared polypropylene mesh (Trelex Boston)
with cadaveric fascia lata (Tutoplast, Mentor), and more recently
Culligan 2013 polypropylene mesh (Pelvitex, Bard) with acellular
collagen matrix porcine dermis (Pelvisoft, Bard). Both cadaveric
fascia and porcine dermis are classified as biological grafts
PRIMARY OUTCOMES
5.1 Awareness of prolapse
We are uncertain whether there is any difference between sacral
colpopexy with mesh (polypropylene mesh) compared with sacral
colpopexy without mesh (biological graft) (RR 0.33, 95%CI 0.04
to 3.02; 1 RCT, n= 58; very low-quality evidence Analysis 5.1).
These data suggest that if 10% of women were aware of prolapse
after sacral colpopexy without mesh, then 0% to 31% would be
aware of prolapse after sacral colpopexywithmesh.Caution should
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be taken in interpreting the results due to wide confidence inter-
vals, small sample size and low event rates suggestive of impreci-
sion.
5.2 Repeat surgery
5.2.1 Repeat surgery for prolapse
There may be no difference between sacral colpopexy with mesh
(polypropylene mesh) compared with sacral colpopexy without
mesh (biological graft) (RR 1.00, 95% CI 0.07 to 15.24; 2 RCTs,
n = 173; I2 = 0% low-quality evidence, Analysis 5.2. The trial by
Culligan 2013 reported no events in either the intervention or the
control group. The data suggest that if 2% of women required re-
peat prolapse surgery after sacral colpopexy without mesh (biolog-
ical graft), then 0% to 26% would require repeat prolapse surgery
after sacral colpopexy with mesh.
5.2.2 Repeat surgery for stress urinary incontinence (SUI)
There was no evidence of a difference between sacral colpopexy
with mesh and without for repeat surgery for SUI (RR 3.00, 95%
CI 0.13 to 70.74; 1 RCT, n = 58; Analysis 5.3).
5.2.3 Repeat surgery for prolapse, stress urinary incontinence,
or mesh exposure (composite outcome)
No data were reported for this outcome.
5.3 Any recurrent prolapse
There may be no difference between the sacral colpopexy with
mesh and without mesh (RR 0.49, 99% CI 0.20 to 1.25; 2 RCTs,
n = 173; I2 = 48%, low-quality evidence Analysis 5.4). These
data suggest that if 25% of women have any recurrent prolapse
after sacral colpopexy without mesh (biological graft), then 6% to
25% would have recurrent prolapse on examination after sacral
colpopexy with mesh.
SECONDARY OUTCOMES
5.4 Adverse effects
5.4.1 Death (related to surgery)
No data were reported for this outcome.
5.4.2 Mesh exposure
There may be no difference between sacral colpopexy with mesh
(polypropylenemesh) orwithoutmesh (biological graft) (RR2.35,
95% CI 0.36 to 15.40; 2 RCTs, n = 173; I2 = 0% Analysis
5.5). Caution should be taken in interpreting the results due to
wide confidence intervals, small sample size and low event rates
suggestive of imprecision.
5.4.3 Bladder injury
There may be no difference between sacral colpopexy with mesh
(polypropylene mesh) or without mesh (biological graft) for this
outcome (RR 2.51, 95% CI 0.10 to 60.13; 2 RCTs, n = 224; I
2 = 0% low-quality evidence Analysis 5.6). The Culligan 2013
trial reported no events in either the intervention or the control
group. Caution should be taken in interpreting the results due to
wide confidence intervals, small sample size and low event rates
suggestive of imprecision.
5.4.4 Bowel injury
No events reported in a single study (0/113) Analysis 5.7.
5.4.5 Repeat surgery for mesh exposure
There may be no difference between sacral colpopexy with mesh
(polypropylenemesh) orwithoutmesh (biological graft) (RR2.00,
95% CI 0.19 to 20.86; 2 RCTs, n = 173; I2 = 0%, Analysis 5.8)
Caution should be taken in interpreting the results due to wide
confidence intervals, small sample size and low event rates sugges-
tive of imprecision.
5.5 Objective failure by site
5.5.1 Objective failure of anterior vaginal compartment
No data were available.
5.5.2 Objective failure of apical compartment
No data were available.
5.5.3 Objective failure of posterior vaginal compartment
No data were available.
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5.5.4 Pelvic organ prolapse quantification scores
1. Point Ba: we are uncertain whether there is a difference
between sacral colpopexy with mesh (polypropylene mesh) or
without mesh (biological graft) (MD 0.80, 95% CI 0.20 to 1.40,
1 RCT, n = 58; Analysis 5.10).
2. Point Bp: we are uncertain whether there is a difference
between sacral colpopexy with mesh (polypropylene mesh) or
without mesh (biological graft) (MD -0.20, 95% CI -0.51 to
0.11, 1 RCT, n = 58, Analysis 5.10).
3. Point C: we are uncertain whether there is a difference
between sacral colpopexy with mesh (polypropylene mesh) or
without mesh (biological graft) (MD 0.31, 95% CI -0.41 to
1.03, 1 RCT, n = 58, Analysis 5.10). No events of recurrent
apical prolapse were reported between polypropylene mesh in
one trial (0/103) and biological graft (0/101).
4. Total vaginal length: we are uncertain whether there is a
difference between sacral colpopexy with mesh (polypropylene
mesh) or without mesh (biological graft) (MD -0.10 , 95% CI -
0.69 to 0.49, 1 RCT, n = 58; Analysis 5.10).
5.6 Bladder function
5.6.1 stress urinary incontinence
No data were reported for this outcome.
5.7 Quality of life
There may be no difference between the groups for quality of life
measured by the pelvic floor impact questionnaire (PFIQ-7) (MD
-7.00, 95% CI -29.48 to 15.48; 1 RCT, n = 115; I2 = 0%) or the
pelvic floor distress inventory (PFDI-20) (MD -6.00, 95% CI -
25.75 to 13.75; 1 RCT, n = 115; I2 = 0%, Analysis 5.13).
5.8 Measures associated with surgery
Operating time
There may be no difference between the groups in operating time
(MD -6.00, 95% CI -31.51 to 19.51; 1 RCT, n = 100; I2 = 0%)
Analysis 5.14
6.0 Sacral colpopexy: laparoscopic versus other
Sacral colpopexy can be performed with an abdominal incision
(ASC), laparoscopically (LSC) or robotically (RSC). Two trials
(Costantini 2013; Freeman 2013) compared ASC and LSC and
two (Anger 2014; Paraiso 2011) compared LSC and RSC.
PRIMARY OUTCOMES
6.1 Awareness of prolapse
No data were reported for this outcome.
6.2 Repeat surgery for prolapse
1. 6.2.1 There may be no difference between laparoscopic and
abdominal (open) sacral colpopexy for this outcome (RR 1.04,
95% CI 0.16 to 6.80; 1 RCT, n = 47; low-quality evidence;
Analysis 6.1). The data suggest that if 8% of women require
repeat prolapse surgery after abdominal (open) approach, then
1% to 56% would require repeat prolapse surgery after
laparoscopic sacral colpopexy. No data were reported for
laparoscopic versus robotic sacral colpopexy.
2. 6.2.2 Surgery for stress incontinence - No data were
reported for this outcome.
3. 6.2.3 Surgery for prolapse, stress urinary incontinence, or
mesh exposure (composite outcome) - no data were reported for
this outcome.
6.3 Any recurrent prolapse
We are uncertain whether there is any difference between laparo-
scopic and other interventions for sacral colpopexy (abdominal
and robotic) for this outcome (RR 0.87; 95%CI 0.25 to 3.06; 2
RCTs, n = 96; very low-quality evidence; Analysis 6.2). These data
suggest that if 9% of women have any recurrent prolapse on ex-
amination after open or robotic interventions for sacral colpopexy,
between 2% and 27% would have recurrent prolapse on exami-
nation following laparoscopic sacral colpopexy.
SECONDARY OUTCOMES
6.4 Adverse effects
6.4.1 Death (related to surgery)
No data were reported for this outcome.
6.4.2 Mesh exposure
We are uncertain whether there is any difference between laparo-
scopic and other interventions for sacral colpopexy for this out-
come (RR 0.22, 95% CI 0.01 to 4.40; 3 RCTs, n = 186; I2 =
0%, Analysis 6.3). No events of mesh exposure were reported in
laparoscopic versus abdominal (open) sacral colpopexy (Freeman
2013). Caution is advised in interpreting the results due to wide
30Surgery for women with apical vaginal prolapse (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
confidence intervals, small sample size and low event rates that
suggest imprecision.
6.4.3 Bladder injury
We are uncertain whether there is any difference between laparo-
scopic and abdominal or robotic interventions for sacral colpopexy
for this outcome (RR 1.75, 95% CI 0.43 to 7.14, 3 RCTs, n =
199; I2 = 0%; Analysis 6.4). Caution is advised in interpreting the
results due to wide confidence intervals, small sample size and low
event rates that suggest imprecision. The data suggest that if 2%
of women had bladder injury following abdominal or robotic in-
terventions then between 1% to 14% would have a bladder injury
following a laparoscopic intervention.
6.4.4 Bowel injury
There was no evidence of a difference between laparoscopic and
other interventions (abdominal or robotic) for sacral colpopexy
(RR 0.36, 95% CI 0.04 to 3.32; 2 RCTs, n = 108; I2 = 0%;
Analysis 6.5).
6.4.5 Repeat surgery for mesh exposure
No data were reported for this outcome. Caution is advised in
interpreting the results due to wide confidence intervals, small
sample size and low event rates that suggest imprecision.
6.5 Objective failure, by site
6.5.1 Objective failure of anterior vaginal compartment
No data were available.
6.5.2 Objective failure of apical compartment
No data were available.
6.5.3 Objective failure of posterior vaginal compartment
No data were available.
6.5.4 Pelvic organ prolapse quantification scores
1. Point Ba - Data from one trial found no evidence of a
difference for this outcome between laparoscopic and robotic
interventions for sacral colpopexy (MD 0.05; 95% CI -0.31 to
0.41; 1 RCT, n = 78; Analysis 6.6).
2. Point BP was more supported in the laparoscopic sacral
colpopexy group than open or robotic interventions (MD -0.40,
95% CI -0.76 to -0.05; 2 RCTs, n = 125; I2 = 0%; Analysis 6.7).
3. Point C - There was no evidence of a difference between
laparoscopic and open or abdominal interventions for sacral
colpopexy (MD 0.15, 95% CI -0.52 to 0.83; 3 RCTs, n = 197; I
2 = 0%; Analysis 6.8).
4. Total vaginal length - No data were reported for this
outcome.
6.6 Bladder function
6.6.1 Stress urinary incontinence
We are uncertain whether there is a difference between a laparo-
scopic versus a robotic intervention for this outcome (RR 1.63
95%CI 0.29, 9.18, 1 RCT, n = 73; Analysis 6.9; moderate-quality
evidence).
6.6.2 de novo stress urinary incontinence
No data were reported for this outcome.
6.6.3 de novo urge incontinence
No data were reported for this outcome.
6.6.4 urinary voiding dysfunction
No data were reported for this outcome.
6.7 Bowel function
6.7.1 de novo faecal incontinence
No data were reported for this outcome.
6.7.2 de novo obstructed defecation
No data were reported for this outcome.
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6.7.3 constipation
No data were reported for this outcome.
6.8 Sexual function
6.8.1 Dyspareunia
No data were reported for this outcome.
6.8.2 de novo dyspareunia
No data were reported for this outcome.
6.8.3 Pelvic organ prolapse/ urinary incontinence sexual
questionnaire (PISQ)
No data were reported for this outcome.
6.9 Quality of life and satisfaction
6.9.1 Patient Global Impression of Improvement
questionnaire
No data were reported for this outcome.
6.9.2 Prolapse quality of life (PQoL)
We are uncertain whether there is a difference in scores between a
laparoscopic and an open intervention for sacral colpopexy (MD
0.70, 95% CI -19.14 to 20.54; 1 RCT, n = 47; Analysis 6.10).
6.9.3 Pelvic floor impact questionnaire (PFIQ-7)
We are uncertain whether there is a difference in scores between a
laparoscopic and a robotic intervention for sacral colpopexy (MD
21.00, 95% CI -46.76 to 88.76; 1 RCT, n = 78; Analysis 6.10).
6.9.4 Pelvic floor distress inventory (PFDI-20)
We are uncertain whether there is a difference in scores between a
laparoscopic and a robotic intervention for sacral colpopexy (MD
21.00, 95% CI -46.76 to 88.76; 1 RCT, n = 78; Analysis 6.10).
6.10 Measures associated with surgery
6.10.1 Operating time
We are uncertain whether there is a difference in operating time
between laparoscopic and open or robotic interventions for sacral
colpopexy (MD-12.30minutes, 95%CI -52.65 to 28.05; 4 RCTs,
n = 265; I2 = 92%; Analysis 6.11). In order to try and explain
the high heterogeneity we looked at the comparison groups. The
operating time was longer in the laparoscopic group compared
to the abdominal (open) intervention group (MD 19.93, 95%
CI 2.42 to 37.45; 2 RCTs, n = 120; studies = 2; I2 = 17%;
Analysis 6.11). The operating time was less in the laparoscopic
group compared to the robotic group (random-effectsMD -45.27,
95% CI -85.45 to -5.09; 2 RCTs; n = 145, I2 = 85%; Analysis
6.11). Caution is required when interpreting the results due to the
heterogeneity and small sample size.
6.10.2 Length of hospital stay
Laparoscopic surgerywas associatedwith a decreased length of hos-
pital stay compared with open or robotic interventions for sacral
colpopexy (random-effects MD -0.99 days, 95% CI -1.85 to -
0.14; 3 RCTS, n = 194; I2 = 87%; Analysis 6.12). We tried to ex-
plain the heterogeneity by looking at the treatment subgroups. La-
paroscopic sacral colpopexy was associated with a decreased length
of hospital stay compared with an open interventions (random-
effects model MD -1.35, 95%CI -2.12 to -0.57; 2 RCTs, n = 126;
I2 = 67%; Analysis 6.12). There was no evidence of a difference
between groups when the laparoscopic intervention was compared
with a robotic intervention (MD -0.39, 95% CI -0.81 to 0.03; 1
RCT, n = 68; Analysis 6.12).
6.10.3 Blood transfusion
The Anger 2014 trial reported no events following either laparo-
scopic or robotic sacral colpopexy (Analysis 6.13).
7. Sacral colpopexy with continence surgery versus
without
Four trials evaluated the efficacy of performing continence surgery
at the same time of sacral colpopexy (Brubaker 2008; Costantini
2007; Costantini 2008; Trabuco 2014). Three trials compared
surgery with and without colposuspension (Brubaker 2008;
Costantini 2007; Costantini 2008) and Trabuco 2014 com-
pared colposuspension with mid-urethral sling at time of sacral
colpopexy. In Brubaker 2008 and Costantini 2007, the women
had prolapse and were continent and in the Costantini 2008 and
Trabuco 2014 trials, prolapse and SUI were the inclusion criteria.
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Two trials (Brubaker 2008; Costantini 2007) provided long-term
outcome data: Nygaard 2013 reported seven-year results for the
Brubaker 2008 trial and Costantini 2011 reported eight-year out-
comes for the Costantini 2007 trial .
PRIMARY OUTCOMES
7.1 Awareness of prolapse (seven years)
There may be no difference between sacral colpopexy with col-
posuspension 37% (27/73) as compared to 31% (22/71) sacral
colpopexy without colposuspension (RR 1.19, 95% CI 0.75 to
1.89; 1 RCT, n = 144; Analysis 7.1). No data were reported
for sacral colpopexy with colposuspension versus sacral colpopexy
with mid-urethral sling.
7.2 Repeat surgery (two to eight years)
7.2.1 Repeat surgery for prolapse (pessary or surgery)
There may be no difference between sacral colpopexy with and
sacral colpopexy without colposuspension (RR 0.71, 95%CI 0.24
to 2.15; 3 RCTs, n = 256; I2 = 0%; Analysis 7.2). Two of the trials
(Costantini 2007; Costantini 2008) reported no events in either
group.Nodatawere reported for this outcome for sacral colpopexy
with colposuspension versus sacral colpopexy with mid-urethral
sling.
7.2.2 Repeat surgery for stress incontinence (seven years)
There may be no difference between sacral colpopexy with and
sacral colpopexy without colposuspension (RR 1.42, 95%CI 0.47
to 4.30; 1 RCT, n = 183; Analysis 7.3). No data were available
for sacral colpopexy with colposuspension versus sacral colpopexy
with mid-urethral sling.
7.3 Any recurrent prolapse (stage 2 or more: seven-year
review)
There may be no difference between sacral colpopexy with col-
posuspension and sacral colpopexy without colposuspension (RR
1.20, 95% CI 0.69 to 2.10; 1 RCT, n = 70; Analysis 7.4). No data
were reported for sacral colpopexy with colposuspension versus
sacral colpopexy with mid-urethral sling.
SECONDARY OUTCOMES
7.4 Adverse effects
7.4.1 Death (related to surgery)
No data were reported for this outcome.
7.4.2 Mesh exposure
No data were reported for this outcome.
7.4.3 Bladder injury
No data were reported for this outcome.
7.4.4 Bowel injury
No data were reported for this outcome.
7.4.5 Repeat surgery for mesh exposure
No data were reported for this outcome.
7.5 Objective failure by site
7.5.1 Objective failure of anterior vaginal compartment
No data were available.
7.5.2 Objective failure of apical compartment
No data were available.
7.5.3 Objective failure of posterior vaginal compartment
No data were available.
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7.5.4 Pelvic organ prolapse quantification scores
1. Point Ba (two-year) - Point Ba was better supported in
sacral colpopexy with colposuspension compared to sacral
colpopexy without colposuspension (MD -0.40, 95% CI -0.62
to -0.18; 1 RCT, n = 322; Analysis 7.5).
2. Point Bp (two-year) - Point Bp had less support in the
sacral colpopexy with colposuspension as compared to sacral
colpopexy without colposuspension (MD 0.30, 95% CI 0.11 to
0.49; 1 RCT, n = 322; Analysis 7.6).
3. Point C (two-year) -there was no evidence of a difference
for sacral colpopexy with or without colposuspension (MD 0.20,
95% CI -0.11 to 0.51; 1 RCT, n = 322; Analysis 7.7).
4. Total vaginal length - no data were reported for this
outcome.
7.6 Bladder function
7.6.1 Stress urinary incontinence (four to seven years)
There may be no difference between sacral colpopexy with and
without colposuspension: (random-effects RR 1.13, 95% CI 0.63
to 2.04; 3 RCTs, n = 295; I2 = 70% Analysis 7.8). No data were
reported for sacral colpopexy with colposuspension versus sacral
colpopexy with mid-urethral sling.
7.6.2 De novo stress urinary incontinence
No data were reported for this outcome.
7.6.3 De novo bladder overactivity or urge incontinence
No data were reported for this outcome.
7.6.4 Urinary voiding dysfunction
No data were reported for this outcome.
7.7 Bowel function
7.7.1 De novo faecal incontinence
No data were reported for this outcome.
7.7.2 De novo obstructed defecation
No data were reported for this outcome.
7.7.3 Constipation
No data were reported for this outcome.
7.8 Sexual function
7.8.1 dyspareunia
No data were reported for this outcome.
7.8.2 de novo dyspareunia
No data were reported for this outcome.
7.8.3 Prolapse and Incontinence Sexual Questionnaire
No data were reported for this outcome.
7.9 Quality of life and satisfaction measured by questionnaire
7.9.1 Patient Global Impression of Improvement
questionnaire
No data were reported for this outcome.
7.9.2 Prolapse quality of life (PQoL)
No data were reported for this outcome.
7.9.3 Pelvic floor impact questionnaire (PFIQ-7)
No data were reported for this outcome.
7.9.4 Pelvic floor distress inventory (PFDI-20)
No data were reported for this outcome.
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7.10 Measures associated with surgery
7.10.1 Operating time
Sacral colpopexy with colposuspension was associated with a
longer operating time than sacral colpopexy without colposuspen-
sion (MD 20.00 minutes; 95% CI 7.44 to 32.56; 1 RCT; n = 322;
Analysis 7.9).
7.10.2 Length of hospital stay
No data were reported for this outcome.
7.10.3 Blood transfusion
We are uncertain whether there is a difference between sacral
colpopexy with and sacral colpopexy without colposuspension for
this outcome (RR 0.94, 95% CI 0.20 to 4.33; 1 RCT, n = 66;
Analysis 7.10). No data were reported for sacral colpopexy with
colposuspension versus sacral colpopexy with mid-urethral sling.
Other analyses
We were unable to conduct our planned assessment of reporting
bias or our planned sensitivity analyses, as there were insufficient
studies in any one comparison to permit meaningful analysis.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Vaginal mesh compared with no vaginal mesh for women with apical vaginal prolapse
Patient or population: Women with apical vaginal prolapse
Setting: Inpat ient
Intervention: Vaginal mesh
Comparison: No vaginal mesh (vaginal colpopexy)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Vaginal colpopexy Vaginal mesh
Awareness of prolapse
(3 years)
179 per 1000 193 per 1000
(63 to 589)
RR 1.08
(0.35 to 3.30)
54
(1 study)
⊕©©©
low4
Repeat surgery for pro-
lapse (1 to 3 years)
42 per 1000 29 per 1000
(13 to 67)
RR 0.69
(0.3 to 1.60)
497
(5 studies)
⊕©©©
low1,2
Repeat surgery for stress
urinary incontinence
(2 years)
19 per 1000 94 per 1000
(17 to 536)
RR 4.91
(0.86 to 27.94)
220
(2 studies)
⊕©©©
low4
Recurrent prolapse on ex-
amination (1-3 years)
615 per 1000 222 per 1000
(55 to 862)
0.36
(0.09 to 1.40)
269
(3 studies)
⊕©©©
low2,3
Bladder injury 13 per 1000 38 per 1000
(11 to 124)
RR 3.00
(0.91 to 9.89)
445
(4 studies)
⊕©©©
very low1,2
Stress urinary incontinence
(de novo 1 to 3 years)
219 per 1000 300 per 1000
(206 to 436)
RR 1.37
(0.94 to 1.99)
295
(4 studies)
⊕⊕⊕©
moderate2
Dyspareunia (1 to 3 years) 31 per 1000 39 per 1000
(18 to 86)
RR 1.21
(0.55 to 2.66)
501
(5 studies)
⊕⊕⊕©
moderate2
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* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Imprecision: wide conf idence intervals crossing the line of no ef fect; small sample size and low event rates: downgraded
one level
2Risk of bias: Allocat ion concealment poorly reported in majority of studies: downgraded one level
3 Inconsistency: Very high stat ist ical heterogeneity: I2 91%, downgraded one level
4 Imprecision: wide conf idence intervals crossing the line of no ef fect; very small sample size and very low event rates:
downgraded two levels
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D I S C U S S I O N
Summary of main results
There is an increasing volume of data available on trials relating
to apical (uterine and vault or post-hysterectomy) prolapse.
Vaginal procedure versus sacral colpopexy
Sacral colpopexy is associated with lower risk of awareness of
prolapse, any recurrent prolapse on examination, repeat surgery
for prolapse, postoperative stress urinary incontinence (SUI)
and dyspareunia than a variety of vaginal interventions (vagi-
nal sacrospinous colpopexy, uterosacral colpopexy and transvagi-
nal mesh) for apical prolapse with a longer operating time be-
ing the only disadvantage (Summary of findings for the main
comparison). While these trials demonstrate significant advan-
tages of sacral colpopexy over vaginal-based interventions for api-
cal prolapse the reader should be aware of the following points.
Firstly, although data were available for bowel outcomes they were
too few to provide sufficiently precise estimates to identify or rule
out clinically important differences. Secondly, these data relate pri-
marily to post-hysterectomy apical prolapse and finally, that not
all women will be suitable for sacral colpopexy but may be suitable
to undergo vaginal-based interventions.
Route of sacral colpopexy
Four trials compared access route of sacral colpopexy and impor-
tantly, in short- term results demonstrated equal anatomical out-
comes between the open, laparoscopic and robotic approaches to
sacral colpopexy The laparoscopic approach was associated with
a longer operating time and reduced blood loss as compared to
the open approach with similar admission time. When compar-
ing the laparoscopic and robotic approaches the laparoscopic ap-
proach was associated with reduced operating times with no other
differences detected.
Vaginal surgery with mesh versus without mesh
Six randomised controlled trials (RCTs) compared vaginal na-
tive tissue repairs with transvaginal polypropylene mesh for apical
prolapse and demonstrated no significant differences between the
groups except that the rate of mesh exposure after transvaginal
mesh was 18% and surgery for mesh exposure was required in
9.5%. No patients in the six trials that evaluated transvaginal mesh
underwent surgery for any other reason than the management of
mesh exposure. No trials performed a cost-analysis.
Vaginal hysterectomy versus uterine preserving surgery
No clear conclusion can be reached from the available data on
the efficacy or otherwise of uterine preserving surgery versus vagi-
nal hysterectomy for uterine prolapse as there was significant dis-
parity between interventions and outcome data supplied by the
five trials (Detollenaere 2015; Dietz 2010; Jeng 2005, Rahmanou
2015; Roovers 2004).When comparing vaginal hysterectomy and
sacrospinous hysteropexy the early anatomic data appears equal
between the two groups (Detollenaere 2015;Dietz 2010) and peri-
operative outcomes including decreased operating time, blood loss
and recovery time were seen in the hysteropexy group in one trial
(Dietz 2010). Two trials compared vaginal hysterectomy with ab-
dominal uterine suspending surgeries. Roovers 2004 reported at
eight-year review a reduced awareness of prolapse in the vaginal
hysterectomy group as compared to abdominal sacrohysteropexy.
No difference was detected in apical compartment prolapse or re-
operation for prolapse between the groups.
Choice of graft at sacral colpopexy
Finally, two trials compared polypropylene mesh with alternative
graft materials at sacral colpopexy. The polypropylene had supe-
rior anatomical outcomes when compared with cadaveric fascia at
the five-year review. However at one-year review no difference in
outcomes was seen when compared with acellular porcine dermis
at one year. Further evaluation of different graft materials at the
time of sacral colpopexy is required.
These findings raise an interesting dilemma for clinicians when
counselling women regarding choice of surgical intervention.
These data are supportive of sacral colpopexy as the procedure
of choice for post-hysterectomy prolapse in those suitable for the
intervention. The laparoscopic access has small peri-operative ad-
vantages over both the open and robotic approach based on lim-
ited data. However, uterine prolapse is much more common than
vault prolapse and as many clinicians are reluctant to perform hys-
terectomy at the time of sacral colpopexy due to higher rates of
mesh exposure following sacral colpopexywith hysterectomy as ap-
posed to sacral colpopexy performed post-hysterectomy (Gutman
2013), the management of uterine prolapse remains a challenging
problem. The data comparing traditional vaginal hysterectomy
with vault suspending procedures to either vaginal sacrospinous
hysteropexy or abdominal sacrohysteropexy are relatively limited,
however, vaginal hysterectomy is generally a longer intervention.
Significant further well-conducted trials are required for the man-
agement of uterine prolapse.
In those not suitable for sacral colpopexy and in those with uter-
ine prolapse, we were unable to detect an advantage to utilis-
ing transvaginal mesh as compared to vaginal colpopexy, and the
transvaginal mesh was associated with a one in 10 risk of a sub-
sequent surgical intervention for the management of mesh expo-
sure. All the transvaginal mesh kits that have been evaluated in this
review have been voluntarily removed from the market following
transvaginal mesh alert issued by the American Food and Drug
Administration (FDA 2011). The principal concern raised by the
FDA related to vaginal pain and dyspareunia that accounted for
36% of adverse events reported to the FDA . These concerns have
not been realised in this analysis with the rate of dyspareunia and
sexual function scores on the validated Pelvic organ prolapse/uri-
nary Incontinence Sexual Questionnaire (PISQ) being the same
between native tissue and transvaginal mesh interventions. There
were no reports of mesh being removed in any of these trials except
for the management of mesh exposure.
Newer lighter weight transvaginal mesh kits are currently available
for the surgical management of apical vaginal prolapse, however
to date, these have not been reviewed under the auspices of a ran-
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domised controlled trial. Further rigorous evaluation of transvagi-
nal mesh procedures compared with native tissue vaginal surgery
and sacral colpopexy are required specifically in the management
of uterine prolapse. Further evaluation of newer graft material at
time of sacral colpopexy are required as is long-term outcome data
on the route of sacral colpopexy.
Overall completeness and applicability of
evidence
Although 30 trials are available for review on apical prolapse, due
to very significant heterogeneity in study methodology and inter-
ventions undertaken, further trials are required in most areas of
apical prolapse with the exception of sacrospinous colpopexy ver-
sus transvaginal mesh.
All trials reported in the last four years included a consort flow
diagramand all trials reported some formof objective assessment of
apical vaginal support, however site-specific outcomes are available
in 18 trials Anger 2014; Barber 2014; Benson 1996; Brubaker
2008; Culligan 2005; Culligan 2013; da Silviera 2015; de Tayrac
2008; Detollenaere 2015; Dietz 2010; Iglesia 2010; Maher 2004;
Maher 2011; Meschia 2004a; Natale 2010; Rahmanou 2015;
Rondini 2015; Svabik 2014.
Two trials (Anger 2014; Detollenaere 2015), reported median fol-
low-up of less than one year. Two-year results were reported in
six studies (Barber 2014; Benson 1996; Braun 2007; Lo 1998;
Maher 2004; Maher 2011); three-year outcomes in three stud-
ies (Costantini 2007; Iglesia 2010; Rondini 2015), and three tri-
als reported outcomes at greater than five years (Brubaker 2008,
Culligan 2005, Roovers 2004). A number of trials remain reported
only as abstracts (Braun 2007; Costantini 2013; Detollenaere
2015; Lim 2012; Trabuco 2014).
Thirteen trials adequately described the randomisationprocess and
confirmed that secure concealment of the randomisation process
was used, for example allocation by a remote person or sealed en-
velopes (Anger 2014; Barber 2014; Benson 1996; Brubaker 2008;
Costantini 2008; Culligan 2005; Culligan 2013, Dietz 2010;
Iglesia 2010; Maher 2004; Maher 2011; Rondini 2015; Roovers
2004). Blinding of participants and assessors is impossible when
different routes of access were utilised including vagina versus ab-
dominal or open versus laparoscopic access for abdominal pro-
cedures. Blinding of patients and the postoperative assessor were
performed in five trials (Barber 2014; Brubaker 2008; Culligan
2005; Iglesia 2010; Paraiso 2011).
Generally, the reporting of the impact of surgery on bladder and
sexual function is improving, however significant variation exists
in the trialist’s choice of outcome measures. Validated pelvic floor
quality of life outcomes are generally included in recent trials and
reported with data suitable for meta-analysis (mean and standard
deviation) Anger 2014; Barber 2014; Brubaker 2008; Culligan
2005; Culligan 2013; da Silviera 2015; Detollenaere 2015; Dietz
2010; Freeman 2013; Halaska 2012; Iglesia 2010; Maher 2011;
Natale 2010; Rahmanou 2015; Rondini 2015; Roovers 2004;
Svabik 2014
Trials on all aspects on uterine prolapse are urgently required in-
cluding different routes of hysterectomy and uterine preservation
and comparisons between uterine preservation and hysterectomy.
Furthermore, trials comparing all aspects of sacral colpopexy in-
cluding different access routes, grafts utilised and role of con-
comitant surgery, including interventions for continence, poste-
rior compartment prolapse and rectal prolapse. Cost outcomes
were reported in five trials (Anger 2014; Benson 1996; Maher
2004; Maher 2011; Paraiso 2011), although significant variation
exists in the cost-analysis reported.
Quality of the evidence
The quality of the reporting is generally improving with the ran-
domisation process being well-reported and reporting of flow dia-
grams, allocation concealment and methods of blinding of partic-
ipants and reviewers also improving. Most recent trials are includ-
ing validated pelvic questionnaires, however there is significant
variation in the questionnaires utilised, which limit the ability for
meta-analysis. All trials should include a cost-analysis.
The quality of evidence was largely moderate (dyspareunia
was low) for comparisons of vaginal interventions versus sacral
colpopexy (Summary of findings for the main comparison).
The quality of evidence ranged fromvery low tomoderate for com-
parisons of vaginal interventionswith andwithoutmesh Summary
of findings 2).
The quality of evidence ranged from low to moderate for com-
parisons of one vaginal native tissue repair versus another native
tissue repair.
The quality of the evidence ranged from low to very low for
comparisons of vaginal hysterectomy versus alternatives, mesh or
biological graft at sacral colpopexy, laparoscopic access at sacral
colpopexy versus open or robotic access and sacral colpopexy with
versus without continence surgery.
The main reasons for downgrading the quality of the evidence
were imprecision, inconsistency and lack of information to be able
to judge ’Risk of bias’ domains.
Potential biases in the review process
The author of the review was also first author in two of the 30
trials included in the review. Any possible bias is mitigated in
the methodology process as two review authors assessed each trial
and checked each data entry. Systematic searches of the literature
for published and unpublished trials was rigorous and we do not
believe that any publications have been omitted.
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Agreements and disagreements with other
studies or reviews
Two recent reviews Barber 2013; Siddiqui 2015 evaluated topics
relating to apical compartment prolapse that are included in our
review. Barber evaluated all levels of evidence and reported similar
outcomes to our review when evaluating sacral colpopexy and
vaginal-based procedures. The review did not evaluate different
graft and access techniques that are included in this review.
A second systematic review Siddiqui 2015 evaluated sacral
colpopexy and native tissue vaginal repairs, which was an impor-
tant aspect of our review. The Siddiqui 2015 review was quite dif-
ferent methodologically compared to our review with both ran-
domised and non randomised published trials included for pri-
mary outcomes (anatomical outcomes, re-operation rate) with
meta-analysis only performed if outcome data were reported in
three or more trials. Adverse events data were retrieved from
non-comparative studies. The authors concluded similarly to our-
selves that improved anatomic outcomes were obtained in sacral
colpopexy as compared to vaginal native tissue repairs. They were
not able to detect any other differences between the groups in
other primary outcomes, which is not unexpected as meta-anal-
ysis was not performed unless three or more trials included out-
come data. They also determined from non-comparative studies
that complications including ileus or small bowel obstruction and
thromboembolic events were more frequent following the sacral
colpopexy intervention as compared to native tissue groups.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Sacral colpopexy is associated with a lower risk of awareness of
prolapse, any recurrent prolapse on examination, repeat surgery
for prolapse, postoperative stress urinary incontinence (SUI)
and dyspareunia than a variety of vaginal interventions (vagi-
nal sacrospinous colpopexy, uterosacral colpopexy and transvagi-
nal mesh) for apical prolapse with a longer operating time be-
ing the only disadvantage (Summary of findings for the main
comparison). However, the reader should also be aware that most
of these data related to post-hysterectomy prolapse and that in
some cases due to medical and or surgical co-morbidities the vagi-
nal approach maybe more appropriate. The data were not conclu-
sive on the preferred route of sacral colpopexy.
The native tissue vaginal repairs had similar rates of awareness of
prolapse, any recurrent prolapse on examination, repeat surgery
for prolapse, dyspareunia and SUI when compared to transvagi-
nal mesh procedures for apical vaginal prolapse. However the
transvaginal mesh was associated with higher rates of cystotomy,
and significant rates of mesh exposure and surgery for mesh ex-
posure. Most of the evaluated transvaginal apical mesh products
have been removed from the market and the newer lighter mesh
products have not been evaluated in a randomised controlled trial
(RCT). The implication for clinical practice is that while the newer
mesh products may be as anatomically beneficial with a lower
complication rate than their preceding mesh products, this has
not been rigorously evaluated and these products should be used
cautiously until level one comparative data become available.
The evidence was not conclusive when comparing different access
routes for sacral colpopexy.
No clear conclusion can be reached from the available data on the
efficacy or otherwise of uterine preserving surgery versus vaginal
hysterectomy for uterine prolapse.
Implications for research
Significant further research is required in all areas of apical pro-
lapse. The surgical management of women with uterine prolapse
needs urgent attention including but not limited to:
1. vaginal hysterectomy and apical suspension versus
abdominal (minimally invasive, subtotal) hysterectomy and
apical suspension;
2. vaginal hysteropexy versus abdominal hysteropexy;
3. vaginal hysterectomy with apical suspension versus vaginal
hysteropexy.
Newer lightweight single incision polypropylene mesh kits should
be compared with native tissue repairs and also sacral colpopexy.
Further evaluation of appropriate graft and access route is also
required.
Future research should include a range of outcomes including,
but not limited to, subjective and objective data, validated pelvic
floor questionnaires evaluating bladder, bowel and sexual function,
and quality of life assessments, patient satisfaction, peri-operative
outcomes, re-operations, complications and cost.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anger 2014
Methods Multi-centre (2 sites, USA) RCT, parallel design.
Participants Inclusion criteria - women undergoing sacral colpopexy with symptomatic prolapse
POPq stage 2 with apical descent at least halfway down the vagina and able to consent
and complete 12-month review
Exclusion criteria: pregnancy in last 12 months or planned pregnancy,
Interventions Sacral colpopexy 2 separate pieces synthetic mesh with Goretex permanent sutures
LSC 4 ports
RSC 5 ports
Surgeon preference on type of mesh and wether the peritoneum was reperitonealised
concomitant hysterectomy (58%), posterior repair (6) and retropubicmid-urethral slings
(60%)
84 consented, 78 randomised
LSC 38, 6 months 35
RSC 40, 6 months 38
Outcomes Primary outcome cost between groups (hospital and physician cost, robot cost and
maintenance - cost estimated from average purchase price, number of years service,
procedures performed and resale value)
Secondary outcomepostoperative pain, POPqmeasurements,adverse events (Dindo clas-
sification) and QOL (short form health survey, EuroQol-5D, PGI-I, PFDI, PFII, PISQ
Quality adjusted life years calculated from EuroQOL-5D at baseline, 2 and 6 weeks
Convalescence and Recovery Evaluation (CARE), an activity assessment, and Likert pain
scale postoperatively day 1, 2 and 6 weeks
No difference in demographics and concomitant surgery
1. POPq outcomes Ba, Bp C 6 months
2. continence surgery
3. SUI
4. perioperative outcomes, operating time (minutes), blood loss
5. Quality of life: PFDI ( 0-300) PFIQ (0-400)
6. complications, bladder injury, transfusion, mesh exposure
7. pain score at 1 week (0-10)
8. cost (US dollars)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated blocked for sites and
hysterectomy
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Anger 2014 (Continued)
Allocation concealment (selection bias) Low risk Web page with secure login to access
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinded for 6 weeks postoperative
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors unblinded due to nature of inter-
vention
Incomplete outcome data (attrition bias)
All outcomes
Low risk 35/38 LSC at 6 months
38/40 RSC
Selective reporting (reporting bias) Low risk While no primary outcomes reported,
main outcomes relevant to comparison of
access are reported
Other bias Low risk No COI authors
Barber 2014
Methods Multi-centre (9 sites, USA) RCT, parallel design.
Participants 1996 evaluated, 409 included
Inclusion criteria - > 18 years undergoing vaginal surgery for Stage 2-4 prolapse (vaginal
or uterine descent 1 cm proximal to the hymen or beyond) with a) complaints of vaginal
bulge symptoms; b) SUI symptoms; and c) objective demonstrationof stress incontinence
by office or urodynamic testing in the previous 12 months
BPMT randomised 186, completed review 24 months 152
Usual care randomised 188, completed 24 months n = 164
USLS randomised 188 , completed 24 months n = 157
SSF randomised 186, completed review 24 months n = 159
Interventions BPMT randomised preoperatively and stratified by site
USLS versus SSF randomised in OT, stratified by surgeon and hysterectomy
1. with perioperative behavioural therapy with pelvic floor muscle training (BPMT)
or usual care n = 188 BPMT received an individualised program that included one visit
2-4 weeks prior to surgery, and four postoperative visits (2, 4-6, 8, and 12 weeks after
surgery). Pelvic floor muscle training, individualised progressive pelvic floor muscle
exercise, and education on behavioural strategies to reduce urinary and colorectal
symptoms were performed at each visit. Self-reported adherence to BPMT was assessed
at 6, 12, and 24 months. All BPMT
2. sacrospinous colpopexy (SSF) or uterosacral colpopexy (USLS)
All underwent TVT SUI
All with uterine prolapse vaginal hysterectomy
SSF unilateral Michagan 4 wall technique 9 2 x permanent sutures and 2 x delayed
absorbable:
USLS Shull technique 2 permanent and 2 absorbable sutures
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Barber 2014 (Continued)
Concomitant surgery surgeon’s discretion
No grafts utilised
Outcomes Outcomes (uterosacral versus sacrospinous) 6,12, 24 months:
1. awareness of prolapse (symptoms vaginal bulge from affirmative response
questions PFDI)
2. re-operation prolapse
3. apical, anterior and posterior compartment prolapse (hymen and beyond)
4. POPq points Ba, Bp
5. bladder injury, ureteric injury detected in OT, ureteric injury detected
postoperatively, bowel injury
6. complications: transfusion, intervention for neurological pain
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated stratified by sur-
geon and hysterectomy, computer-gener-
ated block design centrally
Allocation concealment (selection bias) Low risk Separate closed opaque envelopes each trial
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded to surgery
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded to assignment to surgery
and behavioural treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Accounted for all data: intention-to-treat
analysis: USLS 157/188, SSF 159/186
no BPMT 152/186 BPMT164/188
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Low risk Funded by The Eunice Kennedy Shriver
National Institute of ChildHealth andHu-
man Development some authors reported
COI none of which was directly related
to study. Preoperative comparison groups
same except > vaginal deliveries ULS than
SSF. BMI < ULS (mean 28.7 SD 5.2) than
SSF 29.0 (SD 5.7) > posterior compart-
ment descent SSF 0.8 ± 2.9 ULS 0.2 ± 2.5
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Benson 1996
Methods Single-centre RCT for uterine or vault prolapse
Participants 101 randomised
13 withdrawals (10 did not want surgery, 3 in group A wanted vaginal surgery)
88 analysed
8 lost to follow-up
Inclusion criteria: cervix to or beyond hymen, vaginal vault inversion > 50% length and
anterior wall to or beyond introitus
Exclusion criteria: uterus > 12 weeks, adnexal mass, short vagina, central cystocele, > 2
abdominal surgeries, obesity, prior inflammatory bowel or pelvic disease
Interventions Group A (40): abdominal group: sacral colpopexy (mesh not specified), paravaginal
repair, Halban, posterior vaginal wall repair with colposuspension or sling for SUI, non
standardised continence surgery
Group B (48): vaginal group: bilateral sacrospinous colpopexy, vaginal paravaginal repair,
McCall culdoplasty, needle suspension or sling; permanent sutures
Outcomes Optimal: asymptomatic vaginal apex > levator plate: no vaginal tissue beyond the hymen
A: 22/38, B: 12/42
Satisfactory: asymptomatic for prolapse and prolapse improved from preoperative:
Symptomatic: prolapse apex descent > 50% of its length or vaginal tissue beyond hymen
Outcomes:
1. re-operation for prolapse
2. re-operation SUI
3. prolapse on examination (any stage 2 or beyond)
4. injuries: bladder, bowel
5. SUI
6. dyspareunia
7. transfusion
8. hospital stay (days)
9. cost (US dollars)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation table held by non-surgeon
Allocation concealment (selection bias) Low risk The surgeon received the randomisation
assignment from the non-surgeon. Co-au-
thor who had sole access to the randomisa-
tion table after the workup
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No data
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Benson 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No data
Incomplete outcome data (attrition bias)
All outcomes
Low risk 80/88 (90%): completed 2.5 year review
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Unclear risk No data
Braun 2007
Methods Single-centre, parallel design, RCT comparing abdominal and vaginal approaches for
surgically treating central compartment prolapse
Participants Inclusion criteria: POP-Q Stage 3-4 prolapse
Exclusion criteria: not specified
Randomised: 47
Analysed: 47
Interventions Group A (23): TAH ± BSO + abdominal (open) sacral colpopexy
Group B (24): vaginal hysterectomy + anterior & posterior colporrhaphy +MayoMcCall
stitch
Materials used:
GroupA: vypromesh (combined absorbable - non-absorbable); prolene (non-absorbable)
sutures to both sacrum and vagina
Group B: delayed absorbable (PDS) sutures
Outcomes 1. Repeat prolapse surgery
2. Prolapse on examination (stage 2 or beyond)
3. Mesh exposure
Prolapse assessment: POP-Q
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
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Braun 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 47/47at 33-month review
Selective reporting (reporting bias) Unclear risk Moderate outcome data reported, however
as mean and SD not reported some out-
come data were not able to be included (ab-
stract only)
Other bias Unclear risk Not stated
Brubaker 2008
Methods RCT, parallel design. Multi-centre study in USA (7 sites)
Participants 322 women. CONSORT statement
Inclusion criteria: POP-Q stage 2-4 prolapse (Aa must be -1 or worse) and stress con-
tinence based on responses of ‘never’ or ‘rarely’ to 6 of the 9 SUI questions of MESA.
Despite these criteria, preoperatively 19.2% participants had SUI defined by PFDI, 10%
had bothersome SUI (PFDI questionnaire) and 39% had a positive stress test, with or
without prolapse reduction prior to intervention. From table 2 of the 3-month data it
appears these participants were equally distributed between the groups.
Exclusion criteria: Immobile urethrovesical junction, pregnancy, anticipated move away
after surgery
Groups were comparable at baseline on age, race, ethnic group, marital status, education,
parity, method of delivery, distribution of women with positive stress test, OAB, prior
hysterectomy continence and prolapse surgery
Surgeons were unaware of urodynamic findings including urodynamic stress inconti-
nence or occult stress incontinence with or without the prolapse reduced
Interventions Group A (157): abdominal sacral colpopexy with Burch colposuspension
Group B (165): abdominal sacral colpopexy without Burch colposuspension (control
group)
Compliance: women treated according to randomised groups: group A, 154/157; group
B, 164/165. concomitant surgery paravaginal repair group A 31/157 20% group B
34/165 20.6%, hysterectomy group A 29%: group B 28% standardised surgery for
colposuspension: not standardised paravaginal repair or sacral colpopexy (17% biological
grafts, 43% Mersilene and 39% polypropylene and minimal use of PFTE (Gore-tex)
(6%)
While surgery was standardised for colposuspension neither the paravaginal repair nor
sacral colpopexy was standardised with variation in use of suture type and graft materials:
17% biological grafts, 43% Mersilene 39% polypropylene 6% Gore-tex. No data on
further performed surgeries were provided in the publication
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Brubaker 2008 (Continued)
Outcomes Reports at 3 months, 2 year and 7 years
1. Awareness of Prolapse ( 7 years)
2. Prolapse on examination any site (7 years)
3. Repeat prolapse surgery or pessary (7 years)
4. Surgery SUI (7 years)
5. SUI (7 years)
6. POPq Q points C, Bp, Ba (2 years)
7. Operating time
8. Blood loss
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Sealed envelopes opened at time of surgery
after anaesthetic was administered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded patients
Incomplete outcome data (attrition bias)
All outcomes
High risk At 2 years 302 of 322 completed some part
of the review
Sc - urethropexy randomised 165, 7 years
44 examined, 60 interviews
SC + urethropexy; randomised 157, 7 years
46 examined, 66 interviews
Selective reporting (reporting bias) Low risk Main outcome data included
Other bias Low risk Funded competitive research grants,
Costantini 2007
Methods Single-centre RCT
Participants 66 women
Inclusion criteria: continent women (women with negative stress test before and after
prolapse reduction, no preoperative symptoms of UI, negative symptom questionnaire
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Costantini 2007 (Continued)
and no leakage during urodynamics) with ’severe’ uterovaginal and vault prolapse (not
clearly defined)
Exclusion criteria: N/S
66 randomised
66 analysed
Interventions Group A (32): sacral colpopexy (open)
Group B (34): sacral colpopexy + Burch (open)
concomitant surgeries: abdominal hysterectomy
Outcomes Review 2 and 8 years
1. Repeat surgery prolapse (8 years)
2. Repeat surgery SUI (8 years)
3. Transfusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk 66/66 at 1 year
Selective reporting (reporting bias) Unclear risk Moderate outcome data only
Other bias Unclear risk No conflict of interest statement or funding statement
Costantini 2008
Methods Single site RCT, parallel design
Participants Inclusion criteria: women age 18-75 years, POP > Stage 2 (BW and POPQ), UI defined
by ICS
Exclusion criteria: uterine fibroids, uterine/cervical malignancy, active PID, allergy to
synthetic graft/suture materials, pregnancy/lactation, significant illnesses, inability to
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Costantini 2008 (Continued)
provide informed consent or comply with study protocol
47 randomised A 23; B 24
No loss to follow-up
Distribution of POP between groups not clear: 24 uterovaginal, 13 vault, 8 cystocele
and 2 cystocele and rectocele
Interventions Group A (23): sacral colpopexy 17, sacral hysteropexy 6, no colposuspension
Group B (24): sacral colpopexy + Burch 14, sacral hysteropexy + Burch 10
Preoperatively incontinence defined by urodynamics: 13 USI, 30mixed, 4 occult (incon-
tinence with coughing or Valsalva manoeuvre with the prolapse reduced). Distribution
of patients with prolapse and incontinence preoperatively between the groups is unclear
Outcomes Primary incontinence outcome: combination of bladder diary, number of pads and stress
test without clear definition: group A 9/23, group B 13/24 (P = 0.46)
1. Surgery for prolapse (4 years)
2. Surgery SUI (4 years)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk 47/47 completed review
Selective reporting (reporting bias) Unclear risk Limited outcome data, 2 of 4 primary outcomes
Other bias Unclear risk COI or funding statement not included
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Costantini 2013
Methods Single-centre RCT
Participants Inclusion Grade 3-4 prolapse POPq without contraindications to both procedures
Interventions Group A 36 open sacrocolpopexy
Group B 37 laparoscopic sacrocolpopexy
Outcomes 1. POpq point C (1 year)
2. Operating time (1 year)
3. Hospital stay (1 year)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk Limited outcome data (abstract)
Other bias Unclear risk Not stated
Culligan 2005
Methods Single-centre RCT
Fascia lata versus polypropylene mesh for sacral colpopexy
Follow-up: 1 year
Participants 100 randomised
Lost to follow-up: 11 (A 2, B 9)
Inclusion criteria: post-hysterectomy vault prolapse
Groups comparable at baseline on age, weight, height, parity, incontinence severity,
POP-Qmeasurements, prolapse stage, previous prolapse or incontinence surgery (A 19/
46, B 24/54)
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Culligan 2005 (Continued)
Randomised group compared with women who declined randomisation (101 women),
no statistically significant differences found
Interventions A (46): abdominal sacral colpopexy with cadaveric fascia lata graft (Tutoplast) attached
with Goretex to anterior and posterior vaginal wall and to S1-S2, covered with peri-
toneum
B (54): abdominal sacral colpopexy as above, using polypropylene mesh (Trelex)
Concomitant surgery: TVT, paravaginal and rectocele repair; conditions not defined
Outcomes Data from 1 and 5 year reports
1. Awareness of prolapse (Do you have any symptoms of prolapse?) 5 years
2. Prolpase on examination (2 or greater at any site) 5 years
3. Repeat prolapse surgery (5 year)
4. Repeat continence surgery
5. Apical prolapse
6. POPq points Ba, Bp, C, TVL
7. Peri-operative data: blood loss, operating time
8. Mesh exposure
9. Bladder injury
10. Transfusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded assessor nurse
Incomplete outcome data (attrition bias)
All outcomes
Low risk 11/100 at 1 year: 5 years 42/100 lost to
review
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Unclear risk Authors had COI with Bard whose mesh
was assessed. Funding study not stated
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Culligan 2013
Methods Single-centre, double-blinded RCT
Participants Inclusion criteria: stage 2 or greater apical prolapse scheduled LSC
Exclusion criteria: pregnancy or desire for pregnancy, prior mesh POP surgery
184 suitable and 120 randomised
58 porcine dermis 1 year 57
62 mesh 1 year 58
No difference between groups in preoperative assessment
1 in the porcine group converted to vaginal surgery and removed from the study?
Interventions Mesh SC: polypropylene mesh (Pelvitex)
Porcine SC: porcine dermis acellular collagen matrix (Pelvisoft)
Technique y-shaped, ant graft 4 cm to 7 cm, posterior 8cm to 10 cm supracervical
hysterectomy with morcellation, permanent sutures secured to anterior longitudinal
ligament at level of sacral promontory with permanent sutures.Mid-urethral sling offered
to all patients
operating time: incision to removal of all trocars and excluded closure of trocars, mid-
urethral sling and perineorrhaphy
95 RSC and 24 LSC (change access technique during trial)
70 underwent MUS. 64/70 dry
49 no MUS 34/49 dry: 4/49 underwent subsequent MUS: groups not defined
Outcomes 1. Re-operation prolapse (1 year)
2. Prolapse on examination (any stage 2 or greater:) 1 year
3. Surgery mesh exposure
4. Mesh exposure
5. Qol: PFDI-20, PFIQ-7, PISQ
6. Dyspareunia
7. Peri-operative data: hospital stay,
8. Bladder, bowel injuries
9. Transfusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocked computer-generated randomisation list
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded
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Culligan 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 year porcine 57/58: mesh 58/62
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias High risk Author COI with bard supplier of porcine mesh
and study funded by unrestricted Bard grant
da Silviera 2015
Methods Multi-centre (4 sites, Brazil) RCT for stage 3-4 POPq (any compartment)
Participants Inclusion criteria: Grade 3-4 POP ( any POPq measurement > +1)
No exclusion criteria
199 screened, 184 randomised
Native tissue n = 90 randomised n = 81 completed 1 year
Mesh n = 94 randomised n = 88 1 year
Interventions Site-specific native tissue; site-specific anterior and or posterior 1.0 non-absorbable su-
ture (polypropylene) apical 1.0 non absorbable sacrospinous right: uterine prolapse hys-
terectomy in both groups; mesh group: polypropylene macro porous monofilament Pro-
lift mesh.
Concomitant surgery allowed
Prior to study each centre performed at least 3 surgeries
Hb 24 hours postoperatively
Assessed 1 week 1, 6 ,12 months
Pain assessed variable rating scale
NT group 74/90 anterior compartment prolapse ± other surgery, posterior alone n = 7,
apical alone n = 9; mesh group similar breakdown
Mid urethral slings: 5/90 native tissue, 9/94 mesh; vaginal hysterectomy 32/90 29/94
Outcomes Assessed at one year post operatively
Reports the following review outcomes:
1. repeat prolapse surgery
2. repeat surgery for prolapse, SUI or mesh exposure
3. bladder injury
4. bowel injury
5. repeat continence surgery
6. surgery for mesh exposure
7. anterior compartment prolapse (Ba)
8. POPq assessment points Ba, Bp,C
9. sexual function Quality of sexual function questionnaire data not entered not
PISQ
10. dyspareunia
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da Silviera 2015 (Continued)
11. quality of Life PQOL end score
12. operating time
13. blood transfusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation lust
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Native tissue randomised 90 at 1 year 81
completed
Mesh 94 randomised at 1 year 88 com-
pleted
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Low risk J&J donated product no financial input
study
de Tayrac 2008
Methods Multi-centre RCT comparing Infracoccygeal sacropexy and sacrospinous suspension for
uterine or vaginal vault prolapse
Participants Inclusion: symptomatic uterine or vaginal vault prolapse (stage 2 or higher)
Exclusion: isolated cystocele, stage 1 prolapse, rectal prolapse, and intestinal inflamma-
tory disease
49 randomised
4 lost to follow-up
45 analysed
Interventions Group A (21): infracoccygeal sacropexy (multi-filament polypropylene tape, posterior
IVS)
Group B (24): sacrospinous suspension
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de Tayrac 2008 (Continued)
Concomitant surgery: cystocele repair, posterior repair, hysterectomy, suburethral tape.
Types of repair and indications for repair were not described
Outcomes Assessed at “Medium term” follow-up
Reports the following review outcomes:
1. repeat surgery for prolapse
2. recurrent prolapse on examination (not defined)
3. bladder injury
4. bowel injury
5. anterior compartment prolapse
6. posterior compartment prolapse
7. bladder function: de novo SUI, de novo voiding disorder
8. sexual function: PISQ end scores
9. operating time
10. days in hospital
11. prolapse assessment: POP-QValidated questionnaires: PFDI, PFIQ, PISQ-12,
French version
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation centralised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Participant completed questionnaires
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Unclear risk COI or funding unstated
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Detollenaere 2015
Methods Open-label non inferiority RCT
Multi-centre (4) Dutch centres, experienced surgeons (performed 20 procedures prior)
Participants Inclusion criteria: POP-Q grade 2 or greater uterine descent
Exclusion criteria: prior POP surgery, knownmalignancy, or abnormal cervical cystology,
bleeding or ultrasound of uterus or ovaries, wish to preserve fertility, language barriers,
unwilling to return
Groups were similar except posterior repair was performed more frequently in the hys-
terectomy group (50%) than in the hysteropexy group 29%
gp A 30/103 gp B 50/105 P = 0.003
Interventions Group A sacrospinous hysteropexy (2 x permanent polypropylene sutures direct vision
R sacrospinous ligament)
Group B vaginal hysterectomy with suspension uterosacral ligament (sutures not speci-
fied)
Concomitant surgery anterior and posterior repair or MUS
12-month review by doctor not related to surgery
Unblinded surgeons and participants; impossible to do so
Outcomes Reports outcomes at 1 year:
1. awareness of prolapse ( symptoms of vaginal bulge from UDI)
2. repeat prolapse surgery
3. repeat surgery for SUI
4. recurrent prolapse on examination ( stage 2 any site POPq)
5. anterior compartment prolapse
6. posterior compartment prolapse
7. apical prolapse
8. POPq assessments: Ba, Bp, C, TVL
9. sexual function: PISQ end scores
10. quality of Life: UDI and DDI (median and interquartile range) not included
11. hospital stay.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomised stratified for each
centre and stage of POP
Allocation concealment (selection bias) Low risk Allocated from web-based randomisation
program
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
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Detollenaere 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded. 12-month review conducted
by non surgeon doctor
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12 months 98/103 Gp A: GP B 102/105
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Low risk Funded by competitive grants from Isala
hospital research foundation
Dietz 2010
Methods RCT
Participants Inclusion criteria: stage 2 or greater uterine prolapse
Randomised = 71: group A, 34 group B, 37
Withdrew 3, 2
Surgery 31, 35
Lost to follow-up 0, 2
Analysed 31, 33 (the article results quote 34 SS hysteropexy group)
Groups were comparable at baseline
Interventions Group A (31) vaginal hysterectomy with uterosacral suspension
Group B (34) vaginal sacrospinous hysteropexy with uterine preservation
Outcomes Reported outcomes at 1 year:
1. repeat prolapse surgery
2. apical compartment prolapse
3. posterior compartment prolapse
4. anterior compartment prolapse
5. bladder injury
6. bowel injury
7. POPq assessments: Ba, Bp, TVL
8. quality of life: UDI and IIQ reported mean and SDs
9. hospital stay (Median and range)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Via research nurse by mail
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Dietz 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participant-completed questionnaires
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reported last data carried forward and worse case scenario 69/
71 at 1 year
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Low risk COI none: no statement on funding
Freeman 2013
Methods RCT pilot comparing abdominal open and laparoscopic sacral colpopexy
Participants Inclusion criteria: symptomatic vault prolapse stage ≥ 2 POP
Exclusion criteria: medical unfitness for a sacral colpopexy, and the need for any con-
comitant pelvic or continence surgery, BMI > 35, prior prolapse surgery
Randomised: 30
Analysed: 30
Demographic characteristics were similar in both groups
Interventions Group A (24): abdominal (open) sacral colpopexy
Group B (23): laparoscopic sacral colpopexy
No concomitant surgeries in either group
Outcomes Reported outcome data 1 year:
1. repeat surgery prolapse
2. recurrent prolapse on examination ( any stage 2 or >)
3. repeat surgery SUI
4. POPq C, Bp
5. hospital stay
6. operating time
7. blood loss
8. quality of life (PQol mean and SDs)
9. bladder injury
10. bowel injury
11. morphine use postoperative (not included)
12. prolapse assessment: POP-Q
13. follow-up: 12 weeks
Notes
Risk of bias
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Freeman 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated blocked to ensure
similar number patients per surgeon
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded - 1 year
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 1 year: 24/27 open 23/26 laparoscopic
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Unclear risk Competitive grant Plymouth surgical ser-
vices trust; COI for some authors in prod-
ucts being evaluated
Halaska 2012
Methods Multi-centre randomised trial
Participants Inclusion criteria: central post-hysterectomy vault prolapse: POP-Q greater or equal
Stage 2 POP greater or equal Excluded pelvic malignancy, < 18 years, prior radiotherapy,
those requiring hysterectomy
Allocated group A 83; group B (TVM) 85
I year group A 72; group B 79
Recurrence defined as stage 2 or greater POP-Q
Not clear who performed assessments
Interventions Group A (83) anterior repair( Sutures? type?) R sacrospinous colpopexy ( 2 x non-
absorbable sutures Nurolen) ± Posterior repair (approximation of levator muscles) and
moderate excision of redundant vagina
Group B (85) Total Prolift mesh secured with 2.0 PDS sutures
intervention performed by surgeons with greater than 20 cases experience of each type
surgery
Outcomes Assessed at 1 year
Reports the following review outcomes:
1. repeat surgery for prolapse
2. recurrent prolapse 9 stage to or greater any site)
3. mesh exposure
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Halaska 2012 (Continued)
4. bladder injury
5. bowel injury
6. POPq assessments: reported graphically and without SD.s
7. bladder function: de novo SUI, de novo OAB
8. sexual function: dyspareunia, PISQ-12 no SDs reported
9. quality of life: POPIQ no SDs reported
10. operating time reported as mean and range
11. transfusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for in flow study: 151/168
(89%) reviewed 1 year
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Low risk Funded by grant from Czeck ministry health care, au-
thors no COI
Iglesia 2010
Methods Multi-centre RCT
Participants 173 excluded variety reasons
Group A 33; group B 32
Lost to follow-up: group A = 0; group B = 0
Prior to surgery all demographic details similar between the 2 groups: except group B
lower POPDI-6 score than group A
Inclusion criteria: ≥21 yrs, grade 2-4 (POP-Q) uterovaginal or vaginal prolapse who
agreed to undergo vaginal surgery, available 12 months review and can complete ques-
tionnaires
Exclusion criteria: multiple medical contraindications, short vagina, uterus > 12 weeks’
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Iglesia 2010 (Continued)
size, desire future fertility, and postpartum
Interventions Group A uterosacral colpopexy with polytetrafluoroethylene sutures or sacrospinous
colpopexy (Gortex sutures) and hysterectomy performed if uterus present
Group B: B if point C or D on POPq was≥-3 apical suspension with Total vaginal mesh
(Prolift) and if C or D was <-3 anterior Prolift utilised. No T incisions were performed
and hysterectomy performed if uterus present
Outcomes Assessed at 1,2 and 3 years
Reported outcomes 3 years unless otherwise stated:
1. awareness of prolapse ( vaginal bulge)
2. repeat prolapse surgery
3. repeat surgery SUI
4. repeat surgery for prolapse, SUI or mesh exposure
5. recurrent prolapse ( POPq stage >1)
6. mesh exposure
7. surgery mesh exposure
8. POPq points Ba, Bp and C ( median and range) not included
9. bladder injury
10. bowel injury
11. bladder function: de novo SUI
12. sexual function: de novo dyspareunia, PISQ ( median and range) not included
13. quality of life: PFDI-20, PFIQ-7, ( median and range)
14. transfusion
15. days in hospital (P value only not included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Equal assessment groups: 51/65 completed 3 years
Selective reporting (reporting bias) Low risk Main outcome data reported
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Iglesia 2010 (Continued)
Other bias Low risk Funded by American Urogynecology Society foundation and
Medstar research; authors reported no conflict of interest
Jeng 2005
Methods RCT
Total vaginal hysterectomy versus transvaginal sacrospinous uterine suspension
Follow-up: 6 months
Participants 158 women
Dropouts: 0
Inclusion criteria: age <50 years; Grade 2-3 uterine or cervical prolapse; sexually active
Exclusion criteria: previous anterior or posterior vaginal wall repair, or oophorectomy
Groups comparable at baseline on age, parity, height, weight, partners’ health status,
sexual functioning
Interventions Group A (80): transvaginal sacrospinous uterine suspension (without hysterectomy)
Group B (78): total vaginal hysterectomy
All operations done by one surgeon
Outcomes Reported outcomes 6 months:
1. dyspareunia: A, 4/80; B, 4/78
Adverse effects:
1. UTI: A, 1/80; B, 2/78
2. buttock pain: A, 12/80; B, 0/78
3. acute urinary retention: A, 0/80; B, 1/78
4. vaginal dryness after surgery: A, 4/80; B, 4/78
5. time to resumption of intercourse (mean weeks, range): A, 8 (4-16 weeks); B, 8
(5-16)
6. sexual functioning: no differences between the groups after surgery (P > 0.05)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
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Jeng 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear
Selective reporting (reporting bias) Unclear risk Very limited outcome data
Other bias Unclear risk COI and funding not stated
Lim 2012
Methods A multi-centre RCT
Participants Inclusion criteria: post-hysterectomy anterior and vault prolapse of ≥ stage 2 POPQ
Exclusion criteria: past history of urogenital fistula, SCP, VEULS or major mesh com-
plications
Screened: not stated
Randomised: 80
Interventions Group A: vaginal group fascial plication and overlayUltraPro (Ethicon,NJ). vaginal extra
peritoneal uterosacral ligament suspension (VEULS) were performed with two 0 PDS
sutures on each side
Group B: Sacral Colpopexy performed laparoscopically or abdominally at surgeon’s dis-
cretion
concomitant continence surgery: Mid urethral slings were performed when required
Outcomes Reported outcomes 1 year abstract (Mean follow-up of 14.1 (SD10.9) months):
1. recurrent prolapse examination (anterior or vault prolapse < POPQ stage 2)
2. bladder injury
3. mesh exposure
4. hospital stay ( mean without SD)
5. sexual function PISQ-12 (P values, only not included)
6. quality of Life PFDI-20 and PFIQ-7 (statements without data)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Low risk Computer-generated off-site phone contact (personnel commu-
nication)
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Lim 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No statement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 70/80 reviewed 1 year
Selective reporting (reporting bias) Unclear risk Moderate outcome data, only 1 of 4 primary outcomes
Other bias Low risk Unfunded no author COI
Lo 1998
Methods Single-centre RCT (using random number tables)
Follow-up: 1 to 5.2 years (median 2.1)
Participants 138 randomised, 20 withdrew due to age or not willing to be followed up
Inclusion criteria: prolapse at least Grade III (ICS classification)
Exclusion criteria: UI
Past medical history: previous pelvic surgery A: 19, B: 22
Sexually active: A: 11, B: 18
Interventions Group A (52): abdominal sacral colpopexy with Mersiline mesh: + 7 posterior repair; +
12 posterior repair and abdominal hysterectomy; + 21 abdominal hysterectomy
GroupB (66): vaginal sacrospinous colpopexywith 1-0 nylon: + 20 anterior and posterior
repair and vaginal hysterectomy; + 44 anterior and posterior repair
Postoperatively, all women had oestrogen treatment
Outcomes Reported outcomes median 2-year review:
1. recurrent prolapse on examination (stage 2 or >)
2. repeat surgery SUI
3. repeat surgery mesh exposure
4. bladder injury
5. bowel injury
6. mesh exposure
7. blood loss
8. operating time
9. hospital stay
10. sexual function < dyspareunia
Notes
Risk of bias
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Lo 1998 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number list
Allocation concealment (selection bias) Low risk Consecutive sealed opaque envelopes (per-
sonal communication)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Non-surgeon unaware allocation (personal
communication)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 118/138 reviewed 2 years
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Low risk No COI (personal communication)
Maher 2004
Methods Multi-centre RCT (stratified by SUI); multiple surgeons
Participants 95 women
Withdrawals: 0
Lost to follow-up: 6 (group A: 1, group B: 5)
Inclusion: vault prolapse to introitus
Exclusion: prior sacral colpopexy, unfit for general anaesthetic, foreshortened vagina
Interventions Group A (46): abdominal group = sacral colpopexy prolene mesh, paravaginal repair,
Moschcowitz, posterior vaginal repair and colposuspension for SUI
Group B (43): vaginal group: R sided sacrospinous colpopexy, enterocele and anterior
and post repair, colposuspension for SUI,
PDS (slowly absorbable sutures)
Both groups: colposuspension for occult or potential SUI
Outcomes Reported outcomes 2 years:
1. awareness of prolapse
2. re-operation prolapse
3. re-operation SUI
4. recurrent prolapse on examination ( Stage 2 or > any site)
5. bladder injury
6. blood loss
7. transfusion
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Maher 2004 (Continued)
8. hospital stay
9. sexual function: dyspareunia and de novo dyspareunia
10. bladder function: de novo SUI
11. operating time
12. cost (US dollars)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number list
Allocation concealment (selection bias) Low risk Randomisation list held nurse
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Non-blinded non surgeon reviewer, partic-
ipant-completed validated questionnaires
Incomplete outcome data (attrition bias)
All outcomes
Low risk Adequately accounted for 89/95 at 2 years
Selective reporting (reporting bias) Low risk Significant outcome data
Other bias Low risk Funded by competitive research grant
RANZCOG:
Maher 2011
Methods Single-centre RCT
Participants Inclusion criteria: consecutive women with symptomatic stage 2 or greater (point C ≥
-1 POP-Q) vault prolapse
Exclusion criteria: Age < 18, inability to comprehend questionnaires, to give informed
consent or to return for review, vault prolapse < St. 2, unable to undergo general anaes-
thesia, BMI > 35, ≥ 5 previous laparotomies, prior sacral colpopexy, or vaginal mesh
prolapse procedure, vaginal length < 6 cm suitable participate
142 randomised and surgery group A 53; group B 55. Lost to full follow-up 2 years
group A 2; group B 3
Interventions Group A: laparoscopic sacral colpopexy
Group: B TVM Prolift
Concomitant surgery: yes
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Maher 2011 (Continued)
SUI or occult SUI
Group A: laparoscopic colposuspension; group B: TVT-O
Posterior repair and paravaginal surgery if required in A
Outcomes Reported outcomes 2 years:
1. awareness of prolapse
2. re-operation prolapse
3. recurrent prolapse on examination (stage 2 or greater any site)
4. mesh exposure
5. surgery mesh exposure
6. bladder injury
7. bowel injury
8. POPq assessments: Ba, Bp, C, TVL
9. bladder function: SUI, overactive bladder, voiding dysfunction, urodynamic
outcomes
10. transfusion
11. operating time and days in hospital (reported as median and range not included)
12. quality of life: PQoL and Australian Pelvic Flor Questionnaire (APFQ)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded non-surgeon reviewers validated patient-completed
questionnaires
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow patients accounted for 103/108 2 years
Selective reporting (reporting bias) Low risk Main outcome data reported
Other bias Low risk Funded by competitive research grant Australian Gynaecology
Fndoscopy Society authors no conflict of interest reported
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Meschia 2004a
Methods RCT (computer-generated number table, opaque envelopes) on posterior IVS and
sacrospinous fixation for vault prolapse
Median follow-up: group A 19, group B 17 months
Participants 66 randomised
Group A 33, group B 33
No withdrawals or losses to follow-up
Inclusion criteria: vault (vaginal cuff ) prolapse ICS stage II or more
Baseline SUI: group A 11/33, group B 7/33
Baseline overactive bladder: group A 14/33, group B 11/33
Baseline voiding dysfunction: group A 19/33, group B 18/33
Women in Group A were significantly younger than in group B (63 years vs 68 years, P
< 0.05)
Interventions Group A (33): infracoccygeal sacropexy (posterior IVS) using multi-filament Polypropy-
lene tape
Group B (33): sacrospinous ligament fixation (vaginal sacrospinous colpopexy)
Concomitant surgery: anterior (A 64% B 66%) and posterior (70%, 88%) repair, high
closure of pouch of Douglas if indicated (36%, 42%)
Outcomes Reports the following outcomes at median 7-19 months:
1. awareness of prolapse (subjective success)
2. anterior wall prolapse
3. posterior wall prolapse
4. operative time
5. days in hospital
6. bladder function: SUI, overactive bladder
7. sexual function: dyspareunia
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Adequate allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
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Meschia 2004a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data complete 66/66
Selective reporting (reporting bias) Low risk Significant outcome data
Other bias Unclear risk No statement
Natale 2010
Methods Single-centre RCT on vaginal vault suspension at time of vaginal hysterectomy.Multiple
surgeons
Participants 229 women with apical POP stage 2 or more
Excluded SUI, prior hysterectomy or prolapse or continence surgery
All completed one-year follow-up
Demographic parameters and previous prolapse surgeries did not differ between the two
groups
Interventions Group A: n= 116 high levator myorrhaphy
Group B: n= 113 uterosacral vault suspension
Concomitant surgery in all women: vaginal hysterectomy and “tension-free” cystocele
repair with self-styled monofilament polypropylene mesh group A113 and group B 106.
Operations performed by three different surgeons
Outcomes Reported outcomes at 1 year:
1. apical prolapse (Stage 2 Point C)
2. anterior compartment prolapse ( Stage 2 Point Ba)
3. posterior compartment prolapse ( Stage 2 point Bp)
4. sexual function: de novo dyspareunia, PISQ ( mean without SDs not included)
5. quality of Life; PQoL (Mean and SDs reported)
6. bladder function:SUI, Overactive bladder,
7. ureteric injury
8. POPq assessment: TVL
9. mesh erosion
10. POPQ, urodynamics,
11. Q-tip testPQoL,
12. Wexner score for constipation
13. PISQ-12
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
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Natale 2010 (Continued)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data complete
Selective reporting (reporting bias) Low risk Significant outcome data
Other bias Unclear risk No COI statement
Paraiso 2011
Methods Single-centre, single-blinded RCT
Participants inclusion: > 21 years, Stages 2-4 apical post-hysterectomy vaginal prolapse
Partcipants were excluded if they were not candidates for general anaesthesia, underwent
a prior sacral colpopexy or rectopexy, had a suspicious adnexal mass or other factors that
may indicate pelvic malignancy, reported a history of pelvic inflammatory disease, were
morbidly obese (BMI > 40 kg/m2), or were scheduled for a concomitant laparoscopic
rectopexy with or without sigmoid resection
Concomitant continence and prolapse surgery at surgeons discretion
Interventions Group A (32): laparoscopic SC
Group B (35): robotic assisted laparoscopic sacral colpopexy
Outcomes Reported the following outcomes 1 year:
Primary outcome operating time from skin to closure
1. prolapse on examination (Stage 2 or > any site)
2. POPq assessment: Ba, Bp, C TVL (reported mean and range, not included)
3. bladder injury
4. bowel injury
5. mesh exposure
6. operating time
7. hospital stay
8. cost surgery (US dollars)
9. pain score (VAS 0-10)
10. PFDI -20
11. PFIQ -7
12. PISQ
Notes
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Paraiso 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Adequate opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients blinded 12 months
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data complete 61/70 reviewed 1 year
Selective reporting (reporting bias) Low risk Significant outcome data
Other bias Low risk Funded Cleveland clinic research institute and au-
thors report no conflict of interest
Rahmanou 2015
Methods Single-centre RCT
Participants Symptomatic uterine prolapse Grade 2 and above requesting surgery 132 eligible:
Inclusion criteria: with no desire to preserve fertility
Exclusion criteria: abnormal cervical cytology or uterine bleeding: enlarged uterus and
those not suitable for steep Trendelberg position
101 randomised 1 year group A 32/50; group B 31/51
Interventions Group A vaginal hysterectomy; group B laparoscopic hysteropexy
Performed more than 50 of each intervention:
Group A: vaginal hysterectomy group vault attached to uterosacral lig Vicryl 1 and with
sacrospinous (PDS 2.0) fixation in those with complete procidentia
Group B:uterus suspended permanent polypropylene mesh ( Prolite, Atrium) fixed to
the cervix anteriorly (ethibond sutures) and reperitonealised
Outcomes Reported the following outcomes at 1 year:
1. re-operation for prolapse
2. POPq assessments; Point Ba, Bp, C ( reported mean with SDs) not included
3. blood loss (reported mean and range not included)
4. hospital stay (reported mean and range not included)
5. quality ol life: ICIQ-VS (reported mean without SD not included)
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Rahmanou 2015 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Blinded envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to be blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unable to be blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Group A hysterectomy: 35/50: Group B hysterectomy 37/51 at
1 year:
Selective reporting (reporting bias) Low risk Significant outcome data
Other bias Low risk No funding and no COI
Rondini 2015
Methods RCT
Participants Inclusion criteria: apical defects point C ≥ 1, sexually active
Exclusion criteria: if not sexually active or prior apical reconstruction surgery
Objective success point c < 2
Demographics and PFDI-20, P-QOL, and PISQ-12 equal both groups preoperatively
Rrandomised group A 63; group B 61
Declined surgery: group A 9; group B 5
4 years 106/124 group A 50; group B 56
Interventions Group A (54): sacral colpopexy (prolene mesh: 4 polypropylene sutures anterior and
posterior) subtotal hysterectomy in those with uterine prolapse: no posterior repair
Group B (56): High uterosacral vault suspension (Shull technique 4 PDS sutures to USL
above ischial spine)
Outcomes Reported outcomes at 1 year full manuscript, 4 years abstract:
1. re-operation prolapse
2. pical compartment prolapse (Point C stage 2 or >)
3. posterior compartment prolapse (Point Bp stage 2 or >)
4. anterior compartment prolapse ( Point Ba stage 2 or >)
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Rondini 2015 (Continued)
5. bladder injury
6. ureteric injury identified at surgery
7. mesh exposure
8. sexual function: PISQ-12
9. quality of life: PFDI-20, PQoL
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned with equal probability using Millers
and Park minimal standard method, which allocated patients in
a 1:1 ratio
Allocation concealment (selection bias) Low risk Group allocation was performed by a gynaecologist at the hos-
pital who did not participate in the baseline assessment, surgery,
or postoperative follow-up and the surgeon was unaware of al-
location until surgery
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk USLS 54/54: SCP 56/56
Selective reporting (reporting bias) Low risk Significant outcome data
Other bias Unclear risk No statement
Roovers 2004
Methods RCT multi-centre
Definition of cure/failure: failure defined as recurrent prolapse stage ≥ 2 plus symptoms
of pelvic floor dysfunction
Follow-up (mean): 94 months (range 84 to 120)
Prolapse assessment: POP-Q
Participants 82 women
Inclusion criteria: uterine prolapse stage 2-4 on POP-Q
Exclusion criteria: uterus size > 12 weeks gestation, prior hysterectomy, adnexal mass,
previous abdominal pelvic surgeries > 2, BMI > 35, prior inflammatory bowel or pelvic
disease, faecal incontinence d/t sphincter defect
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Roovers 2004 (Continued)
Offered participation: 124, 3 excluded, 39 refused to participate, 2 withdrew from
abdominal group as wanted vaginal surgery
Randomised: 82 (41 in each arm)
Analysed: 82
At 8 years follow-up: 74 of the original 84 patients were alive and able to be contacted.
60/74 (81%) completed questionnaires and 31/74 (42%) were examined
Interventions Group A (41): abdominal: sacral colpopexy with preservation of uterus: colposuspension
for SUI
Group B (41): vaginal: vaginal hysterectomywith vaginal repair and uterosacral ligament
plication: bladder neck needle suspension for SUI
Concomitant surgery: anterior colporrhaphy, posterior colporrhaphy, Burch colposus-
pension, Pereyra or Raz needle bladder neck suspension
Outcomes Reported following outcomes with reviews 1-year, and median 8 years abstract)
1. re-operation prolapse (performed or planned)
2. operating time
3. blood loss
4. days in hospital
5. bowel injury
6. transfusion
7. quality of life: UDI, DDI, IIQ
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number chart, computer-gener-
ated random number table
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Non-surgeon review
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete data set: 60/82 completed 7
year review
Selective reporting (reporting bias) Low risk Significant outcome data
Other bias Unclear risk No statement
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Svabik 2014
Methods Single-centre RCT
Participants Inclusion criteria: symptomatic post-hysterectomy patients with at least two-compart-
ment prolapse (with affected apical/vault compartment, stage II or higher (POP-Q),
requesting pelvic floor reconstructive surgery, and diagnosed with a complete unilateral
or bilateral avulsion injury
Exclusion criteria: nil further stated
Assessment pre- and postoperative POP-Q examination, 4D ultrasonography with ac-
quisition of volume data sets at rest, during pelvic floor muscle contraction (PFMC),
and on maximum Valsalva manoeuvre, PISQ-12, POPDI, UDI, CRADI
142 reviewed and 72 excluded ( 70 no avulsion, 2 refused)
SSF 34 1 year 31
Mesh : 36 1 year 36
Interventions Native tissue SSF: all cases: anterior repair with 2.0 Vicryl plus (ethicon), posterior high
levatorplasty Vicryl plus 1: 2x Nurolon 1.0 ethicon permanent R sacrospinous ligament
Mesh Prolift total ethicon: 3 arms each side with mesh secured to apex with Vicryl plus
2.0 and to introitus posteriorly
Primary outcome: Failure defined: Ba, C, or Bp at hymen or below
USS definition 10mm descent of the bladder below the lower margin of the symphysis
pubis on maximum Valsalva
Outcomes Assessed at 3 months and 1 year
Reported outcomes at 1 year include:
1. recurrent prolapse (POPq grade 2 or >)
2. mesh exposure
3. Surgery for mesh exposure
4. POPq assessments: Ba, Bp, C, TVL
5. bladder function: de novo SUI
6. sexual function: PISQ-12 end score
7. quality of life (UDI, POPDI, CRADI questionnaires mean and SDs)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation based on hospital number
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
High risk No attempt to blind
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Svabik 2014 (Continued)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 year 31/34 SSF, Prolift mesh 36/38
Selective reporting (reporting bias) Low risk Significant outcome data
Other bias Low risk Funded by Czechministry health andCharles university Prague:
one author financial COI
Trabuco 2014
Methods Single-blinded randomised trial
Participants 113 patients randomised 53 MUS; 57 Burch
104 6 months; MUS 53; 51 Burch
Interventions Group A Sc with MUS; group B SC with Burch
Outcomes Reported in abstract with 6-month review:
1. objective continence (defined as above, not included)
2. satisfaction rate (somewhat or completely +ve response, not included)
3. patient perception of improvement (VAS 0-10 not included)
4. bladder function: de novo UUI
5. mesh exposure (statement with no outcomes, not included)
Notes Authors summary: MUS resulted in greater pt satisfaction higher continence rates com-
pared to Burch
standardised surgery
No POP outcomes
Consort and intention-to-treat not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not clear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded
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Trabuco 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 months MUS 53/53 colposuspension: 51/57
Selective reporting (reporting bias) Unclear risk Main prolapse outcomes not reported, focused on
continence outcomes in abstract
Other bias Unclear risk No statement
BMI = Body mass index
BPMT = behavioural therapy and pelvic floor muscle training
Hb = Haemoglobin
ICS = International Continence Society
IIQ = Incontinence impact questionnaire
IVS = intravaginal slingplasty
LSC = laparoscopically
OAB = Overactive bladder
PDS = Absorbable polydioxanone surgical suture (PDS)
PFDI = Pelvic Floor Distress Inventory
PFIQ = Pelvic Floor Impact Questionnaire
PISQ = Pelvic organ prolapse/urinary Incontinence Sexual Questionnaire
PGI-I= Patient Global Impression of Improvement
POP = Pelvic organ prolapse
POP-Q = Pelvic organ prolapse quantification (according to ICS)
P-QOL= Prolapse Quality of Life Questionnaire
QoL = Quality of Life
RCT = randomised controlled trial
RSC = robotically
SUI = Stress Urinary Incontinence (symptom diagnosis)
TVT = Tension-free vaginal tape
UDI = Urogenital Distress Inventory
UI = Urinary incontinence
USLS = uterosacral colpopexy
UTI = Urinary tract infection
VAS = visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Altman 2013 Not a RCT
Balci 2011 Not a RCT
Chao 2012 Evaluated effects of intraoperative traction on uterine descent without randomisation of prolapse interventions
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(Continued)
Heinonen 2011 Heinonen and Nieminen evaluated outcomes of anterior vaginal wall mesh augmentation with concomitant
sacrospinous ligament fixation (SSLF) (n = 14) or with concomitant posterior intravaginal slingplasty (IVS) (n =
8) for uterovaginal or vaginal vault prolapse. Due to a predefined decision that papers with less than 20 in each
treatment group would not be included in the review the manuscript was excluded
Juneja 2010 Juneja and colleagues compared in a pilot randomised study hysterectomy (n = 9) versus no hysterectomy (n = 7)
for uterine prolapse in conjunction with posterior infracoccygeal colpopexy. Due to a pre-defined decision that
papers with less than 20 in each treatment group would not be included in the review the manuscript was excluded
RCT = Randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Cortesse 2010
Trial name or title ATHENA
Methods RCT
Participants Women with occult UI
Interventions POP+SUI surgery vs POP surgery alone
Outcomes
Starting date
Contact information
Notes
Glazener 2009
Trial name or title PROSPECT (PROlapse Surgery: Pragmatic Evaluaiton and randomised Controlled Trials)
Methods RCT
Participants Women having prolapse surgery
Interventions Anterior and posterior repair (colporrhaphy) with or without non-absorbable or biological mesh inlay, or
mesh kit
Outcomes Prolapse symptoms (POP-SS); prolapse stage (POP-Q), economic outcomes
Starting date 01 09 2009
83Surgery for women with apical vaginal prolapse (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Glazener 2009 (Continued)
Contact information c.glazener@abdn.ac.uk
Notes HTA funded study in UK
van der Steen 2010
Trial name or title CUPIDO 1 and CUPIDO 2
Methods RCT
Participants Women with SUI (CUPIDO 1) and women with occult SUI (CUPIDO 2)
Interventions POP+SUI surgery vs POP surgery alone
Outcomes
Starting date
Contact information
Notes
Verleyen 2004
Trial name or title Porcine dermis versus Vicryl plug in Raz cystocele repair
Methods
Participants 79 women (76 with concomitant prolapse)
Interventions RCT, porcine dermis versus Vicryl
Outcomes UDI, IIQ, urinary urgency, recurrent cystocele
Starting date 2003?
Contact information Dr P Verleyen, University Hospitals, Gassthuisberg
Notes Abstract of ongoing study reported ICS/IUGA Paris 2004
IIQ = Incontinence impact questionnaire
POP = Pelvic organ prolapse
POP-Q = Pelvic organ prolapse quantification (according to ICS)
RCT = randomised controlled trial
SUI = Stress Urinary Incontinence
UDI = Urogenital Distress Inventory
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UI = urinary infection
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D A T A A N D A N A L Y S E S
Comparison 1. Vaginal procedure versus sacral colpopexy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Awareness of prolapse (2 years) 3 277 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [1.06, 4.21]
1.1 Total vaginal mesh versus
abdominal sacrocolpopexy
1 108 Risk Ratio (M-H, Fixed, 95% CI) 4.15 [0.48, 35.94]
1.2 Vaginal sacrospinous
colpopexy vs abdominal sacral
colpopexy
2 169 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [0.91, 3.93]
2 Repeat surgery (2-4 years) 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Repeat surgery prolapse
(2-4 years)
4 383 Risk Ratio (M-H, Fixed, 95% CI) 2.28 [1.20, 4.32]
2.2 Repeat surgery for Urinary
incontinence 2 years
4 395 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [0.72, 4.86]
3 Any recurrent prolapse (1-2
years)
4 390 Risk Ratio (M-H, Fixed, 95% CI) 1.89 [1.33, 2.70]
4 Mesh exposure (1-4 years) 6 574 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.47, 2.69]
4.1 Vaginal mesh versus
abdominal sacrocolpopexy
2 178 Risk Ratio (M-H, Fixed, 95% CI) 2.40 [0.74, 7.83]
4.2 Vaginal sacrospinous
colpopexy vs abdominal sacral
colpopexy
3 286 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.03, 2.91]
4.3 Uterosacral colpopexy
versus sacral colpopexy
1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.22]
5 Injuries 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Bladder 5 511 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.14, 2.36]
5.2 Bowel 3 306 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.12, 3.23]
6 Repeat surgery for mesh
exposure (2-4 years)
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7 Objective failure (2-4 years) 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Anterior compartment
prolapse (2-4 years)
2 199 Risk Ratio (M-H, Fixed, 95% CI) 4.02 [1.71, 9.49]
7.2 Apical compartment
prolapse (2-4 years)
3 275 Risk Ratio (M-H, Fixed, 95% CI) 8.15 [2.71, 24.49]
7.3 Posterior compartment
prolapse (2-4 years)
2 199 Risk Ratio (M-H, Fixed, 95% CI) 3.43 [1.10, 10.66]
8 POPQ assessment (2 years) 1 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Point Ba (POPQ) 1 108 Std. Mean Difference (IV, Fixed, 95% CI) 0.80 [0.41, 1.19]
8.2 Point Bp (POPQ) 1 108 Std. Mean Difference (IV, Fixed, 95% CI) 0.77 [0.38, 1.16]
8.3 Point C (POPQ) 1 108 Std. Mean Difference (IV, Fixed, 95% CI) 0.50 [0.11, 0.88]
8.4 Total vaginal length 1 108 Std. Mean Difference (IV, Fixed, 95% CI) -0.89 [-1.29, -0.50]
9 Stress urinary incontinence (2
years)
3 263 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [1.17, 2.94]
9.1 vaginal mesh versus
abdominal sacrocolpopexy
1 108 Risk Ratio (M-H, Fixed, 95% CI) 1.93 [0.84, 4.40]
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9.2 Vaginal sacrospinous
colpopexy vs abdominal sacral
colpopexy (persistent)
2 155 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [1.05, 3.17]
10 Urge incontinence (de novo (2
years)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Vaginal sacrospinous
colpopexy vs abdominal sacral
colpopexy (de novo)
1 62 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [0.68, 3.81]
11 Urinary Voiding dysfunction
(de novo)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Vaginal sacrospinous
colpopexy vs abdominal sacral
colpopexy (de novo)
1 75 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.07, 15.82]
12 Dyspareunia 3 106 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.17, 5.50]
12.1 Vaginal sacrospinous
colpopexy vs abdominal sacral
colpopexy (persistent)
3 106 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.17, 5.50]
13 Sexual function 1 110 Mean Difference (IV, Fixed, 95% CI) 7.90 [0.70, 15.10]
13.1 Pelvic floor distress
inventory (PFD1-20) 0-300
1 110 Mean Difference (IV, Fixed, 95% CI) 7.90 [0.70, 15.10]
14 Quality of life and satisfaction
(4 years)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 Pelvic organ prolapse/
urinary incontinence sexual
questionnaire (PISQ)
1 110 Mean Difference (IV, Fixed, 95% CI) -1.20 [-4.35, 1.95]
14.2 Prolapse quality of life
questionnaire (P-QOL) 0-100
1 110 Mean Difference (IV, Fixed, 95% CI) 22.70 [-7.53, 52.93]
15 Operating time (minutes) 4 403 Mean Difference (IV, Fixed, 95% CI) -21.49 [-26.00, -14.
98]
15.1 vaginal sacrospinous
colpopexy versus sacral
colpopexy
3 293 Mean Difference (IV, Fixed, 95% CI) -21.04 [-29.94, -12.
15]
15.2 vaginal mesh versus
sacral colpopexy
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 uterosacral colpopexy
versus sacral colpopexy
1 110 Mean Difference (IV, Fixed, 95% CI) -22.0 [-31.56, -12.
44]
16 Length of hospital stay 4 403 Mean Difference (IV, Random, 95% CI) 0.19 [-0.50, 0.89]
16.1 vaginal sacrospinous
colpopexy versus sacral
colpopexy
3 293 Mean Difference (IV, Random, 95% CI) -0.12 [-1.13, 0.90]
16.2 uterosacral colpopexy
versus sacral colpopexy
1 110 Mean Difference (IV, Random, 95% CI) 0.80 [0.57, 1.03]
17 Blood transfusion 3 277 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.04, 1.57]
17.1 Total vaginal mesh versus
abdominal sacrocolpopexy
1 108 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.72]
17.2 Vaginal sacrospinous
colpopexy vs abdominal sacral
colpopexy
2 169 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.03, 2.11]
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Comparison 2. Vaginal surgery with mesh versus without mesh
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Awareness of prolapse (3 years) 1 54 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.35, 3.30]
2 Repeat surgery (1-3 years) 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Prolapse 5 497 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.30, 1.60]
2.2 Urinary incontinence 2 220 Risk Ratio (M-H, Fixed, 95% CI) 4.91 [0.86, 27.94]
3 Recurrent prolapse on
examination (1-3 years)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 hymen or beyond anterior
compartment
1 169 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.52, 1.38]
3.2 hymen or beyond apical
compartment
1 169 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.21, 1.18]
3.3 hymen or beyond
posterior compartment
1 169 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.03, 0.45]
3.4 POP 3 269 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.09, 1.40]
4 Injuries 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Bladder 4 445 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.91, 9.89]
4.2 Bowel 3 389 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.65]
5 Objective failure 2 336 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.45, 1.34]
5.1 Anterior vaginal prolapse 2 111 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.31, 1.20]
5.2 Apical vaginal prolapse 2 111 Risk Ratio (M-H, Fixed, 95% CI) 3.20 [0.34, 29.78]
5.3 Posterior vaginal prolapse 2 114 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.29, 2.45]
6 POPQ assessment (1 year) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Point Ba POPQ 2 239 Mean Difference (IV, Random, 95% CI) -1.71 [-2.88, -0.55]
6.2 Point Bp POPQ 2 239 Mean Difference (IV, Random, 95% CI) -0.59 [-1.07, -0.12]
6.3 Point C POPQ 2 239 Mean Difference (IV, Random, 95% CI) -1.93 [-3.99, 0.13]
7 Stress urinary incontinence (1-3
years))
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Mesh versus no mesh (de
novo)
4 295 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.94, 1.99]
7.2 native tissue versus mesh 3 178 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.66, 1.92]
7.3 high levator myorrhaphy
versus uterosacral colpopexy
(de novo)
1 116 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.16, 0.68]
7.4 high levator myorrhaphy
versus uterosacral colpopexy
1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [0.54, 5.66]
8 Urge incontinence 4 362 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.72, 2.82]
8.1 sacrospinous colpopexy
versus PIVS mesh (de novo)
2 95 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.30, 7.31]
8.2 vaginal colpopexy versus
transvaginal polypropylene
mesh (de novo)
1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.36, 2.30]
8.3 high levator myorrhaphy
versus uterosacral colpopexy
(de novo)
1 116 Risk Ratio (M-H, Fixed, 95% CI) 3.5 [0.76, 16.14]
9 Voiding dysfunction 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 sacrospinous colpopexy
versus PIVS mesh
2 111 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.29, 1.24]
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10 Dyspareunia (1-3 years) 5 501 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.55, 2.66]
10.1 sacrospinous colpopexy
versus PIVS mesh
1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.90]
10.2 transvaginal
polypropylene mesh versus
native tissue repair
4 435 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.59, 3.10]
11 Pelvic organ prolapse/
urinary incontinence sexual
questionnaire (PISQ) (1 year)
3 180 Mean Difference (IV, Fixed, 95% CI) -1.72 [-3.57, 0.14]
12 Patient Global Impression of
Improvement (PGI-I)( much
or very much better 3 years)
1 51 Odds Ratio (M-H, Fixed, 95% CI) 1.75 [0.37, 8.24]
12.1 transvaginal
polypropylene mesh versus
native tissue repair
1 51 Odds Ratio (M-H, Fixed, 95% CI) 1.75 [0.37, 8.24]
13 Quality of life PROLAPSE 1 167 Mean Difference (IV, Fixed, 95% CI) 5.70 [1.53, 9.87]
13.1 Prolapse Quality of
Life Questioannaire (P-QOL)
0-100
1 167 Mean Difference (IV, Fixed, 95% CI) 5.70 [1.53, 9.87]
14 Operating time (mins) 3 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Transvaginal mesh versus
native tissue repair
3 294 Mean Difference (IV, Random, 95% CI) -3.27 [-14.96, 8.43]
15 Blood transfusion 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 vaginal mesh versus
transvaginal colpopexy
2 249 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.17, 5.46]
Comparison 3. Vaginal surgery: comparison of one native tissue repair versus another
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Awareness of prolapse (2 years) 1 303 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.58, 1.43]
2 Repeat surgery (2 years) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Prolapse 1 316 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.33, 4.40]
3 Injuries 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Bladder 1 316 Risk Ratio (M-H, Fixed, 95% CI) 8.67 [0.47, 159.64]
3.2 ureteric injury (detected
intra-operative)
2 544 Risk Ratio (M-H, Fixed, 95% CI) 15.91 [2.13, 118.51]
3.3 ureteric injury (detected
post-operatively)
2 544 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [0.12, 70.38]
3.4 Bowel 1 316 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.82]
4 Objective failure 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Anterior compartment
prolapse (1-2 years)
2 537 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.85, 1.57]
4.2 Apical compartment
prolapse (1-2 years)
2 536 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.38, 1.67]
4.3 Posterior compartment
prolapse (1-2 years)
2 537 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.63, 2.06]
5 POPQ assessment 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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5.1 Point Ba POPQ 1 374 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.39, 0.19]
5.2 Point Bp POPQ 1 374 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.04, 0.04]
6 Stress urinary incontinence de
novo(1 year)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 uterosacral colpopexy
versus high levator myorrhaphy
de novo
1 228 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.64, 3.98]
7 Urge incontinence 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 uterosacral colpopexy
versus high levator myorrhaphy
(de novo)
1 116 Risk Ratio (M-H, Fixed, 95% CI) 3.5 [0.76, 16.14]
8 Dyspareunia (1 year) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 uterosacral colpopexy
versus levator myorrhaphy
1 228 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.73, 1.95]
8.2 uterosacral colpopexy
versus high levator myorrhaphy
(de novo)
1 228 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.50, 3.39]
9 Blood transfusion 1 315 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.50, 5.60]
Comparison 4. Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Awareness of prolapse 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Vaginal hysterectomy
vs vaginal uterus-preserving
surgery ( 1 year review)
1 208 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.33, 2.94]
1.2 Vaginal hysterectomy vs
abdominal uterus-preserving
surgery ( 1 year review)
1 84 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.15, 0.98]
2 Repeat prolapse surgery 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Vaginal vs abdominal
hysterectomy
1 47 Risk Ratio (M-H, Random, 95% CI) 2.88 [0.12, 67.29]
2.2 Vaginal hysterectomy
vs vaginal uterus-preserving
surgery ( 1 year review)
2 270 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.19, 8.91]
2.3 Vaginal hysterectomy vs
abdominal uterus-preserving
surgery 1-8 year review)
2 182 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.36, 1.31]
3 Objective failure any site (POP) 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Vaginal vs abdominal
hysterectomy
1 47 Risk Ratio (M-H, Fixed, 95% CI) 4.8 [0.24, 94.90]
3.2 Vag hysterectomy vs vag
uterus-preserving surgery (1
year review)
1 204 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.67, 1.21]
4 Bladder injuries 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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4.1 Vag hysterectomy vs vag
uterus-preserving surgery (1
year review)
1 65 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Bowel injuries (1 year review) 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Vag hysterectomy vs vag
uterus-preserving surgery
1 67 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Vag hysterectomy vs abdo
uterus-preserving surgery
1 82 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 71.56]
6 Mesh exposure 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Vaginal vs abdominal
hysterectomy
1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.48]
6.2 Vag hysterectomy vs abdo
uterus-preserving surgery
1 82 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 4.04]
7 Repeat surgery for mesh
exposure
0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Vag hysterectomy vs abdo
uterus-preserving surgery
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Repeat surgery for incontinence 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Vag hysterectomy vs vag
uterus-preserving surgery
1 204 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.45, 35.18]
9 Anterior compartment prolapse
( 1 year review)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Vag hysterectomy vs vag
uterus-preserving surgery
2 265 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.53, 1.70]
9.2 Vag hysterectomy vs abdo
uterus-preserving surgery
1 83 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.60, 1.82]
10 Apical compartment prolapse 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Vag hysterectomy vs vag
uterus-preserving surgery
2 267 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.04, 17.59]
10.2 Vag hysterectomy vs
abdo uterus-preserving surgery
1 82 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.15, 6.76]
11 Posterior compartment
prolapse
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Vag hysterectomy vs vag
uterus-preserving surgery
2 265 Risk Ratio (M-H, Fixed, 95% CI) 2.43 [1.22, 4.87]
11.2 Vag hysterectomy vs
abdo uterus-preserving surgery
1 83 Risk Ratio (M-H, Fixed, 95% CI) 3.07 [0.66, 14.35]
12 POPQ assessment Point Ba 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 Vag hysterectomy vs vag
uterus-preserving surgery
1 57 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.48, 1.28]
12.2 Vag hysterectomy vs
abdo uterus-preserving surgery
1 208 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.65, 0.05]
13 POPQ assessment: Point Bp 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 Vag hysterectomy vs vag
uterus-preserving surgery
1 57 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.45, 0.85]
13.2 Vag hysterectomy vs
abdo uterus-preserving surgery
1 208 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.14, 0.34]
14 POPQ assessment: Point C 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 Vag hysterectomy vs
abdo uterus-preserving surgery
1 208 Mean Difference (IV, Fixed, 95% CI) 0.80 [0.27, 1.33]
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15 POPQ assessment: Total
vaginal length
2 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 Vag hysterectomy vs vag
uterus-preserving surgery
2 265 Mean Difference (IV, Random, 95% CI) -0.98 [-1.86, -0.11]
16 Dyspareunia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Vag hysterectomy vs vag
uterus-preserving surgery
1 158 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.27, 3.96]
17 Quality of life:Pelvic organ
prolapse/ urinary incontinence
sexual questionnaire
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 Vag hysterectomy vs vag
uterus-preserving surgery
1 208 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.23, 1.23]
18 Operating time (minutes) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 Vag hysterectomy vs vag
uterus-preserving surgery
1 207 Mean Difference (IV, Fixed, 95% CI) 13.0 [8.26, 17.74]
18.2 Vag hysterectomy vs
abdo uterus-preserving surgery
1 83 Mean Difference (IV, Fixed, 95% CI) 10.0 [8.20, 11.80]
19 Hospital stay 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
19.1 Vag hysterectomy vs vag
uterus-preserving surgery
1 207 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.27, 0.27]
19.2 Vag hysterectomy vs
abdo uterus-preserving surgery
1 83 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.21, 0.01]
20 Blood transfusion 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 Vag hysterectomy vs
abdo uterus-preserving surgery
1 82 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.21]
Comparison 5. Sacral colpopexy mesh versus biological
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Awareness of prolapse (1-5 years) 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.02]
1.1 polypropylene mesh versus
cadaveric fascia
1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.02]
2 Prolapse surgery (1-5 year) 2 173 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.24]
2.1 polypropylene mesh versus
cadaveric fascia
1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.24]
2.2 polypropylene mesh versus
porcine dermis graft
1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Surgery stress urinary
incontinence 5 years
1 58 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 70.74]
3.1 polypropylene mesh versus
cadaveric fascia
1 58 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 70.74]
4 Recurrent prolapse (any site on
examination (1-5 year))
2 173 Risk Ratio (M-H, Fixed, 99% CI) 0.49 [0.20, 1.25]
4.1 polypropylene mesh versus
cadaveric fascia
1 58 Risk Ratio (M-H, Fixed, 99% CI) 0.22 [0.03, 1.48]
4.2 polypropylene mesh versus
porcine dermis graft
1 115 Risk Ratio (M-H, Fixed, 99% CI) 0.71 [0.24, 2.14]
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5 Mesh exposure (1-5 year) 2 173 Risk Ratio (M-H, Fixed, 95% CI) 2.35 [0.36, 15.40]
5.1 polypropylene mesh versus
cadaveric fascia
1 58 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 20.86]
5.2 polypropylene mesh versus
porcine dermis SC
1 115 Risk Ratio (M-H, Fixed, 95% CI) 3.05 [0.13, 73.39]
6 Bladder injury 2 224 Risk Ratio (M-H, Fixed, 95% CI) 2.51 [0.10, 60.13]
6.1 polypropylene mesh versus
porcine dermis graft
1 125 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 polypropylene mesh versus
cadaveric fascia
1 99 Risk Ratio (M-H, Fixed, 95% CI) 2.51 [0.10, 60.13]
7 Bowel injury 1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.1 polypropylene mesh versus
porcine dermis graft
1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 polypropylene mesh versus
cadaveric fascia
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Surgery mesh exposure 1-5 years 2 173 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 20.86]
8.1 polypropylene mesh versus
cadaveric fascia
1 58 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 20.86]
8.2 polypropylene mesh versus
porcine dermis graft
1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 apical prolapse 2 204 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 POPQ assessment 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Point Ba POPQ 1 58 Mean Difference (IV, Fixed, 95% CI) 0.8 [0.20, 1.40]
10.2 Point Bp POPQ 1 58 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.51, 0.11]
10.3 Point C POPQ 1 58 Mean Difference (IV, Fixed, 95% CI) 0.31 [-0.41, 1.03]
10.4 Total vaginal length 1 58 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.69, 0.49]
11 Dyspareunia (de novo 1 year)) 1 115 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.26, 8.50]
11.1 polypropylene mesh
versus porcine graft SC
1 115 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.26, 8.50]
11.2 polypropylene mesh
versus cadaveric fascia
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Sexual function 1 115 Mean Difference (IV, Fixed, 95% CI) -1.60 [-3.67, 0.47]
12.1 Pelvic organ prolapse/
urinary incontinence sexual
questionnare (PISQ)
1 115 Mean Difference (IV, Fixed, 95% CI) -1.60 [-3.67, 0.47]
13 Quality of life PROLAPSE (i
year)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 Pelvic Floor Impact
Questionnaire (PFIQ-7) 0-400
1 115 Mean Difference (IV, Fixed, 95% CI) -7.0 [-29.48, 15.48]
13.2 Pelvic floor distress
inventory (PFD1-20) 0-300
1 115 Mean Difference (IV, Fixed, 95% CI) -6.0 [-25.75, 13.75]
14 Operating time (mins) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 polypropylene mesh
versus cadaveric fascia
1 100 Mean Difference (IV, Random, 95% CI) -6.0 [-31.51, 19.51]
15 Hospital stay 1 115 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 polypropylene mesh
versus porcine dermis
1 115 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Blood transfusion 2 215 Risk Ratio (M-H, Fixed, 95% CI) 2.56 [0.11, 61.45]
16.1 polypropylene mesh
versus porcine dermis graft
1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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16.2 polypropylene mesh
versus cadaveric fascia
1 100 Risk Ratio (M-H, Fixed, 95% CI) 2.56 [0.11, 61.45]
17 pain at normal acivities (week
one)
1 78 Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.86, 0.06]
18 Surgery or pessary for prolapse 3 256 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.24, 2.15]
Comparison 6. Sacral colpopexy: Laparoscopic versus other
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Repeat Prolapse Surgery 1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.16, 6.80]
1.1 laparoscopic versus open
sacral colpopexy
1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.16, 6.80]
1.2 laparoscopic versus robotic
sacral colpopexy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Recurrent prolapse (any site on
examination)
2 96 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.25, 3.06]
2.1 laparoscopic versus open
sacral colpopexy
1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.16, 6.80]
2.2 laparoscopic versus robotic
sacral colpopexy
1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.14, 4.12]
3 Mesh exposure 3 186 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 4.40]
3.1 laparoscopic versus open
sacral colpopexy
1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 laparoscopic versus robotic
sacral colpopexy
2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 4.40]
4 Bladder injury 3 199 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [0.43, 7.14]
4.1 laparoscopic versus open
sacral colpopexy
1 53 Risk Ratio (M-H, Fixed, 95% CI) 3.11 [0.13, 73.09]
4.2 laparoscopic versus robotic
sacral colpopexy
2 146 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.30, 7.24]
5 Bowel injury 2 108 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.04, 3.32]
5.1 laparoscopic versus open
sacral colpopexy
1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.11]
5.2 laparoscopic versus robotic
sacral colpopexy
1 61 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.02, 8.66]
6 Point Ba 1 78 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.31, 0.41]
6.1 laparoscopic versus robotic
sacral colpopexy
1 78 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.31, 0.41]
7 Point Bp 2 125 Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.76, -0.05]
7.1 laparoscopic versus open
sacral colpopexy
1 47 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.21, 0.01]
7.2 laparoscopic versus robotic
sacral colpopexy
1 78 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.74, 0.14]
8 Point C 3 197 Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.52, 0.83]
8.1 laparoscopic versus open
sacral colpopexy
2 119 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.65, 0.80]
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8.2 laparoscopic versus robotic
sacral colpopexy
1 78 Mean Difference (IV, Fixed, 95% CI) 0.70 [-1.23, 2.63]
9 Stress urinary incontinence (de
novo and persistent)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10 Quality of life PROLAPSE 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 questionnaire (P-QOL)
0-100
1 47 Mean Difference (IV, Fixed, 95% CI) 0.70 [-19.14, 20.54]
10.2 Pelvic Floor Impact
Questionnaire (PFIQ-7) 0-400
1 78 Mean Difference (IV, Fixed, 95% CI) 21.0 [-46.76, 88.76]
10.3 Pelvic floor distress
inventory (PFD1-20) 0-300
1 78 Mean Difference (IV, Fixed, 95% CI) 21.0 [-46.76, 88.76]
11 Operating time (mins) 4 265 Mean Difference (IV, Random, 95% CI) -12.30 [-52.65, 28.
05]
11.1 laparoscopic versus open
sacral-colpopexy
2 120 Mean Difference (IV, Random, 95% CI) 19.93 [2.42, 37.45]
11.2 laparoscopic versus
robotic sacral colpopexy
2 145 Mean Difference (IV, Random, 95% CI) -45.27 [-85.45, -5.
09]
12 Hospital stay 3 194 Mean Difference (IV, Random, 95% CI) -0.99 [-1.85, -0.14]
12.1 Laparoscopic versus open
sacral colpopexy
2 126 Mean Difference (IV, Random, 95% CI) -1.35 [-2.12, -0.57]
12.2 laparoscopic versus
robotic sacral colpopexy
1 68 Mean Difference (IV, Random, 95% CI) -0.39 [-0.81, 0.03]
13 Blood transfusion 1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.1 laparoscopic versus
robotic sacral colpopexy
1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 continence surgery 2 125 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.24, 4.29]
14.1 laparoscopic versus open
sacral colpopexy
1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.48]
14.2 laparoscopic versus
robotic sacral colpopexy
1 78 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.28, 8.94]
Comparison 7. Sacral colpopexy with continence surgery vs without
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Awareness of prolapse (7 years) 1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.75, 1.89]
2 Repeat prolapse surgery or
pessary (2-7 years))
3 256 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.24, 2.15]
3 Repeat surgery for incontinence
(7 years))
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4 Objective failure any site (POP
7 years)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5 POPQ assessment Point Ba 1 322 Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.62, -0.18]
6 POPQ assessment: Point Bp 1 322 Mean Difference (IV, Fixed, 95% CI) 0.30 [0.11, 0.49]
7 POPQ assessment: Point C 1 322 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.11, 0.51]
8 Stress urinary incontinence (4-7
years)
3 295 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.63, 2.04]
9 Operating time (minutes) 1 322 Mean Difference (IV, Fixed, 95% CI) 20.0 [7.44, 32.56]
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10 Blood transfusion 1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.20, 4.33]
Analysis 1.1. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 1 Awareness of prolapse
(2 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 1 Awareness of prolapse (2 years)
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Total vaginal mesh versus abdominal sacrocolpopexy
Maher 2011 4/53 1/55 9.6 % 4.15 [ 0.48, 35.94 ]
Subtotal (95% CI) 53 55 9.6 % 4.15 [ 0.48, 35.94 ]
Total events: 4 (vaginal surgery), 1 (sacral colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
2 Vaginal sacrospinous colpopexy vs abdominal sacral colpopexy
Benson 1996 14/42 6/38 61.9 % 2.11 [ 0.90, 4.94 ]
Maher 2004 4/43 3/46 28.5 % 1.43 [ 0.34, 6.01 ]
Subtotal (95% CI) 85 84 90.4 % 1.90 [ 0.91, 3.93 ]
Total events: 18 (vaginal surgery), 9 (sacral colpopexy)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
Total (95% CI) 138 139 100.0 % 2.11 [ 1.06, 4.21 ]
Total events: 22 (vaginal surgery), 10 (sacral colpopexy)
Heterogeneity: Chi2 = 0.66, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
0.01 0.1 1 10 100
Favours vaginal surgery Favours sacral colpopexy
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Analysis 1.2. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 2 Repeat surgery (2-4
years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 2 Repeat surgery (2-4 years)
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Repeat surgery prolapse (2-4 years)
Benson 1996 11/42 5/38 43.7 % 1.99 [ 0.76, 5.21 ]
Maher 2004 3/43 1/46 8.0 % 3.21 [ 0.35, 29.69 ]
Maher 2011 3/55 0/53 4.2 % 6.75 [ 0.36, 127.62 ]
Rondini 2015 11/56 5/50 44.0 % 1.96 [ 0.73, 5.26 ]
Subtotal (95% CI) 196 187 100.0 % 2.28 [ 1.20, 4.32 ]
Total events: 28 (vaginal surgery), 11 (sacral colpopexy)
Heterogeneity: Chi2 = 0.78, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
2 Repeat surgery for Urinary incontinence 2 years
Benson 1996 5/42 1/38 16.8 % 4.52 [ 0.55, 37.01 ]
Lo 1998 1/66 2/52 35.9 % 0.39 [ 0.04, 4.23 ]
Maher 2004 3/43 2/46 31.0 % 1.60 [ 0.28, 9.14 ]
Maher 2011 3/55 1/53 16.3 % 2.89 [ 0.31, 26.93 ]
Subtotal (95% CI) 206 189 100.0 % 1.87 [ 0.72, 4.86 ]
Total events: 12 (vaginal surgery), 6 (sacral colpopexy)
Heterogeneity: Chi2 = 2.51, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
0.01 0.1 1 10 100
Favours vaginal surgery Favours sacral colpopexy
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Analysis 1.3. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 3 Any recurrent prolapse
(1-2 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 3 Any recurrent prolapse (1-2 years)
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 10/38 9/38 25.7 % 1.11 [ 0.51, 2.42 ]
Maher 2004 13/42 11/46 29.9 % 1.29 [ 0.65, 2.57 ]
Maher 2011 32/55 12/53 34.8 % 2.57 [ 1.49, 4.44 ]
Lo 1998 13/66 3/52 9.6 % 3.41 [ 1.03, 11.35 ]
Total (95% CI) 201 189 100.0 % 1.89 [ 1.33, 2.70 ]
Total events: 68 (vaginal surgery), 35 (sacral colpopexy)
Heterogeneity: Chi2 = 5.10, df = 3 (P = 0.16); I2 =41%
Test for overall effect: Z = 3.54 (P = 0.00040)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vaginal surgery Favours sacral colpopexy
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Analysis 1.4. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 4 Mesh exposure (1-4
years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 4 Mesh exposure (1-4 years)
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal mesh versus abdominal sacrocolpopexy
Lim 2012 2/32 3/38 29.4 % 0.79 [ 0.14, 4.45 ]
Maher 2011 7/55 1/53 10.9 % 6.75 [ 0.86, 52.98 ]
Subtotal (95% CI) 87 91 40.3 % 2.40 [ 0.74, 7.83 ]
Total events: 9 (vaginal surgery), 4 (sacral colpopexy)
Heterogeneity: Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Vaginal sacrospinous colpopexy vs abdominal sacral colpopexy
Benson 1996 0/42 0/38 Not estimable
Lo 1998 0/66 1/52 18.0 % 0.26 [ 0.01, 6.34 ]
Maher 2004 0/42 1/46 15.4 % 0.36 [ 0.02, 8.71 ]
Subtotal (95% CI) 150 136 33.3 % 0.31 [ 0.03, 2.91 ]
Total events: 0 (vaginal surgery), 2 (sacral colpopexy)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
3 Uterosacral colpopexy versus sacral colpopexy
Rondini 2015 0/54 2/56 26.3 % 0.21 [ 0.01, 4.22 ]
Subtotal (95% CI) 54 56 26.3 % 0.21 [ 0.01, 4.22 ]
Total events: 0 (vaginal surgery), 2 (sacral colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 291 283 100.0 % 1.13 [ 0.47, 2.69 ]
Total events: 9 (vaginal surgery), 8 (sacral colpopexy)
Heterogeneity: Chi2 = 5.56, df = 4 (P = 0.23); I2 =28%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi2 = 4.03, df = 2 (P = 0.13), I2 =50%
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Analysis 1.5. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 5 Injuries.
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 5 Injuries
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bladder
Lo 1998 0/66 0/52 Not estimable
Maher 2011 0/55 1/53 29.9 % 0.32 [ 0.01, 7.72 ]
Rondini 2015 0/56 1/54 29.9 % 0.32 [ 0.01, 7.73 ]
Benson 1996 1/42 1/38 20.5 % 0.90 [ 0.06, 13.97 ]
Maher 2004 1/48 1/47 19.8 % 0.98 [ 0.06, 15.20 ]
Subtotal (95% CI) 267 244 100.0 % 0.57 [ 0.14, 2.36 ]
Total events: 2 (vaginal surgery), 4 (sacral colpopexy)
Heterogeneity: Chi2 = 0.51, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Bowel
Benson 1996 0/42 1/38 43.0 % 0.30 [ 0.01, 7.21 ]
Maher 2011 0/55 1/53 41.7 % 0.32 [ 0.01, 7.72 ]
Lo 1998 1/66 0/52 15.3 % 2.37 [ 0.10, 57.08 ]
Subtotal (95% CI) 163 143 100.0 % 0.63 [ 0.12, 3.23 ]
Total events: 1 (vaginal surgery), 2 (sacral colpopexy)
Heterogeneity: Chi2 = 1.05, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
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Analysis 1.6. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 6 Repeat surgery for mesh
exposure (2-4 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 6 Repeat surgery for mesh exposure (2-4 years)
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 0/32 0/38 Not estimable
Lo 1998 0/66 0/52 Not estimable
Maher 2004 0/48 1/47 0.33 [ 0.01, 7.82 ]
Maher 2011 5/55 1/53 4.82 [ 0.58, 39.89 ]
Rondini 2015 0/56 2/50 0.18 [ 0.01, 3.64 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vaginal surgery Favours sacral colpopexy
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Analysis 1.7. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 7 Objective failure (2-4
years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 7 Objective failure (2-4 years)
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Anterior compartment prolapse (2-4 years)
Maher 2004 6/43 3/46 49.6 % 2.14 [ 0.57, 8.03 ]
Rondini 2015 17/54 3/56 50.4 % 5.88 [ 1.83, 18.92 ]
Subtotal (95% CI) 97 102 100.0 % 4.02 [ 1.71, 9.49 ]
Total events: 23 (vaginal surgery), 6 (sacral colpopexy)
Heterogeneity: Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 3.18 (P = 0.0015)
2 Apical compartment prolapse (2-4 years)
Benson 1996 5/42 1/38 29.9 % 4.52 [ 0.55, 37.01 ]
Maher 2004 8/43 2/46 55.1 % 4.28 [ 0.96, 19.04 ]
Rondini 2015 16/56 0/50 15.0 % 29.53 [ 1.82, 479.76 ]
Subtotal (95% CI) 141 134 100.0 % 8.15 [ 2.71, 24.49 ]
Total events: 29 (vaginal surgery), 3 (sacral colpopexy)
Heterogeneity: Chi2 = 1.84, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 3.74 (P = 0.00019)
3 Posterior compartment prolapse (2-4 years)
Maher 2004 8/46 3/43 86.3 % 2.49 [ 0.71, 8.79 ]
Rondini 2015 4/54 0/56 13.7 % 9.33 [ 0.51, 169.20 ]
Subtotal (95% CI) 100 99 100.0 % 3.43 [ 1.10, 10.66 ]
Total events: 12 (vaginal surgery), 3 (sacral colpopexy)
Heterogeneity: Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Chi2 = 1.38, df = 2 (P = 0.50), I2 =0.0%
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Analysis 1.8. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 8 POPQ assessment (2
years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 8 POPQ assessment (2 years)
Study or subgroup vaginal surgery sacral colpopexy
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Point Ba (POPQ)
Maher 2011 55 -1.5 (1.2) 53 -2.2 (0.2) 100.0 % 0.80 [ 0.41, 1.19 ]
Subtotal (95% CI) 55 53 100.0 % 0.80 [ 0.41, 1.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000064)
2 Point Bp (POPQ)
Maher 2011 55 -1.6 (1.1) 53 -2.3 (0.64) 100.0 % 0.77 [ 0.38, 1.16 ]
Subtotal (95% CI) 55 53 100.0 % 0.77 [ 0.38, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.85 (P = 0.00012)
3 Point C (POPQ)
Maher 2011 55 -6.2 (2.6) 53 -7.5 (2.6) 100.0 % 0.50 [ 0.11, 0.88 ]
Subtotal (95% CI) 55 53 100.0 % 0.50 [ 0.11, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
4 Total vaginal length
Maher 2011 55 7.8 (1.4) 53 8.8 (0.7) 100.0 % -0.89 [ -1.29, -0.50 ]
Subtotal (95% CI) 55 53 100.0 % -0.89 [ -1.29, -0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.41 (P = 0.000010)
Test for subgroup differences: Chi2 = 47.54, df = 3 (P = 0.00), I2 =94%
-1 -0.5 0 0.5 1
Favours vaginal surgery Favours sacral colpopexy
103Surgery for women with apical vaginal prolapse (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 9 Stress urinary
incontinence (2 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 9 Stress urinary incontinence (2 years)
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 vaginal mesh versus abdominal sacrocolpopexy
Maher 2011 14/55 7/53 32.7 % 1.93 [ 0.84, 4.40 ]
Subtotal (95% CI) 55 53 32.7 % 1.93 [ 0.84, 4.40 ]
Total events: 14 (vaginal surgery), 7 (sacral colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 Vaginal sacrospinous colpopexy vs abdominal sacral colpopexy (persistent)
Benson 1996 18/42 9/38 43.4 % 1.81 [ 0.93, 3.53 ]
Maher 2004 10/39 5/36 23.9 % 1.85 [ 0.70, 4.89 ]
Subtotal (95% CI) 81 74 67.3 % 1.82 [ 1.05, 3.17 ]
Total events: 28 (vaginal surgery), 14 (sacral colpopexy)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
Total (95% CI) 136 127 100.0 % 1.86 [ 1.17, 2.94 ]
Total events: 42 (vaginal surgery), 21 (sacral colpopexy)
Heterogeneity: Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0084)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 1.10. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 10 Urge incontinence
(de novo (2 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 10 Urge incontinence (de novo (2 years)
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal sacrospinous colpopexy vs abdominal sacral colpopexy (de novo)
Maher 2004 11/33 6/29 100.0 % 1.61 [ 0.68, 3.81 ]
Subtotal (95% CI) 33 29 100.0 % 1.61 [ 0.68, 3.81 ]
Total events: 11 (vaginal surgery), 6 (sacral colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 11 Urinary Voiding
dysfunction (de novo).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 11 Urinary Voiding dysfunction (de novo)
Study or subgroup
Favours
vaginal
surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal sacrospinous colpopexy vs abdominal sacral colpopexy (de novo)
Maher 2004 1/37 1/38 100.0 % 1.03 [ 0.07, 15.82 ]
Subtotal (95% CI) 37 38 100.0 % 1.03 [ 0.07, 15.82 ]
Total events: 1 (Favours vaginal surgery), 1 (sacral colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 12 Dyspareunia.
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 12 Dyspareunia
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal sacrospinous colpopexy vs abdominal sacral colpopexy (persistent)
Maher 2004 7/17 6/19 75.2 % 1.30 [ 0.55, 3.12 ]
Benson 1996 4/26 0/15 8.3 % 5.33 [ 0.31, 92.72 ]
Lo 1998 11/18 1/11 16.5 % 6.72 [ 1.00, 45.16 ]
Total (95% CI) 61 45 100.0 % 2.53 [ 1.17, 5.50 ]
Total events: 22 (vaginal surgery), 7 (sacral colpopexy)
Heterogeneity: Chi2 = 3.49, df = 2 (P = 0.17); I2 =43%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 13 Sexual function.
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 13 Sexual function
Study or subgroup
Favours
vaginal
surgery
Favours
sacral
colpopexy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pelvic floor distress inventory (PFD1-20) 0-300
Rondini 2015 56 29.9 (26) 54 22 (8.8) 100.0 % 7.90 [ 0.70, 15.10 ]
Total (95% CI) 56 54 100.0 % 7.90 [ 0.70, 15.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 14 Quality of life and
satisfaction (4 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 14 Quality of life and satisfaction (4 years)
Study or subgroup vaginal surgery sacral colpopexy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pelvic organ prolapse/ urinary incontinence sexual questionnaire (PISQ)
Rondini 2015 56 29.9 (8) 54 31.1 (8.8) 100.0 % -1.20 [ -4.35, 1.95 ]
Subtotal (95% CI) 56 54 100.0 % -1.20 [ -4.35, 1.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 Prolapse quality of life questionnaire (P-QOL) 0-100
Rondini 2015 56 77.7 (108) 54 55 (40) 100.0 % 22.70 [ -7.53, 52.93 ]
Subtotal (95% CI) 56 54 100.0 % 22.70 [ -7.53, 52.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 2.38, df = 1 (P = 0.12), I2 =58%
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Analysis 1.15. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 15 Operating time
(minutes).
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 15 Operating time (minutes)
Study or subgroup vaginal surgery sacral colpopexy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 vaginal sacrospinous colpopexy versus sacral colpopexy
Benson 1996 42 196 (38) 38 215 (47) 11.9 % -19.00 [ -37.85, -0.15 ]
Lo 1998 66 141 (37) 52 157 (35) 24.9 % -16.00 [ -29.05, -2.95 ]
Maher 2004 48 76 (42) 47 106 (37) 16.8 % -30.00 [ -45.91, -14.09 ]
Subtotal (95% CI) 156 137 53.6 % -21.04 [ -29.94, -12.15 ]
Heterogeneity: Chi2 = 1.84, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 4.64 (P < 0.00001)
2 vaginal mesh versus sacral colpopexy
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 uterosacral colpopexy versus sacral colpopexy
Rondini 2015 56 80 (24) 54 102 (27) 46.4 % -22.00 [ -31.56, -12.44 ]
Subtotal (95% CI) 56 54 46.4 % -22.00 [ -31.56, -12.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.51 (P < 0.00001)
Total (95% CI) 212 191 100.0 % -21.49 [ -28.00, -14.98 ]
Heterogeneity: Chi2 = 1.86, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 6.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 1.16. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 16 Length of hospital stay.
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 16 Length of hospital stay
Study or subgroup vaginal surgery sacral colpopexy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vaginal sacrospinous colpopexy versus sacral colpopexy
Lo 1998 52 7.24 (2.07) 66 8.77 (3.8) 18.1 % -1.53 [ -2.61, -0.45 ]
Benson 1996 38 5.4 (1.1) 42 5.1 (1.2) 27.4 % 0.30 [ -0.20, 0.80 ]
Maher 2004 47 5.4 (2.2) 48 4.8 (1.4) 23.5 % 0.60 [ -0.14, 1.34 ]
Subtotal (95% CI) 137 156 69.0 % -0.12 [ -1.13, 0.90 ]
Heterogeneity: Tau2 = 0.65; Chi2 = 11.12, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 0.23 (P = 0.82)
2 uterosacral colpopexy versus sacral colpopexy
Rondini 2015 54 3 (0.5) 56 2.2 (0.7) 31.0 % 0.80 [ 0.57, 1.03 ]
Subtotal (95% CI) 54 56 31.0 % 0.80 [ 0.57, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.92 (P < 0.00001)
Total (95% CI) 191 212 100.0 % 0.19 [ -0.50, 0.89 ]
Heterogeneity: Tau2 = 0.39; Chi2 = 19.30, df = 3 (P = 0.00024); I2 =84%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 2.97, df = 1 (P = 0.08), I2 =66%
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Analysis 1.17. Comparison 1 Vaginal procedure versus sacral colpopexy, Outcome 17 Blood transfusion.
Review: Surgery for women with apical vaginal prolapse
Comparison: 1 Vaginal procedure versus sacral colpopexy
Outcome: 17 Blood transfusion
Study or subgroup vaginal surgery sacral colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Total vaginal mesh versus abdominal sacrocolpopexy
Maher 2011 0/55 1/53 27.3 % 0.32 [ 0.01, 7.72 ]
Subtotal (95% CI) 55 53 27.3 % 0.32 [ 0.01, 7.72 ]
Total events: 0 (vaginal surgery), 1 (sacral colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2 Vaginal sacrospinous colpopexy vs abdominal sacral colpopexy
Benson 1996 0/42 2/38 46.8 % 0.18 [ 0.01, 3.66 ]
Maher 2004 0/43 1/46 25.9 % 0.36 [ 0.01, 8.51 ]
Subtotal (95% CI) 85 84 72.7 % 0.24 [ 0.03, 2.11 ]
Total events: 0 (vaginal surgery), 3 (sacral colpopexy)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 140 137 100.0 % 0.26 [ 0.04, 1.57 ]
Total events: 0 (vaginal surgery), 4 (sacral colpopexy)
Heterogeneity: Chi2 = 0.11, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 2.1. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 1 Awareness of
prolapse (3 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 1 Awareness of prolapse (3 years)
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Iglesia 2010 5/26 5/28 100.0 % 1.08 [ 0.35, 3.30 ]
Total (95% CI) 26 28 100.0 % 1.08 [ 0.35, 3.30 ]
Total events: 5 (vaginal mesh), 5 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 2 Repeat surgery (1-
3 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 2 Repeat surgery (1-3 years)
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prolapse
da Silviera 2015 2/88 3/81 24.7 % 0.61 [ 0.11, 3.58 ]
de Tayrac 2008 2/24 2/21 16.9 % 0.88 [ 0.13, 5.68 ]
Halaska 2012 1/79 3/72 24.8 % 0.30 [ 0.03, 2.86 ]
Iglesia 2010 3/32 0/33 3.9 % 7.21 [ 0.39, 134.29 ]
Svabik 2014 0/36 3/31 29.7 % 0.12 [ 0.01, 2.30 ]
Subtotal (95% CI) 259 238 100.0 % 0.69 [ 0.30, 1.60 ]
Total events: 8 (vaginal mesh), 11 (vaginal colpopexy)
Heterogeneity: Chi2 = 4.40, df = 4 (P = 0.35); I2 =9%
Test for overall effect: Z = 0.86 (P = 0.39)
2 Urinary incontinence
da Silviera 2015 4/88 0/81 34.7 % 8.29 [ 0.45, 151.65 ]
Iglesia 2010 3/25 1/26 65.3 % 3.12 [ 0.35, 28.03 ]
Subtotal (95% CI) 113 107 100.0 % 4.91 [ 0.86, 27.94 ]
Total events: 7 (vaginal mesh), 1 (vaginal colpopexy)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.80 (P = 0.073)
Test for subgroup differences: Chi2 = 3.97, df = 1 (P = 0.05), I2 =75%
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Analysis 2.3. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 3 Recurrent
prolapse on examination (1-3 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 3 Recurrent prolapse on examination (1-3 years)
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 hymen or beyond anterior compartment
da Silviera 2015 22/88 24/81 100.0 % 0.84 [ 0.52, 1.38 ]
Subtotal (95% CI) 88 81 100.0 % 0.84 [ 0.52, 1.38 ]
Total events: 22 (vaginal mesh), 24 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 hymen or beyond apical compartment
da Silviera 2015 7/88 13/81 100.0 % 0.50 [ 0.21, 1.18 ]
Subtotal (95% CI) 88 81 100.0 % 0.50 [ 0.21, 1.18 ]
Total events: 7 (vaginal mesh), 13 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
3 hymen or beyond posterior compartment
da Silviera 2015 2/88 17/81 100.0 % 0.11 [ 0.03, 0.45 ]
Subtotal (95% CI) 88 81 100.0 % 0.11 [ 0.03, 0.45 ]
Total events: 2 (vaginal mesh), 17 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 3.04 (P = 0.0024)
4 POP
Halaska 2012 13/79 28/72 38.2 % 0.42 [ 0.24, 0.75 ]
Iglesia 2010 16/25 16/26 39.4 % 1.04 [ 0.68, 1.59 ]
Svabik 2014 1/36 21/31 22.4 % 0.04 [ 0.01, 0.29 ]
Subtotal (95% CI) 140 129 100.0 % 0.36 [ 0.09, 1.40 ]
Total events: 30 (vaginal mesh), 65 (vaginal colpopexy)
Heterogeneity: Tau2 = 1.19; Chi2 = 21.71, df = 2 (P = 0.00002); I2 =91%
Test for overall effect: Z = 1.47 (P = 0.14)
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Analysis 2.4. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 4 Injuries.
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 4 Injuries
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bladder
da Silviera 2015 3/94 1/90 29.2 % 2.87 [ 0.30, 27.11 ]
de Tayrac 2008 2/21 1/24 26.7 % 2.29 [ 0.22, 23.44 ]
Halaska 2012 3/79 1/72 29.9 % 2.73 [ 0.29, 25.70 ]
Iglesia 2010 2/32 0/33 14.1 % 5.15 [ 0.26, 103.30 ]
Subtotal (95% CI) 226 219 100.0 % 3.00 [ 0.91, 9.89 ]
Total events: 10 (vaginal mesh), 3 (vaginal colpopexy)
Heterogeneity: Chi2 = 0.19, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.80 (P = 0.072)
2 Bowel
da Silviera 2015 1/88 0/88 100.0 % 3.00 [ 0.12, 72.65 ]
de Tayrac 2008 0/21 0/24 Not estimable
Halaska 2012 0/85 0/83 Not estimable
Subtotal (95% CI) 194 195 100.0 % 3.00 [ 0.12, 72.65 ]
Total events: 1 (vaginal mesh), 0 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 2.5. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 5 Objective failure.
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 5 Objective failure
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Anterior vaginal prolapse
de Tayrac 2008 1/21 6/24 23.3 % 0.19 [ 0.02, 1.46 ]
Meschia 2004a 9/33 11/33 45.7 % 0.82 [ 0.39, 1.71 ]
Subtotal (95% CI) 54 57 69.0 % 0.61 [ 0.31, 1.20 ]
Total events: 10 (vaginal mesh), 17 (vaginal colpopexy)
Heterogeneity: Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 1.43 (P = 0.15)
2 Apical vaginal prolapse
de Tayrac 2008 1/21 0/24 1.9 % 3.41 [ 0.15, 79.47 ]
Meschia 2004a 1/33 0/33 2.1 % 3.00 [ 0.13, 71.07 ]
Subtotal (95% CI) 54 57 4.0 % 3.20 [ 0.34, 29.78 ]
Total events: 2 (vaginal mesh), 0 (vaginal colpopexy)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
3 Posterior vaginal prolapse
de Tayrac 2008 1/24 0/24 2.1 % 3.00 [ 0.13, 70.16 ]
Meschia 2004a 4/33 6/33 24.9 % 0.67 [ 0.21, 2.15 ]
Subtotal (95% CI) 57 57 27.0 % 0.85 [ 0.29, 2.45 ]
Total events: 5 (vaginal mesh), 6 (vaginal colpopexy)
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 165 171 100.0 % 0.78 [ 0.45, 1.34 ]
Total events: 17 (vaginal mesh), 23 (vaginal colpopexy)
Heterogeneity: Chi2 = 4.17, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 2.04, df = 2 (P = 0.36), I2 =2%
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Analysis 2.6. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 6 POPQ assessment
(1 year).
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 6 POPQ assessment (1 year)
Study or subgroup vaginal mesh vaginal colpopexy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Point Ba POPQ
da Silviera 2015 88 -1.1 (1.8) 81 0.01 (2.3) 49.4 % -1.11 [ -1.74, -0.48 ]
Svabik 2014 36 -2.4 (0.6) 34 -0.1 (1.6) 50.6 % -2.30 [ -2.87, -1.73 ]
Subtotal (95% CI) 124 115 100.0 % -1.71 [ -2.88, -0.55 ]
Heterogeneity: Tau2 = 0.61; Chi2 = 7.56, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 2.88 (P = 0.0040)
2 Point Bp POPQ
da Silviera 2015 88 -2.4 (1.3) 81 -2 (1.9) 61.2 % -0.40 [ -0.89, 0.09 ]
Svabik 2014 36 -2.3 (0.7) 34 -1.4 (1.9) 38.8 % -0.90 [ -1.58, -0.22 ]
Subtotal (95% CI) 124 115 100.0 % -0.59 [ -1.07, -0.12 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.36, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 2.44 (P = 0.015)
3 Point C POPQ
da Silviera 2015 88 -5.1 (3.2) 81 -4.2 (4.2) 50.8 % -0.90 [ -2.03, 0.23 ]
Svabik 2014 36 -6.2 (1.3) 34 -3.2 (3.5) 49.2 % -3.00 [ -4.25, -1.75 ]
Subtotal (95% CI) 124 115 100.0 % -1.93 [ -3.99, 0.13 ]
Heterogeneity: Tau2 = 1.83; Chi2 = 5.95, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Chi2 = 4.23, df = 2 (P = 0.12), I2 =53%
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Analysis 2.7. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 7 Stress urinary
incontinence (1-3 years)).
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 7 Stress urinary incontinence (1-3 years))
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mesh versus no mesh (de novo)
de Tayrac 2008 0/21 1/24 4.2 % 0.38 [ 0.02, 8.83 ]
Halaska 2012 27/79 18/72 56.4 % 1.37 [ 0.83, 2.26 ]
Iglesia 2010 4/13 3/19 7.3 % 1.95 [ 0.52, 7.30 ]
Svabik 2014 16/36 10/31 32.2 % 1.38 [ 0.74, 2.58 ]
Subtotal (95% CI) 149 146 100.0 % 1.37 [ 0.94, 1.99 ]
Total events: 47 (vaginal mesh), 32 (vaginal colpopexy)
Heterogeneity: Chi2 = 0.91, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
2 native tissue versus mesh
de Tayrac 2008 0/21 2/24 12.9 % 0.23 [ 0.01, 4.48 ]
Meschia 2004a 5/33 5/33 27.6 % 1.00 [ 0.32, 3.13 ]
Svabik 2014 16/36 10/31 59.4 % 1.38 [ 0.74, 2.58 ]
Subtotal (95% CI) 90 88 100.0 % 1.12 [ 0.66, 1.92 ]
Total events: 21 (vaginal mesh), 17 (vaginal colpopexy)
Heterogeneity: Chi2 = 1.55, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
3 high levator myorrhaphy versus uterosacral colpopexy (de novo)
Natale 2010 8/58 24/58 100.0 % 0.33 [ 0.16, 0.68 ]
Subtotal (95% CI) 58 58 100.0 % 0.33 [ 0.16, 0.68 ]
Total events: 8 (vaginal mesh), 24 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
4 high levator myorrhaphy versus uterosacral colpopexy
Natale 2010 7/58 4/58 100.0 % 1.75 [ 0.54, 5.66 ]
Subtotal (95% CI) 58 58 100.0 % 1.75 [ 0.54, 5.66 ]
Total events: 7 (vaginal mesh), 4 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi2 = 12.70, df = 3 (P = 0.01), I2 =76%
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Analysis 2.8. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 8 Urge incontinence.
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 8 Urge incontinence
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 sacrospinous colpopexy versus PIVS mesh (de novo)
de Tayrac 2008 0/21 1/24 11.0 % 0.38 [ 0.02, 8.83 ]
Meschia 2004a 3/25 1/25 7.8 % 3.00 [ 0.33, 26.92 ]
Subtotal (95% CI) 46 49 18.8 % 1.47 [ 0.30, 7.31 ]
Total events: 3 (vaginal mesh), 2 (vaginal colpopexy)
Heterogeneity: Chi2 = 1.12, df = 1 (P = 0.29); I2 =11%
Test for overall effect: Z = 0.47 (P = 0.64)
2 vaginal colpopexy versus transvaginal polypropylene mesh (de novo)
Halaska 2012 8/79 8/72 65.5 % 0.91 [ 0.36, 2.30 ]
Subtotal (95% CI) 79 72 65.5 % 0.91 [ 0.36, 2.30 ]
Total events: 8 (vaginal mesh), 8 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
3 high levator myorrhaphy versus uterosacral colpopexy (de novo)
Natale 2010 7/58 2/58 15.7 % 3.50 [ 0.76, 16.14 ]
Subtotal (95% CI) 58 58 15.7 % 3.50 [ 0.76, 16.14 ]
Total events: 7 (vaginal mesh), 2 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Total (95% CI) 183 179 100.0 % 1.42 [ 0.72, 2.82 ]
Total events: 18 (vaginal mesh), 12 (vaginal colpopexy)
Heterogeneity: Chi2 = 3.34, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 2.19, df = 2 (P = 0.33), I2 =9%
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Analysis 2.9. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 9 Voiding
dysfunction.
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 9 Voiding dysfunction
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 sacrospinous colpopexy versus PIVS mesh
de Tayrac 2008 3/21 8/24 48.3 % 0.43 [ 0.13, 1.41 ]
Meschia 2004a 6/33 8/33 51.7 % 0.75 [ 0.29, 1.92 ]
Subtotal (95% CI) 54 57 100.0 % 0.59 [ 0.29, 1.24 ]
Total events: 9 (vaginal mesh), 16 (vaginal colpopexy)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 10 Dyspareunia (1-
3 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 10 Dyspareunia (1-3 years)
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 sacrospinous colpopexy versus PIVS mesh
Meschia 2004a 0/33 1/33 13.9 % 0.33 [ 0.01, 7.90 ]
Subtotal (95% CI) 33 33 13.9 % 0.33 [ 0.01, 7.90 ]
Total events: 0 (vaginal mesh), 1 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 transvaginal polypropylene mesh versus native tissue repair
da Silviera 2015 (1) 3/88 5/81 48.2 % 0.55 [ 0.14, 2.24 ]
Halaska 2012 (2) 6/79 2/72 19.4 % 2.73 [ 0.57, 13.12 ]
Iglesia 2010 (3) 2/25 1/26 9.1 % 2.08 [ 0.20, 21.52 ]
Svabik 2014 (4) 2/33 1/31 9.5 % 1.88 [ 0.18, 19.70 ]
Subtotal (95% CI) 225 210 86.1 % 1.35 [ 0.59, 3.10 ]
Total events: 13 (vaginal mesh), 9 (vaginal colpopexy)
Heterogeneity: Chi2 = 2.55, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 258 243 100.0 % 1.21 [ 0.55, 2.66 ]
Total events: 13 (vaginal mesh), 10 (vaginal colpopexy)
Heterogeneity: Chi2 = 3.22, df = 4 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 0.70, df = 1 (P = 0.40), I2 =0.0%
0.01 0.1 1 10 100
favours vaginal mesh favours vaginal colpopexy
(1) Persistent
(2) persistent
(3) de novo
(4) persistent
121Surgery for women with apical vaginal prolapse (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.11. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 11 Pelvic organ
prolapse/ urinary incontinence sexual questionnaire (PISQ) (1 year).
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 11 Pelvic organ prolapse/ urinary incontinence sexual questionnaire (PISQ) (1 year)
Study or subgroup vaginal mesh vaginal colpopexy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
de Tayrac 2008 21 13.6 (9.3) 24 12.5 (9.3) 11.6 % 1.10 [ -4.35, 6.55 ]
Iglesia 2010 32 34 (6) 33 35 (6) 40.4 % -1.00 [ -3.92, 1.92 ]
Svabik 2014 36 32.6 (6.3) 34 35.6 (5.1) 48.0 % -3.00 [ -5.68, -0.32 ]
Total (95% CI) 89 91 100.0 % -1.72 [ -3.57, 0.14 ]
Heterogeneity: Chi2 = 2.14, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 12 Patient Global
Impression of Improvement (PGI-I)( much or very much better 3 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 12 Patient Global Impression of Improvement (PGI-I)( much or very much better 3 years)
Study or subgroup vaginal mesh vaginal colpopexy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 transvaginal polypropylene mesh versus native tissue repair
Iglesia 2010 (1) 22/25 21/26 100.0 % 1.75 [ 0.37, 8.24 ]
Total (95% CI) 25 26 100.0 % 1.75 [ 0.37, 8.24 ]
Total events: 22 (vaginal mesh), 21 (vaginal colpopexy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 13 Quality of life
PROLAPSE.
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 13 Quality of life PROLAPSE
Study or subgroup vaginal mesh vaginal colpopexy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prolapse Quality of Life Questioannaire (P-QOL) 0-100
da Silviera 2015 81 29.9 (17) 86 24.2 (9.1) 100.0 % 5.70 [ 1.53, 9.87 ]
Total (95% CI) 81 86 100.0 % 5.70 [ 1.53, 9.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 14 Operating time
(mins).
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 14 Operating time (mins)
Study or subgroup vaginal mesh vaginal colpopexy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Transvaginal mesh versus native tissue repair
da Silviera 2015 90 110 (43) 94 106 (46) 35.9 % 4.00 [ -8.86, 16.86 ]
de Tayrac 2008 21 105 (41) 23 101 (46) 15.6 % 4.00 [ -21.71, 29.71 ]
Meschia 2004a 33 58 (17) 33 69 (17) 48.4 % -11.00 [ -19.20, -2.80 ]
Subtotal (95% CI) 144 150 100.0 % -3.27 [ -14.96, 8.43 ]
Heterogeneity: Tau2 = 55.99; Chi2 = 4.33, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Vaginal surgery with mesh versus without mesh, Outcome 15 Blood
transfusion.
Review: Surgery for women with apical vaginal prolapse
Comparison: 2 Vaginal surgery with mesh versus without mesh
Outcome: 15 Blood transfusion
Study or subgroup vaginal mesh vaginal colpopexy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 vaginal mesh versus transvaginal colpopexy
da Silviera 2015 1/94 2/90 80.1 % 0.48 [ 0.04, 5.19 ]
Iglesia 2010 1/33 0/32 19.9 % 2.91 [ 0.12, 68.95 ]
Subtotal (95% CI) 127 122 100.0 % 0.96 [ 0.17, 5.46 ]
Total events: 2 (vaginal mesh), 2 (vaginal colpopexy)
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Vaginal surgery: comparison of one native tissue repair versus another,
Outcome 1 Awareness of prolapse (2 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 3 Vaginal surgery: comparison of one native tissue repair versus another
Outcome: 1 Awareness of prolapse (2 years)
Study or subgroup
uterosacral
colpopexy alternative surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barber 2014 29/151 32/152 100.0 % 0.91 [ 0.58, 1.43 ]
Total (95% CI) 151 152 100.0 % 0.91 [ 0.58, 1.43 ]
Total events: 29 (uterosacral colpopexy), 32 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Vaginal surgery: comparison of one native tissue repair versus another,
Outcome 2 Repeat surgery (2 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 3 Vaginal surgery: comparison of one native tissue repair versus another
Outcome: 2 Repeat surgery (2 years)
Study or subgroup
uterosacral
colpopexy alternative surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prolapse
Barber 2014 5/161 4/155 100.0 % 1.20 [ 0.33, 4.40 ]
Subtotal (95% CI) 161 155 100.0 % 1.20 [ 0.33, 4.40 ]
Total events: 5 (uterosacral colpopexy), 4 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Vaginal surgery: comparison of one native tissue repair versus another,
Outcome 3 Injuries.
Review: Surgery for women with apical vaginal prolapse
Comparison: 3 Vaginal surgery: comparison of one native tissue repair versus another
Outcome: 3 Injuries
Study or subgroup
uterosacral
colpopexy alternative surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bladder
Barber 2014 4/161 0/155 100.0 % 8.67 [ 0.47, 159.64 ]
Subtotal (95% CI) 161 155 100.0 % 8.67 [ 0.47, 159.64 ]
Total events: 4 (uterosacral colpopexy), 0 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
2 ureteric injury (detected intra-operative)
Barber 2014 5/161 0/155 50.7 % 10.59 [ 0.59, 189.97 ]
Natale 2010 10/113 0/115 49.3 % 21.37 [ 1.27, 360.38 ]
Subtotal (95% CI) 274 270 100.0 % 15.91 [ 2.13, 118.51 ]
Total events: 15 (uterosacral colpopexy), 0 (alternative surgery)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0069)
3 ureteric injury (detected post-operatively)
Barber 2014 1/161 0/155 100.0 % 2.89 [ 0.12, 70.38 ]
Natale 2010 0/113 0/115 Not estimable
Subtotal (95% CI) 274 270 100.0 % 2.89 [ 0.12, 70.38 ]
Total events: 1 (uterosacral colpopexy), 0 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
4 Bowel
Barber 2014 0/161 1/155 100.0 % 0.32 [ 0.01, 7.82 ]
Subtotal (95% CI) 161 155 100.0 % 0.32 [ 0.01, 7.82 ]
Total events: 0 (uterosacral colpopexy), 1 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
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Analysis 3.4. Comparison 3 Vaginal surgery: comparison of one native tissue repair versus another,
Outcome 4 Objective failure.
Review: Surgery for women with apical vaginal prolapse
Comparison: 3 Vaginal surgery: comparison of one native tissue repair versus another
Outcome: 4 Objective failure
Study or subgroup
uterosacral
colpopexy alternative surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Anterior compartment prolapse (1-2 years)
Barber 2014 (1) 24/159 21/149 39.3 % 1.07 [ 0.62, 1.84 ]
Natale 2010 (2) 40/113 34/116 60.7 % 1.21 [ 0.83, 1.76 ]
Subtotal (95% CI) 272 265 100.0 % 1.15 [ 0.85, 1.57 ]
Total events: 64 (uterosacral colpopexy), 55 (alternative surgery)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
2 Apical compartment prolapse (1-2 years)
Barber 2014 (3) 7/155 9/152 60.5 % 0.76 [ 0.29, 2.00 ]
Natale 2010 (4) 5/113 6/116 39.5 % 0.86 [ 0.27, 2.72 ]
Subtotal (95% CI) 268 268 100.0 % 0.80 [ 0.38, 1.67 ]
Total events: 12 (uterosacral colpopexy), 15 (alternative surgery)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
3 Posterior compartment prolapse (1-2 years)
Barber 2014 (5) 11/159 7/149 37.9 % 1.47 [ 0.59, 3.70 ]
Natale 2010 (6) 11/113 12/116 62.1 % 0.94 [ 0.43, 2.04 ]
Subtotal (95% CI) 272 265 100.0 % 1.14 [ 0.63, 2.06 ]
Total events: 22 (uterosacral colpopexy), 19 (alternative surgery)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Chi2 = 0.82, df = 2 (P = 0.66), I2 =0.0%
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(4) uterosacral colpopexy versus high levator myorrhaphy
(5) uterosacral versus sacrospinous colpopexy
(6) uterosacral colpopexy versus high levator myorrhaphy
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Analysis 3.5. Comparison 3 Vaginal surgery: comparison of one native tissue repair versus another,
Outcome 5 POPQ assessment.
Review: Surgery for women with apical vaginal prolapse
Comparison: 3 Vaginal surgery: comparison of one native tissue repair versus another
Outcome: 5 POPQ assessment
Study or subgroup
uterosacral
colpopexy alternative surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Point Ba POPQ
Barber 2014 188 -0.5 (2) 186 -0.4 (0.2) 100.0 % -0.10 [ -0.39, 0.19 ]
Subtotal (95% CI) 188 186 100.0 % -0.10 [ -0.39, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Point Bp POPQ
Barber 2014 188 -1.6 (0.2) 186 -1.6 (0.2) 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 188 186 100.0 % 0.0 [ -0.04, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
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Analysis 3.6. Comparison 3 Vaginal surgery: comparison of one native tissue repair versus another,
Outcome 6 Stress urinary incontinence de novo(1 year).
Review: Surgery for women with apical vaginal prolapse
Comparison: 3 Vaginal surgery: comparison of one native tissue repair versus another
Outcome: 6 Stress urinary incontinence de novo(1 year)
Study or subgroup
uterosacral
colpopexy alternative surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 uterosacral colpopexy versus high levator myorrhaphy de novo
Natale 2010 11/113 7/115 100.0 % 1.60 [ 0.64, 3.98 ]
Subtotal (95% CI) 113 115 100.0 % 1.60 [ 0.64, 3.98 ]
Total events: 11 (uterosacral colpopexy), 7 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Vaginal surgery: comparison of one native tissue repair versus another,
Outcome 7 Urge incontinence.
Review: Surgery for women with apical vaginal prolapse
Comparison: 3 Vaginal surgery: comparison of one native tissue repair versus another
Outcome: 7 Urge incontinence
Study or subgroup
uterosacral
colpopexy alternative surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 uterosacral colpopexy versus high levator myorrhaphy (de novo)
Natale 2010 (1) 7/58 2/58 100.0 % 3.50 [ 0.76, 16.14 ]
Subtotal (95% CI) 58 58 100.0 % 3.50 [ 0.76, 16.14 ]
Total events: 7 (uterosacral colpopexy), 2 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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(1) High levator myorrhaphy vs uterosacral vag vault suspension
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Analysis 3.8. Comparison 3 Vaginal surgery: comparison of one native tissue repair versus another,
Outcome 8 Dyspareunia (1 year).
Review: Surgery for women with apical vaginal prolapse
Comparison: 3 Vaginal surgery: comparison of one native tissue repair versus another
Outcome: 8 Dyspareunia (1 year)
Study or subgroup
uterosacral
colpopexy alternative surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 uterosacral colpopexy versus levator myorrhaphy
Natale 2010 27/113 23/115 100.0 % 1.19 [ 0.73, 1.95 ]
Subtotal (95% CI) 113 115 100.0 % 1.19 [ 0.73, 1.95 ]
Total events: 27 (uterosacral colpopexy), 23 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 uterosacral colpopexy versus high levator myorrhaphy (de novo)
Natale 2010 9/113 7/115 100.0 % 1.31 [ 0.50, 3.39 ]
Subtotal (95% CI) 113 115 100.0 % 1.31 [ 0.50, 3.39 ]
Total events: 9 (uterosacral colpopexy), 7 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 3.9. Comparison 3 Vaginal surgery: comparison of one native tissue repair versus another,
Outcome 9 Blood transfusion.
Review: Surgery for women with apical vaginal prolapse
Comparison: 3 Vaginal surgery: comparison of one native tissue repair versus another
Outcome: 9 Blood transfusion
Study or subgroup
uterosacral
colpopexy alternative surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barber 2014 7/161 4/154 100.0 % 1.67 [ 0.50, 5.60 ]
Total (95% CI) 161 154 100.0 % 1.67 [ 0.50, 5.60 ]
Total events: 7 (uterosacral colpopexy), 4 (alternative surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours uterosacral favours alternative
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Analysis 4.1. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 1
Awareness of prolapse.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 1 Awareness of prolapse
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal hysterectomy vs vaginal uterus-preserving surgery ( 1 year review)
Detollenaere 2015 6/105 6/103 100.0 % 0.98 [ 0.33, 2.94 ]
Subtotal (95% CI) 105 103 100.0 % 0.98 [ 0.33, 2.94 ]
Total events: 6 (Vaginal hysterectomy), 6 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
2 Vaginal hysterectomy vs abdominal uterus-preserving surgery ( 1 year review)
Roovers 2004 5/42 13/42 100.0 % 0.38 [ 0.15, 0.98 ]
Subtotal (95% CI) 42 42 100.0 % 0.38 [ 0.15, 0.98 ]
Total events: 5 (Vaginal hysterectomy), 13 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Chi2 = 1.61, df = 1 (P = 0.20), I2 =38%
0.01 0.1 1 10 100
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Analysis 4.2. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 2 Repeat
prolapse surgery.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 2 Repeat prolapse surgery
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal vs abdominal hysterectomy
Braun 2007 1/24 0/23 100.0 % 2.88 [ 0.12, 67.29 ]
Subtotal (95% CI) 24 23 100.0 % 2.88 [ 0.12, 67.29 ]
Total events: 1 (Vaginal hysterectomy), 0 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Vaginal hysterectomy vs vaginal uterus-preserving surgery ( 1 year review)
Detollenaere 2015 4/102 1/102 43.1 % 4.00 [ 0.45, 35.18 ]
Dietz 2010 2/31 4/35 56.9 % 0.56 [ 0.11, 2.87 ]
Subtotal (95% CI) 133 137 100.0 % 1.31 [ 0.19, 8.91 ]
Total events: 6 (Vaginal hysterectomy), 5 (Other surgery)
Heterogeneity: Tau2 = 0.99; Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 0.28 (P = 0.78)
3 Vaginal hysterectomy vs abdominal uterus-preserving surgery 1-8 year review)
Rahmanou 2015 7/50 8/50 47.8 % 0.88 [ 0.34, 2.23 ]
Roovers 2004 6/41 11/41 52.2 % 0.55 [ 0.22, 1.34 ]
Subtotal (95% CI) 91 91 100.0 % 0.68 [ 0.36, 1.31 ]
Total events: 13 (Vaginal hysterectomy), 19 (Other surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 1.10, df = 2 (P = 0.58), I2 =0.0%
0.01 0.1 1 10 100
Favours vag hysterectomy Favours other surgery
135Surgery for women with apical vaginal prolapse (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 3 Objective
failure any site (POP).
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 3 Objective failure any site (POP)
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal vs abdominal hysterectomy
Braun 2007 2/24 0/23 100.0 % 4.80 [ 0.24, 94.90 ]
Subtotal (95% CI) 24 23 100.0 % 4.80 [ 0.24, 94.90 ]
Total events: 2 (Vaginal hysterectomy), 0 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 Vag hysterectomy vs vag uterus-preserving surgery (1 year review)
Detollenaere 2015 44/100 51/104 100.0 % 0.90 [ 0.67, 1.21 ]
Subtotal (95% CI) 100 104 100.0 % 0.90 [ 0.67, 1.21 ]
Total events: 44 (Vaginal hysterectomy), 51 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 1.20, df = 1 (P = 0.27), I2 =17%
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Analysis 4.4. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 4 Bladder
injuries.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 4 Bladder injuries
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery (1 year review)
Dietz 2010 0/31 0/34 Not estimable
Subtotal (95% CI) 31 34 Not estimable
Total events: 0 (Vaginal hysterectomy), 0 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 4.5. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 5 Bowel
injuries (1 year review).
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 5 Bowel injuries (1 year review)
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Dietz 2010 0/31 0/36 Not estimable
Subtotal (95% CI) 31 36 Not estimable
Total events: 0 (Vaginal hysterectomy), 0 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Vag hysterectomy vs abdo uterus-preserving surgery
Roovers 2004 1/41 0/41 100.0 % 3.00 [ 0.13, 71.56 ]
Subtotal (95% CI) 41 41 100.0 % 3.00 [ 0.13, 71.56 ]
Total events: 1 (Vaginal hysterectomy), 0 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 4.6. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 6 Mesh
exposure.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 6 Mesh exposure
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal vs abdominal hysterectomy
Braun 2007 0/24 1/23 100.0 % 0.32 [ 0.01, 7.48 ]
Subtotal (95% CI) 24 23 100.0 % 0.32 [ 0.01, 7.48 ]
Total events: 0 (Vaginal hysterectomy), 1 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 Vag hysterectomy vs abdo uterus-preserving surgery
Roovers 2004 0/41 2/41 100.0 % 0.20 [ 0.01, 4.04 ]
Subtotal (95% CI) 41 41 100.0 % 0.20 [ 0.01, 4.04 ]
Total events: 0 (Vaginal hysterectomy), 2 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.83), I2 =0.0%
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Analysis 4.8. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 8 Repeat
surgery for incontinence.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 8 Repeat surgery for incontinence
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Detollenaere 2015 4/102 1/102 100.0 % 4.00 [ 0.45, 35.18 ]
Subtotal (95% CI) 102 102 100.0 % 4.00 [ 0.45, 35.18 ]
Total events: 4 (Vaginal hysterectomy), 1 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 9 Anterior
compartment prolapse ( 1 year review).
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 9 Anterior compartment prolapse ( 1 year review)
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Detollenaere 2015 33/99 47/101 52.2 % 0.72 [ 0.51, 1.01 ]
Dietz 2010 20/31 17/34 47.8 % 1.29 [ 0.84, 1.97 ]
Subtotal (95% CI) 130 135 100.0 % 0.95 [ 0.53, 1.70 ]
Total events: 53 (Vaginal hysterectomy), 64 (Other surgery)
Heterogeneity: Tau2 = 0.14; Chi2 = 4.52, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.18 (P = 0.86)
2 Vag hysterectomy vs abdo uterus-preserving surgery
Roovers 2004 16/42 15/41 100.0 % 1.04 [ 0.60, 1.82 ]
Subtotal (95% CI) 42 41 100.0 % 1.04 [ 0.60, 1.82 ]
Total events: 16 (Vaginal hysterectomy), 15 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 4.10. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 10 Apical
compartment prolapse.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 10 Apical compartment prolapse
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Dietz 2010 1/31 7/34 47.7 % 0.16 [ 0.02, 1.20 ]
Detollenaere 2015 7/100 2/102 52.3 % 3.57 [ 0.76, 16.77 ]
Subtotal (95% CI) 131 136 100.0 % 0.80 [ 0.04, 17.59 ]
Total events: 8 (Vaginal hysterectomy), 9 (Other surgery)
Heterogeneity: Tau2 = 4.12; Chi2 = 5.83, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Vag hysterectomy vs abdo uterus-preserving surgery
Roovers 2004 2/41 2/41 100.0 % 1.00 [ 0.15, 6.76 ]
Subtotal (95% CI) 41 41 100.0 % 1.00 [ 0.15, 6.76 ]
Total events: 2 (Vaginal hysterectomy), 2 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 4.11. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 11
Posterior compartment prolapse.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 11 Posterior compartment prolapse
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Detollenaere 2015 (1) 14/99 4/101 40.9 % 3.57 [ 1.22, 10.47 ]
Dietz 2010 (2) 9/31 6/34 59.1 % 1.65 [ 0.66, 4.09 ]
Subtotal (95% CI) 130 135 100.0 % 2.43 [ 1.22, 4.87 ]
Total events: 23 (Vaginal hysterectomy), 10 (Other surgery)
Heterogeneity: Chi2 = 1.20, df = 1 (P = 0.27); I2 =16%
Test for overall effect: Z = 2.51 (P = 0.012)
2 Vag hysterectomy vs abdo uterus-preserving surgery
Roovers 2004 (3) 6/41 2/42 100.0 % 3.07 [ 0.66, 14.35 ]
Subtotal (95% CI) 41 42 100.0 % 3.07 [ 0.66, 14.35 ]
Total events: 6 (Vaginal hysterectomy), 2 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Favours vag hysterectomy Favours other surgery
(1) vaginal hysterectomy versus sacrospinous hysteropexy
(2) vaginal hysterectomy with apical suspension versus sacrospinous hysteropexy
(3) vaginal hysterectomy versus abdo sacrohysteropexy
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Analysis 4.12. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 12 POPQ
assessment Point Ba.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 12 POPQ assessment Point Ba
Study or subgroup Vaginal hysterectomy Other surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Dietz 2010 27 -0.7 (1.5) 30 -1.1 (1.9) 100.0 % 0.40 [ -0.48, 1.28 ]
Subtotal (95% CI) 27 30 100.0 % 0.40 [ -0.48, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.38)
2 Vag hysterectomy vs abdo uterus-preserving surgery
Detollenaere 2015 (1) 105 -2 (1.2) 103 -1.7 (1.4) 100.0 % -0.30 [ -0.65, 0.05 ]
Subtotal (95% CI) 105 103 100.0 % -0.30 [ -0.65, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Chi2 = 2.07, df = 1 (P = 0.15), I2 =52%
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Analysis 4.13. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 13 POPQ
assessment: Point Bp.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 13 POPQ assessment: Point Bp
Study or subgroup Vaginal hysterectomy Other surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Dietz 2010 27 -2 (1.3) 30 -2.2 (1.2) 100.0 % 0.20 [ -0.45, 0.85 ]
Subtotal (95% CI) 27 30 100.0 % 0.20 [ -0.45, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 Vag hysterectomy vs abdo uterus-preserving surgery
Detollenaere 2015 (1) 105 -2.7 (1.2) 103 -2.8 (0.4) 100.0 % 0.10 [ -0.14, 0.34 ]
Subtotal (95% CI) 105 103 100.0 % 0.10 [ -0.14, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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(1) vaginal hysterectomy versus sacrospinous hysteropexy
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Analysis 4.14. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 14 POPQ
assessment: Point C.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 14 POPQ assessment: Point C
Study or subgroup Vaginal hysterectomy Other surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vag hysterectomy vs abdo uterus-preserving surgery
Detollenaere 2015 (1) 105 -6.6 (2.2) 103 -7.4 (1.7) 100.0 % 0.80 [ 0.27, 1.33 ]
Subtotal (95% CI) 105 103 100.0 % 0.80 [ 0.27, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Not applicable
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(1) vaginal hysterectomy versus sacrospinous hysteropexy
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Analysis 4.15. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 15 POPQ
assessment: Total vaginal length.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 15 POPQ assessment: Total vaginal length
Study or subgroup Vaginal hysterectomy Other surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Detollenaere 2015 (1) 105 8.5 (1.2) 103 9.1 (0.9) 57.3 % -0.60 [ -0.89, -0.31 ]
Dietz 2010 27 7.3 (1.5) 30 8.8 (1.3) 42.7 % -1.50 [ -2.23, -0.77 ]
Subtotal (95% CI) 132 133 100.0 % -0.98 [ -1.86, -0.11 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 5.02, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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(1) vaginal hysterectomy with apical support versus sacrospinous hysteropexy
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Analysis 4.16. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 16
Dyspareunia.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 16 Dyspareunia
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Jeng 2005 (1) 4/78 4/80 100.0 % 1.03 [ 0.27, 3.96 ]
Subtotal (95% CI) 78 80 100.0 % 1.03 [ 0.27, 3.96 ]
Total events: 4 (Vaginal hysterectomy), 4 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Favours vag hysterectomy Favours other surgery
(1) Vaginal hysterectomy versus vaginal sacrospinous uterine suspension
Analysis 4.17. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 17 Quality
of life:Pelvic organ prolapse/ urinary incontinence sexual questionnaire.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 17 Quality of life:Pelvic organ prolapse/ urinary incontinence sexual questionnaire
Study or subgroup Vaginal hysterectomy Other surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Detollenaere 2015 105 37 (4) 103 37 (5) 100.0 % 0.0 [ -1.23, 1.23 ]
Subtotal (95% CI) 105 103 100.0 % 0.0 [ -1.23, 1.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.18. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 18
Operating time (minutes).
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 18 Operating time (minutes)
Study or subgroup Vaginal hysterectomy Other surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Detollenaere 2015 105 72 (21) 102 59 (13) 100.0 % 13.00 [ 8.26, 17.74 ]
Subtotal (95% CI) 105 102 100.0 % 13.00 [ 8.26, 17.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.37 (P < 0.00001)
2 Vag hysterectomy vs abdo uterus-preserving surgery
Roovers 2004 42 107 (4.7) 41 97 (3.6) 100.0 % 10.00 [ 8.20, 11.80 ]
Subtotal (95% CI) 42 41 100.0 % 10.00 [ 8.20, 11.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.90 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.34, df = 1 (P = 0.25), I2 =26%
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Analysis 4.19. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 19
Hospital stay.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 19 Hospital stay
Study or subgroup Vaginal hysterectomy Other surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vag hysterectomy vs vag uterus-preserving surgery
Detollenaere 2015 105 3 (1) 102 3 (1) 100.0 % 0.0 [ -0.27, 0.27 ]
Subtotal (95% CI) 105 102 100.0 % 0.0 [ -0.27, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Vag hysterectomy vs abdo uterus-preserving surgery
Roovers 2004 42 7.6 (0.3) 41 7.7 (0.2) 100.0 % -0.10 [ -0.21, 0.01 ]
Subtotal (95% CI) 42 41 100.0 % -0.10 [ -0.21, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
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Analysis 4.20. Comparison 4 Vaginal hysterectomy vs alternatives for uterine prolapse, Outcome 20 Blood
transfusion.
Review: Surgery for women with apical vaginal prolapse
Comparison: 4 Vaginal hysterectomy vs alternatives for uterine prolapse
Outcome: 20 Blood transfusion
Study or subgroup Vaginal hysterectomy Other surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vag hysterectomy vs abdo uterus-preserving surgery
Roovers 2004 2/41 1/41 100.0 % 2.00 [ 0.19, 21.21 ]
Subtotal (95% CI) 41 41 100.0 % 2.00 [ 0.19, 21.21 ]
Total events: 2 (Vaginal hysterectomy), 1 (Other surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 1 Awareness of prolapse (1-
5 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 1 Awareness of prolapse (1-5 years)
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 polypropylene mesh versus cadaveric fascia
Culligan 2005 1/29 3/29 100.0 % 0.33 [ 0.04, 3.02 ]
Total (95% CI) 29 29 100.0 % 0.33 [ 0.04, 3.02 ]
Total events: 1 (sacral colpopexy % mesh), 3 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 2 Prolapse surgery (1-5
year).
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 2 Prolapse surgery (1-5 year)
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 polypropylene mesh versus cadaveric fascia
Culligan 2005 1/29 1/29 100.0 % 1.00 [ 0.07, 15.24 ]
Subtotal (95% CI) 29 29 100.0 % 1.00 [ 0.07, 15.24 ]
Total events: 1 (sacral colpopexy % mesh), 1 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 polypropylene mesh versus porcine dermis graft
Culligan 2013 0/58 0/57 Not estimable
Subtotal (95% CI) 58 57 Not estimable
Total events: 0 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 87 86 100.0 % 1.00 [ 0.07, 15.24 ]
Total events: 1 (sacral colpopexy % mesh), 1 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 3 Surgery stress urinary
incontinence 5 years.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 3 Surgery stress urinary incontinence 5 years
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 polypropylene mesh versus cadaveric fascia
Culligan 2005 1/29 0/29 100.0 % 3.00 [ 0.13, 70.74 ]
Total (95% CI) 29 29 100.0 % 3.00 [ 0.13, 70.74 ]
Total events: 1 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 4 Recurrent prolapse (any
site on examination (1-5 year)).
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 4 Recurrent prolapse (any site on examination (1-5 year))
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 polypropylene mesh versus cadaveric fascia
Culligan 2005 2/29 9/29 44.8 % 0.22 [ 0.03, 1.48 ]
Subtotal (99% CI) 29 29 44.8 % 0.22 [ 0.03, 1.48 ]
Total events: 2 (sacral colpopexy % mesh), 9 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
2 polypropylene mesh versus porcine dermis graft
Culligan 2013 8/58 11/57 55.2 % 0.71 [ 0.24, 2.14 ]
Subtotal (99% CI) 58 57 55.2 % 0.71 [ 0.24, 2.14 ]
Total events: 8 (sacral colpopexy % mesh), 11 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Total (99% CI) 87 86 100.0 % 0.49 [ 0.20, 1.25 ]
Total events: 10 (sacral colpopexy % mesh), 20 (sacral colpopexy biologic)
Heterogeneity: Chi2 = 1.93, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 1.96 (P = 0.049)
Test for subgroup differences: Chi2 = 1.89, df = 1 (P = 0.17), I2 =47%
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Analysis 5.5. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 5 Mesh exposure (1-5 year).
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 5 Mesh exposure (1-5 year)
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 polypropylene mesh versus cadaveric fascia
Culligan 2005 2/29 1/29 66.9 % 2.00 [ 0.19, 20.86 ]
Subtotal (95% CI) 29 29 66.9 % 2.00 [ 0.19, 20.86 ]
Total events: 2 (sacral colpopexy % mesh), 1 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 polypropylene mesh versus porcine dermis SC
Culligan 2013 1/57 0/58 33.1 % 3.05 [ 0.13, 73.39 ]
Subtotal (95% CI) 57 58 33.1 % 3.05 [ 0.13, 73.39 ]
Total events: 1 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 86 87 100.0 % 2.35 [ 0.36, 15.40 ]
Total events: 3 (sacral colpopexy % mesh), 1 (sacral colpopexy biologic)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.83), I2 =0.0%
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Analysis 5.6. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 6 Bladder injury.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 6 Bladder injury
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 polypropylene mesh versus porcine dermis graft
Culligan 2013 0/57 0/68 Not estimable
Subtotal (95% CI) 57 68 Not estimable
Total events: 0 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 polypropylene mesh versus cadaveric fascia
Culligan 2005 1/54 0/45 100.0 % 2.51 [ 0.10, 60.13 ]
Subtotal (95% CI) 54 45 100.0 % 2.51 [ 0.10, 60.13 ]
Total events: 1 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 111 113 100.0 % 2.51 [ 0.10, 60.13 ]
Total events: 1 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 7 Bowel injury.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 7 Bowel injury
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 polypropylene mesh versus porcine dermis graft
Culligan 2013 0/57 0/58 Not estimable
Subtotal (95% CI) 57 58 Not estimable
Total events: 0 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 polypropylene mesh versus cadaveric fascia
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 57 58 Not estimable
Total events: 0 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 5.8. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 8 Surgery mesh exposure 1-
5 years.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 8 Surgery mesh exposure 1-5 years
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 polypropylene mesh versus cadaveric fascia
Culligan 2005 2/29 1/29 100.0 % 2.00 [ 0.19, 20.86 ]
Subtotal (95% CI) 29 29 100.0 % 2.00 [ 0.19, 20.86 ]
Total events: 2 (sacral colpopexy % mesh), 1 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 polypropylene mesh versus porcine dermis graft
Culligan 2013 0/57 0/58 Not estimable
Subtotal (95% CI) 57 58 Not estimable
Total events: 0 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 86 87 100.0 % 2.00 [ 0.19, 20.86 ]
Total events: 2 (sacral colpopexy % mesh), 1 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 5.9. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 9 apical prolapse.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 9 apical prolapse
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Culligan 2005 0/44 0/45 Not estimable
Culligan 2013 0/57 0/58 Not estimable
Total (95% CI) 101 103 Not estimable
Total events: 0 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.10. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 10 POPQ assessment.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 10 POPQ assessment
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Point Ba POPQ
Culligan 2005 29 -1.8 (1.5) 29 -2.6 (0.7) 100.0 % 0.80 [ 0.20, 1.40 ]
Subtotal (95% CI) 29 29 100.0 % 0.80 [ 0.20, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0093)
2 Point Bp POPQ
Culligan 2005 29 -2.9 (0.3) 29 -2.7 (0.8) 100.0 % -0.20 [ -0.51, 0.11 ]
Subtotal (95% CI) 29 29 100.0 % -0.20 [ -0.51, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
3 Point C POPQ
Culligan 2005 29 -7.8 (1.4) 29 -8.11 (1.4) 100.0 % 0.31 [ -0.41, 1.03 ]
Subtotal (95% CI) 29 29 100.0 % 0.31 [ -0.41, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
4 Total vaginal length
Culligan 2005 (1) 29 8.4 (1.2) 29 8.5 (1.1) 100.0 % -0.10 [ -0.69, 0.49 ]
Subtotal (95% CI) 29 29 100.0 % -0.10 [ -0.69, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 9.14, df = 3 (P = 0.03), I2 =67%
-100 -50 0 50 100
sacral colpopexy % mesh sacral colpopexy biologic
(1) cadaveric fascia at sacral colpopexy versus monofilament polypropylene mesh at sacral co
160Surgery for women with apical vaginal prolapse (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.11. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 11 Dyspareunia (de novo 1
year)).
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 11 Dyspareunia (de novo 1 year))
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 polypropylene mesh versus porcine graft SC
Culligan 2013 3/58 2/57 100.0 % 1.47 [ 0.26, 8.50 ]
Subtotal (95% CI) 58 57 100.0 % 1.47 [ 0.26, 8.50 ]
Total events: 3 (sacral colpopexy % mesh), 2 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
2 polypropylene mesh versus cadaveric fascia
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 58 57 100.0 % 1.47 [ 0.26, 8.50 ]
Total events: 3 (sacral colpopexy % mesh), 2 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 5.12. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 12 Sexual function.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 12 Sexual function
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pelvic organ prolapse/ urinary incontinence sexual questionnare (PISQ)
Culligan 2013 57 3.3 (5.8) 58 4.9 (5.5) 100.0 % -1.60 [ -3.67, 0.47 ]
Total (95% CI) 57 58 100.0 % -1.60 [ -3.67, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 5.13. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 13 Quality of life
PROLAPSE (i year).
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 13 Quality of life PROLAPSE (i year)
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pelvic Floor Impact Questionnaire (PFIQ-7) 0-400
Culligan 2013 57 56 (60) 58 63 (63) 100.0 % -7.00 [ -29.48, 15.48 ]
Subtotal (95% CI) 57 58 100.0 % -7.00 [ -29.48, 15.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Pelvic floor distress inventory (PFD1-20) 0-300
Culligan 2013 57 81 (63) 58 87 (43) 100.0 % -6.00 [ -25.75, 13.75 ]
Subtotal (95% CI) 57 58 100.0 % -6.00 [ -25.75, 13.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 5.14. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 14 Operating time (mins).
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 14 Operating time (mins)
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 polypropylene mesh versus cadaveric fascia
Culligan 2005 54 227 (67) 46 233 (63) 100.0 % -6.00 [ -31.51, 19.51 ]
Subtotal (95% CI) 54 46 100.0 % -6.00 [ -31.51, 19.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 5.15. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 15 Hospital stay.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 15 Hospital stay
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 polypropylene mesh versus porcine dermis
Culligan 2013 57 1 (0) 58 1 (0) Not estimable
Total (95% CI) 57 58 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 5.16. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 16 Blood transfusion.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 16 Blood transfusion
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 polypropylene mesh versus porcine dermis graft
Culligan 2013 0/57 0/58 Not estimable
Subtotal (95% CI) 57 58 Not estimable
Total events: 0 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 polypropylene mesh versus cadaveric fascia
Culligan 2005 1/54 0/46 100.0 % 2.56 [ 0.11, 61.45 ]
Subtotal (95% CI) 54 46 100.0 % 2.56 [ 0.11, 61.45 ]
Total events: 1 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 111 104 100.0 % 2.56 [ 0.11, 61.45 ]
Total events: 1 (sacral colpopexy % mesh), 0 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 5.17. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 17 pain at normal acivities
(week one).
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 17 pain at normal acivities (week one)
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Anger 2014 38 2.7 (2.2) 40 3.6 (2.1) 100.0 % -0.90 [ -1.86, 0.06 ]
Total (95% CI) 38 40 100.0 % -0.90 [ -1.86, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 5.18. Comparison 5 Sacral colpopexy mesh versus biological, Outcome 18 Surgery or pessary for
prolapse.
Review: Surgery for women with apical vaginal prolapse
Comparison: 5 Sacral colpopexy mesh versus biological
Outcome: 18 Surgery or pessary for prolapse
Study or subgroup
sacral
colpopexy
% mesh
sacral
colpopexy
biologic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brubaker 2008 5/73 7/73 100.0 % 0.71 [ 0.24, 2.15 ]
Costantini 2007 0/31 0/32 Not estimable
Costantini 2008 0/24 0/23 Not estimable
Total (95% CI) 128 128 100.0 % 0.71 [ 0.24, 2.15 ]
Total events: 5 (sacral colpopexy % mesh), 7 (sacral colpopexy biologic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 1 Repeat Prolapse
Surgery.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 1 Repeat Prolapse Surgery
Study or subgroup laparoscopic another approach Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 laparoscopic versus open sacral colpopexy
Freeman 2013 2/23 2/24 100.0 % 1.04 [ 0.16, 6.80 ]
Subtotal (95% CI) 23 24 100.0 % 1.04 [ 0.16, 6.80 ]
Total events: 2 (laparoscopic), 2 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
2 laparoscopic versus robotic sacral colpopexy
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (laparoscopic), 0 (another approach)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 23 24 100.0 % 1.04 [ 0.16, 6.80 ]
Total events: 2 (laparoscopic), 2 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 2 Recurrent prolapse
(any site on examination).
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 2 Recurrent prolapse (any site on examination)
Study or subgroup laparoscopic another approach Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 laparoscopic versus open sacral colpopexy
Freeman 2013 2/23 2/24 41.0 % 1.04 [ 0.16, 6.80 ]
Subtotal (95% CI) 23 24 41.0 % 1.04 [ 0.16, 6.80 ]
Total events: 2 (laparoscopic), 2 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
2 laparoscopic versus robotic sacral colpopexy
Paraiso 2011 2/23 3/26 59.0 % 0.75 [ 0.14, 4.12 ]
Subtotal (95% CI) 23 26 59.0 % 0.75 [ 0.14, 4.12 ]
Total events: 2 (laparoscopic), 3 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 46 50 100.0 % 0.87 [ 0.25, 3.06 ]
Total events: 4 (laparoscopic), 5 (another approach)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 6.3. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 3 Mesh exposure.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 3 Mesh exposure
Study or subgroup laparoscopic another approach Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 laparoscopic versus open sacral colpopexy
Freeman 2013 0/23 0/24 Not estimable
Subtotal (95% CI) 23 24 Not estimable
Total events: 0 (laparoscopic), 0 (another approach)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 laparoscopic versus robotic sacral colpopexy
Anger 2014 0/38 0/40 Not estimable
Paraiso 2011 0/29 2/32 100.0 % 0.22 [ 0.01, 4.40 ]
Subtotal (95% CI) 67 72 100.0 % 0.22 [ 0.01, 4.40 ]
Total events: 0 (laparoscopic), 2 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 90 96 100.0 % 0.22 [ 0.01, 4.40 ]
Total events: 0 (laparoscopic), 2 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 4 Bladder injury.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 4 Bladder injury
Study or subgroup laparoscopic another approach Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 laparoscopic versus open sacral colpopexy
Freeman 2013 1/26 0/27 16.8 % 3.11 [ 0.13, 73.09 ]
Subtotal (95% CI) 26 27 16.8 % 3.11 [ 0.13, 73.09 ]
Total events: 1 (laparoscopic), 0 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2 laparoscopic versus robotic sacral colpopexy
Anger 2014 1/38 0/40 16.7 % 3.15 [ 0.13, 75.12 ]
Paraiso 2011 2/33 2/35 66.5 % 1.06 [ 0.16, 7.10 ]
Subtotal (95% CI) 71 75 83.2 % 1.48 [ 0.30, 7.24 ]
Total events: 3 (laparoscopic), 2 (another approach)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 97 102 100.0 % 1.75 [ 0.43, 7.14 ]
Total events: 4 (laparoscopic), 2 (another approach)
Heterogeneity: Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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Analysis 6.5. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 5 Bowel injury.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 5 Bowel injury
Study or subgroup laparoscopic another approach Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 laparoscopic versus open sacral colpopexy
Freeman 2013 0/23 1/24 50.7 % 0.35 [ 0.01, 8.11 ]
Subtotal (95% CI) 23 24 50.7 % 0.35 [ 0.01, 8.11 ]
Total events: 0 (laparoscopic), 1 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 laparoscopic versus robotic sacral colpopexy
Paraiso 2011 0/29 1/32 49.3 % 0.37 [ 0.02, 8.66 ]
Subtotal (95% CI) 29 32 49.3 % 0.37 [ 0.02, 8.66 ]
Total events: 0 (laparoscopic), 1 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Total (95% CI) 52 56 100.0 % 0.36 [ 0.04, 3.32 ]
Total events: 0 (laparoscopic), 2 (another approach)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.01 0.1 1 10 100
favours laparoscopic favours another approach
171Surgery for women with apical vaginal prolapse (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.6. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 6 Point Ba.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 6 Point Ba
Study or subgroup
Laparoscopic
colpopexy Another approach
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 laparoscopic versus robotic sacral colpopexy
Anger 2014 38 -2.43 (0.86) 40 -2.48 (0.76) 100.0 % 0.05 [ -0.31, 0.41 ]
Total (95% CI) 38 40 100.0 % 0.05 [ -0.31, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 7 Point Bp.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 7 Point Bp
Study or subgroup laparoscopic another approach
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 laparoscopic versus open sacral colpopexy
Freeman 2013 24 -2.3 (0.9) 23 -1.7 (1.2) 34.2 % -0.60 [ -1.21, 0.01 ]
Subtotal (95% CI) 24 23 34.2 % -0.60 [ -1.21, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
2 laparoscopic versus robotic sacral colpopexy
Anger 2014 38 -2.6 (0.7) 40 -2.3 (1.22) 65.8 % -0.30 [ -0.74, 0.14 ]
Subtotal (95% CI) 38 40 65.8 % -0.30 [ -0.74, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Total (95% CI) 62 63 100.0 % -0.40 [ -0.76, -0.05 ]
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Chi2 = 0.61, df = 1 (P = 0.43), I2 =0.0%
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Analysis 6.8. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 8 Point C.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 8 Point C
Study or subgroup laparoscopic another approach
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 laparoscopic versus open sacral colpopexy
Costantini 2013 36 -6.8 (6.5) 36 -6.5 (6.4) 5.2 % -0.30 [ -3.28, 2.68 ]
Freeman 2013 24 -6.6 (1.4) 23 -6.7 (1.2) 82.6 % 0.10 [ -0.64, 0.84 ]
Subtotal (95% CI) 60 59 87.8 % 0.08 [ -0.65, 0.80 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
2 laparoscopic versus robotic sacral colpopexy
Anger 2014 38 -7.3 (6.04) 40 -8 (0.76) 12.2 % 0.70 [ -1.23, 2.63 ]
Subtotal (95% CI) 38 40 12.2 % 0.70 [ -1.23, 2.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 98 99 100.0 % 0.15 [ -0.52, 0.83 ]
Heterogeneity: Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
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Analysis 6.9. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 9 Stress urinary
incontinence (de novo and persistent).
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 9 Stress urinary incontinence (de novo and persistent)
Study or subgroup laparoscopic another approach Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anger 2014 3/35 2/38 1.63 [ 0.29, 9.18 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours laparoscopic favours another approach
Analysis 6.10. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 10 Quality of life
PROLAPSE.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 10 Quality of life PROLAPSE
Study or subgroup laparoscopic another approach
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 questionnaire (P-QOL) 0-100
Freeman 2013 24 29.3 (39) 23 28.6 (30) 100.0 % 0.70 [ -19.14, 20.54 ]
Subtotal (95% CI) 24 23 100.0 % 0.70 [ -19.14, 20.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
2 Pelvic Floor Impact Questionnaire (PFIQ-7) 0-400
Anger 2014 38 106 (207) 40 85 (52) 100.0 % 21.00 [ -46.76, 88.76 ]
Subtotal (95% CI) 38 40 100.0 % 21.00 [ -46.76, 88.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
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(. . . Continued)
Study or subgroup laparoscopic another approach
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
3 Pelvic floor distress inventory (PFD1-20) 0-300
Anger 2014 38 106 (207) 40 85 (52) 100.0 % 21.00 [ -46.76, 88.76 ]
Subtotal (95% CI) 38 40 100.0 % 21.00 [ -46.76, 88.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 0.59, df = 2 (P = 0.75), I2 =0.0%
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Analysis 6.11. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 11 Operating time
(mins).
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 11 Operating time (mins)
Study or subgroup laparoscopic another approach
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 laparoscopic versus open sacral-colpopexy
Costantini 2013 37 224 (47) 36 194 (58) 24.7 % 30.00 [ 5.74, 54.26 ]
Freeman 2013 23 143 (28) 24 131 (44) 25.2 % 12.00 [ -9.00, 33.00 ]
Subtotal (95% CI) 60 60 49.9 % 19.93 [ 2.42, 37.45 ]
Heterogeneity: Tau2 = 28.05; Chi2 = 1.21, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 2.23 (P = 0.026)
2 laparoscopic versus robotic sacral colpopexy
Anger 2014 38 178 (50) 40 203 (46) 25.2 % -25.00 [ -46.35, -3.65 ]
Paraiso 2011 32 199 (46) 35 265 (50) 24.9 % -66.00 [ -88.99, -43.01 ]
Subtotal (95% CI) 70 75 50.1 % -45.27 [ -85.45, -5.09 ]
Heterogeneity: Tau2 = 712.38; Chi2 = 6.56, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 2.21 (P = 0.027)
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(. . . Continued)
Study or subgroup laparoscopic another approach
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 130 135 100.0 % -12.30 [ -52.65, 28.05 ]
Heterogeneity: Tau2 = 1564.63; Chi2 = 39.15, df = 3 (P<0.00001); I2 =92%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 8.50, df = 1 (P = 0.00), I2 =88%
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Analysis 6.12. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 12 Hospital stay.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 12 Hospital stay
Study or subgroup laparoscopic another approach
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Laparoscopic versus open sacral colpopexy
Costantini 2013 37 4.6 (0.9) 36 6.3 (1.3) 34.2 % -1.70 [ -2.21, -1.19 ]
Freeman 2013 26 3.2 (1.1) 27 4.1 (1.6) 30.2 % -0.90 [ -1.64, -0.16 ]
Subtotal (95% CI) 63 63 64.4 % -1.35 [ -2.12, -0.57 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 3.04, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 3.39 (P = 0.00071)
2 laparoscopic versus robotic sacral colpopexy
Paraiso 2011 33 1.41 (0.4) 35 1.8 (1.2) 35.6 % -0.39 [ -0.81, 0.03 ]
Subtotal (95% CI) 33 35 35.6 % -0.39 [ -0.81, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
Total (95% CI) 96 98 100.0 % -0.99 [ -1.85, -0.14 ]
Heterogeneity: Tau2 = 0.49; Chi2 = 14.95, df = 2 (P = 0.00057); I2 =87%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Chi2 = 4.48, df = 1 (P = 0.03), I2 =78%
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Analysis 6.13. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 13 Blood transfusion.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 13 Blood transfusion
Study or subgroup laparoscopic another approach Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 laparoscopic versus robotic sacral colpopexy
Anger 2014 0/38 0/40 Not estimable
Total (95% CI) 38 40 Not estimable
Total events: 0 (laparoscopic), 0 (another approach)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 6.14. Comparison 6 Sacral colpopexy: Laparoscopic versus other, Outcome 14 continence surgery.
Review: Surgery for women with apical vaginal prolapse
Comparison: 6 Sacral colpopexy: Laparoscopic versus other
Outcome: 14 continence surgery
Study or subgroup laparoscopic another approach Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 laparoscopic versus open sacral colpopexy
Freeman 2013 0/24 1/23 44.0 % 0.32 [ 0.01, 7.48 ]
Subtotal (95% CI) 24 23 44.0 % 0.32 [ 0.01, 7.48 ]
Total events: 0 (laparoscopic), 1 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 laparoscopic versus robotic sacral colpopexy
Anger 2014 3/38 2/40 56.0 % 1.58 [ 0.28, 8.94 ]
Subtotal (95% CI) 38 40 56.0 % 1.58 [ 0.28, 8.94 ]
Total events: 3 (laparoscopic), 2 (another approach)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.61)
Total (95% CI) 62 63 100.0 % 1.03 [ 0.24, 4.29 ]
Total events: 3 (laparoscopic), 3 (another approach)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
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Analysis 7.1. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 1 Awareness of
prolapse (7 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 1 Awareness of prolapse (7 years)
Study or subgroup
With
continence
surgery
Without
continence
s’gery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brubaker 2008 27/73 22/71 100.0 % 1.19 [ 0.75, 1.89 ]
Total (95% CI) 73 71 100.0 % 1.19 [ 0.75, 1.89 ]
Total events: 27 (With continence surgery), 22 (Without continence s’gery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 2 Repeat
prolapse surgery or pessary (2-7 years)).
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 2 Repeat prolapse surgery or pessary (2-7 years))
Study or subgroup
With
continence
surgery
Without
continence
s’gery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brubaker 2008 5/73 7/73 100.0 % 0.71 [ 0.24, 2.15 ]
Costantini 2007 0/31 0/32 Not estimable
Costantini 2008 0/24 0/23 Not estimable
Total (95% CI) 128 128 100.0 % 0.71 [ 0.24, 2.15 ]
Total events: 5 (With continence surgery), 7 (Without continence s’gery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 3 Repeat
surgery for incontinence (7 years)).
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 3 Repeat surgery for incontinence (7 years))
Study or subgroup
With
continence
surgery
Without
continence
s’gery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brubaker 2008 7/91 5/92 1.42 [ 0.47, 4.30 ]
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 4 Objective
failure any site (POP 7 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 4 Objective failure any site (POP 7 years)
Study or subgroup
With
continence
surgery
Without
continence
s’gery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brubaker 2008 15/33 14/37 1.20 [ 0.69, 2.10 ]
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 5 POPQ
assessment Point Ba.
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 5 POPQ assessment Point Ba
Study or subgroup
With
continence
surgery
Without
continence
s’gery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brubaker 2008 157 -2.2 (0.9) 165 -1.8 (1.1) 100.0 % -0.40 [ -0.62, -0.18 ]
Total (95% CI) 157 165 100.0 % -0.40 [ -0.62, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.58 (P = 0.00035)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 6 POPQ
assessment: Point Bp.
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 6 POPQ assessment: Point Bp
Study or subgroup
With
continence
surgery
Without
continence
s’gery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brubaker 2008 157 -2 (0.9) 165 -2.3 (0.8) 100.0 % 0.30 [ 0.11, 0.49 ]
Total (95% CI) 157 165 100.0 % 0.30 [ 0.11, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.16 (P = 0.0016)
Test for subgroup differences: Not applicable
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Analysis 7.7. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 7 POPQ
assessment: Point C.
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 7 POPQ assessment: Point C
Study or subgroup
With
continence
surgery
Without
continence
s’gery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brubaker 2008 157 -8 (1.5) 165 -8.2 (1.3) 100.0 % 0.20 [ -0.11, 0.51 ]
Total (95% CI) 157 165 100.0 % 0.20 [ -0.11, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 7.8. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 8 Stress urinary
incontinence (4-7 years).
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 8 Stress urinary incontinence (4-7 years)
Study or subgroup
With
continence
surgery
Without
continence
s’gery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brubaker 2008 57/89 79/96 47.3 % 0.78 [ 0.65, 0.93 ]
Costantini 2007 9/31 5/31 21.1 % 1.80 [ 0.68, 4.76 ]
Costantini 2008 13/24 9/24 31.5 % 1.44 [ 0.77, 2.72 ]
Total (95% CI) 144 151 100.0 % 1.13 [ 0.63, 2.04 ]
Total events: 79 (With continence surgery), 93 (Without continence s’gery)
Heterogeneity: Tau2 = 0.18; Chi2 = 6.59, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 7.9. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 9 Operating
time (minutes).
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 9 Operating time (minutes)
Study or subgroup
With
continence
surgery
Without
continence
s’gery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brubaker 2008 157 190 (55) 165 170 (60) 100.0 % 20.00 [ 7.44, 32.56 ]
Total (95% CI) 157 165 100.0 % 20.00 [ 7.44, 32.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable
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Analysis 7.10. Comparison 7 Sacral colpopexy with continence surgery vs without, Outcome 10 Blood
transfusion.
Review: Surgery for women with apical vaginal prolapse
Comparison: 7 Sacral colpopexy with continence surgery vs without
Outcome: 10 Blood transfusion
Study or subgroup
With
continence
surgery
Without
continence
s’gery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Costantini 2007 3/34 3/32 100.0 % 0.94 [ 0.20, 4.33 ]
Total (95% CI) 34 32 100.0 % 0.94 [ 0.20, 4.33 ]
Total events: 3 (With continence surgery), 3 (Without continence s’gery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Mesh exposure: vaginal colpopexy versus transvaginal polypropylene mesh
Study ID mesh exposure total cases
da Silviera 2015 18 88
Halaska 2012 16 79
Iglesia 2010 5 32
Svabik 2014 3 36
Table 2. Repeat surgery: Mesh exposure
Study ID Surgery mesh Exposure total cases
da Silviera 2015 7 88
Halaska 2012 10 79
Iglesia 2010 3 32
Svabik 2014 2 36
A P P E N D I C E S
Appendix 1. Types of operations
Sacral colpopexy
Aim
To correct upper genital tract prolapse.
Indication
Usually reserved for recurrent prolapse of the upper vagina (recurrent cystocele, vault or enterocele) or massive vaginal eversion.
Surgical technique
1. Usually performed under general anaesthesia
2. Performed through an incision on the lower abdomen or keyhole
3. The bladder and rectum are freed from the vagina and permanent mesh supports the front and back wall of the vagina
4. This mesh is secured to the sacrum (upper tailbone)
5. Peritoneum (lining of the abdominal cavity) is closed over the mesh
6. Other repairs are performed as required at the same time including paravaginal repair, perineoplasty, colposuspension or
rectopexy
7. Bowel preparation is required prior to the surgery
McCaul culdoplasty
Indications
1. Vault prolapse or an enterocele
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2. Often performed at the time of vaginal hysterectomy to prevent future prolapse
Surgical technique
1. After the uterus is removed at the time of hysterectomy the uterosacral ligaments are identified and incorporated into the closure
of the peritoneum and upper vagina using 1 to 2 sutures
2. An anterior or posterior vaginal repair is often performed at the same time
Sacrospinous fixation
Aim
This surgery offers support to the upper vagina minimising risk of recurrent prolapse at this site. The advantage of this surgery is that
vaginal length is maintained.
Indication
Upper vaginal prolapse (uterine or vault prolapse, enteroceles).
This procedure can be used in reconstructive vaginal surgery where increased vaginal length is required.
Procedure
1. The procedure can be performed under regional or general anaesthesia
2. A routine posterior vaginal incision is made and extended to the top of the vagina
3. Using sharp dissection the vagina is freed from the underlying rectovaginal fascia and rectum until the pelvic floor (puborectalis)
muscle is seen
4. Using sharp and blunt dissection the sacrospinous ligament running from the ischial spine to the sacral bone is palpated and
identified
5. Two sutures are placed through the strong ligament and secured to the top of the vagina. This results in increased support to the
upper vagina. There is no shortening of the vagina
6. Other fascial defects in the vagina are repaired and the vaginal skin is closed
Anterior vaginal repair (colporrhaphy)
Indication
1. Prolapse of the bladder or urethra
2. Sometimes used to treat urinary stress incontinence
Surgical technique
1. The procedure can be performed under regional or general anaesthesia
2. The vagina overlying the bladder and urethra is incised in the midline
3. Dissection in a plane directly below the vagina allows the damaged fascia supporting the bladder and urethra to be exposed
4. The fascia is plicated in the midline using delayed absorbable or permanent sutures
5. Sometimes excessive vaginal skin is removed
6. The vaginal skin is then closed
7. Other sites of prolapse are then repaired as required
Posterior vaginal repair and perineoplasty
Indications
Treatment of rectocele (rectum bulges or herniates forward into the vagina) and defects of the perineum (area separating entrance of
the vagina and anus).
Aim
correct defects in the rectovaginal fascia separating rectum and vagina while allowing bowel function to be maintained or corrected
without interfering with sexual function.
Surgical technique
1. An incision is made on the posterior wall of the vagina starting at the entrance and finishing at the top of the vagina
2. Dissecting the vagina and rectovaginal fascia from the vagina until the pelvic floor muscles (puborectalis) are located
3. Defects in the fascia are corrected by centrally plicating the fascia using delayed absorption sutures
4. The perineal defects are repaired by placing deep sutures into the perineal muscles to build up the perineal body
5. The overlying vaginal and vulval skin is then closed
6. A pack is usually placed into the vagina and a catheter into the bladder at the end of surgery
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Appendix 2. Search strategy
Search strategy:
The Incontinence Group Specialised Register was searched using the Group’s own keyword system (all searches were of the keyword
field of Reference Manager 2012). The search terms used were:
({design.cct*} OR {design.rct*})
AND
({topic.prolapse*})
AND
({intvent.surg*})
Date of the most recent search of the register for this review: 6 July 2015.
WH A T ’ S N E W
Last assessed as up-to-date: 6 July 2015.
Date Event Description
6 July 2016 New search has been performed The comparison of any surgical intervention with an-
other intervention for apical vaginal prolapse was for-
merly part of the 2013 Cochrane review “Surgical man-
agement of pelvic organ prolapse in women”. We now
present this as a separate review. Eleven new trials are in-
cluded that were not in the previous review: Anger 2014;
Barber 2014; Costantini 2013; Culligan 2013; da Silviera
2015; Detollenaere 2015; Freeman 2013; Halaska 2012;
Rahmanou 2015; Rondini 2015; Svabik 2014.
New reviewers include Dr Nir Haya (Israel) and Julie
Brown (Auckland)
New trials evaluated the following topics:
Transvaginal mesh versus native tissue repairs for apical
prolapse
Different routs of sacral colpopexy
Sacral colpopexy versus uterosacral colopoexy
Sacrospinous colpopexy versus uterosacral colpopexy
Uterine preservation versus hysterectomy
6 July 2016 New citation required but conclusions have not changed The inclusion of 11 new trials did not change the conclu-
sions for this comparison
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H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 10, 2016
Date Event Description
14 April 2010 Amended changed citation, added conflicts
17 November 2009 New citation required but conclusions have not
changed
Full reports of 59 potentially eligible studies were
assessed; for this update, 23 new eligible studies
were assessed (Al-Nazer 2007a; Ali 2006a; Allahdin
2008; Barber 2006; Biller 2008; Borstad 2008; Braun
2007a; Carramao 2008a; Constantini 2008; de Tayrac
2008; Dietz 2008a; Glavind 2007; Guerette 2006a;
Lim 2007a; Meschia 2007a; Natale 2007; Natale
2009; Nguyen 2008; Nieminen 2008; Pantazis 2008a;
Schierlitz 2007a; Segal 2007; Sivaslioglu 2008). Over-
all, 17 studies were excluded from the review, six dur-
ing this update (Barber 2006; Biller 2008; Carramao
2008a; Glavind 2007; Meschia 2007a; Segal 2007):
full details are given in the Characteristics of Excluded
Studies
In this the secondupdate, 18new trialswere added (Al-
Nazer 2007; Ali 2006; Allahdin 2008; Borstad 2008;
Braun2007a;Constantini 2007;Constantini 2008; de
Tayrac 2008; Dietz 2008a; Guerette 2006; Lim 2007;
Natale 2007; Natale 2009; Nguyen 2008; Niemi-
nen 2008; Pantazis 2008; Schierlitz 2007; Sivaslioglu
2008) and three previously included studies were up-
dated (Brubaker 2008; Meschia 2007; Roovers 2004)
9 February 2009 New search has been performed new search feb 2009
10 October 2008 Amended Converted to new review format.
17 April 2007 New citation required and conclusions have changed Substantive Update Issue 3 2007. 22 RCTs (8 new in-
cluded trials). The findings are still insufficient to pro-
vide robust evidence to support current and new prac-
tice (such as whether to perform a concurrent conti-
nence operation, or to use mesh or grafts)
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C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to writing the protocol. Four review authors (C Maher, C Schmid, B Feiner, K Baessler) assessed the
relevance and eligibility of studies for inclusion in the review. They then assessed the quality of included studies; four authors (CMaher,
C Schmid, K Baessler, and B Feiner) independently extracted data from trial reports, interpreted the results and contributed to the
writing of the draft version of the review. Julie Brown checked the draft and edited the review.
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The lead review author, Christopher Maher, is an author of two of the included trials (Maher 2004; Maher 2011). No authors have
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review is the result of updating the review ’Surgery for pelvic organ prolapse in women’. As a result of the update, we decided to split
the review into six reviews.
This review should be read as part of a series of six Cochrane reviews relating to the surgical management of prolapse.
1. Surgery for women with anterior compartment prolapse.
2. Surgery for women with posterior compartment prolapse.
3. Surgery for women with apical vaginal prolapse.
4. Continence outcomes in pelvic organ prolapse surgery.
5. Transvaginal mesh or grafts compared with native tissue repair for vaginal prolapse.
6. Perioperative interventions at prolapse surgery.
Differences from the published review methods were a reduction in the number of outcomes and limiting this review to studies that
compared any surgical intervention with another intervention for apical vaginal prolapse.
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